EP3898953A1 - Branched receptor binding multi-subunit protein complexes for use in bacterial delivery vehicles - Google Patents
Branched receptor binding multi-subunit protein complexes for use in bacterial delivery vehiclesInfo
- Publication number
- EP3898953A1 EP3898953A1 EP19829637.8A EP19829637A EP3898953A1 EP 3898953 A1 EP3898953 A1 EP 3898953A1 EP 19829637 A EP19829637 A EP 19829637A EP 3898953 A1 EP3898953 A1 EP 3898953A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- rbp
- seq
- virus
- terminal
- terminal domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 177
- 102000005962 receptors Human genes 0.000 title claims abstract description 33
- 108020003175 receptors Proteins 0.000 title claims abstract description 33
- 230000027455 binding Effects 0.000 title claims abstract description 21
- 108010085220 Multiprotein Complexes Proteins 0.000 title description 4
- 102000007474 Multiprotein Complexes Human genes 0.000 title description 4
- 101710146873 Receptor-binding protein Proteins 0.000 claims abstract description 372
- 241001515965 unidentified phage Species 0.000 claims abstract description 140
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 81
- 210000004027 cell Anatomy 0.000 claims abstract description 62
- 230000004927 fusion Effects 0.000 claims abstract description 39
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 18
- 108091008324 binding proteins Proteins 0.000 claims abstract description 18
- 108700010039 chimeric receptor Proteins 0.000 claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 167
- 241000894006 Bacteria Species 0.000 claims description 141
- 239000003981 vehicle Substances 0.000 claims description 112
- 102000004169 proteins and genes Human genes 0.000 claims description 94
- 150000007523 nucleic acids Chemical class 0.000 claims description 91
- 150000001413 amino acids Chemical group 0.000 claims description 85
- 108020004707 nucleic acids Proteins 0.000 claims description 75
- 102000039446 nucleic acids Human genes 0.000 claims description 75
- 239000000203 mixture Substances 0.000 claims description 56
- 230000037431 insertion Effects 0.000 claims description 53
- 238000003780 insertion Methods 0.000 claims description 53
- 230000003993 interaction Effects 0.000 claims description 45
- 108091033409 CRISPR Proteins 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 34
- 239000000304 virulence factor Substances 0.000 claims description 34
- 230000007923 virulence factor Effects 0.000 claims description 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 33
- 239000013612 plasmid Substances 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 24
- 230000003115 biocidal effect Effects 0.000 claims description 20
- 101710163270 Nuclease Proteins 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 108700012359 toxins Proteins 0.000 claims description 19
- 208000035475 disorder Diseases 0.000 claims description 16
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 208000035143 Bacterial infection Diseases 0.000 claims description 15
- 108010062877 Bacteriocins Proteins 0.000 claims description 15
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 238000010354 CRISPR gene editing Methods 0.000 claims description 13
- 239000003242 anti bacterial agent Substances 0.000 claims description 13
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 108020005004 Guide RNA Proteins 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 8
- 244000005702 human microbiome Species 0.000 claims description 8
- 235000013406 prebiotics Nutrition 0.000 claims description 8
- 239000006041 probiotic Substances 0.000 claims description 8
- 235000018291 probiotics Nutrition 0.000 claims description 8
- 231100000331 toxic Toxicity 0.000 claims description 8
- 230000002588 toxic effect Effects 0.000 claims description 8
- 230000000529 probiotic effect Effects 0.000 claims description 7
- 102000018697 Membrane Proteins Human genes 0.000 claims description 6
- 108010052285 Membrane Proteins Proteins 0.000 claims description 6
- 238000010459 TALEN Methods 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 230000007017 scission Effects 0.000 claims description 6
- 102000018120 Recombinases Human genes 0.000 claims description 5
- 108010091086 Recombinases Proteins 0.000 claims description 5
- 101710172711 Structural protein Proteins 0.000 claims description 5
- 101710117021 Tyrosine-protein phosphatase YopH Proteins 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 230000007170 pathology Effects 0.000 claims description 5
- 102000001253 Protein Kinase Human genes 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108060006633 protein kinase Proteins 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 230000000692 anti-sense effect Effects 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000003214 anti-biofilm Effects 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 238000002255 vaccination Methods 0.000 claims description 2
- 102100024544 SURP and G-patch domain-containing protein 1 Human genes 0.000 claims 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 15
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 13
- 229920001184 polypeptide Polymers 0.000 abstract description 12
- 238000012546 transfer Methods 0.000 abstract description 11
- 210000004897 n-terminal region Anatomy 0.000 abstract 1
- 241000700605 Viruses Species 0.000 description 147
- 241000588722 Escherichia Species 0.000 description 120
- 241000186359 Mycobacterium Species 0.000 description 107
- 235000018102 proteins Nutrition 0.000 description 88
- 235000001014 amino acid Nutrition 0.000 description 62
- 229940024606 amino acid Drugs 0.000 description 62
- 239000000835 fiber Substances 0.000 description 50
- 241000186429 Propionibacterium Species 0.000 description 46
- 239000002245 particle Substances 0.000 description 41
- 241000191940 Staphylococcus Species 0.000 description 40
- 241000588724 Escherichia coli Species 0.000 description 33
- -1 pBCl Proteins 0.000 description 32
- 241000589516 Pseudomonas Species 0.000 description 31
- 230000010076 replication Effects 0.000 description 29
- 241000607142 Salmonella Species 0.000 description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 description 25
- 241000193830 Bacillus <bacterium> Species 0.000 description 22
- 241000194036 Lactococcus Species 0.000 description 21
- 230000006870 function Effects 0.000 description 21
- 208000015181 infectious disease Diseases 0.000 description 19
- 241000194017 Streptococcus Species 0.000 description 17
- 241000607598 Vibrio Species 0.000 description 17
- 239000002775 capsule Substances 0.000 description 17
- 241000186063 Arthrobacter Species 0.000 description 16
- 238000013459 approach Methods 0.000 description 15
- 244000005700 microbiome Species 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 239000003053 toxin Substances 0.000 description 15
- 231100000765 toxin Toxicity 0.000 description 15
- 241000192132 Leuconostoc Species 0.000 description 14
- 241000894007 species Species 0.000 description 14
- 241000588748 Klebsiella Species 0.000 description 13
- 241000187747 Streptomyces Species 0.000 description 13
- 241001337904 Gordonia <angiosperm> Species 0.000 description 12
- 230000002255 enzymatic effect Effects 0.000 description 12
- 241000194033 Enterococcus Species 0.000 description 11
- 108010006519 Molecular Chaperones Proteins 0.000 description 11
- 241000607768 Shigella Species 0.000 description 11
- 241000701539 T4virus Species 0.000 description 11
- 108010014459 endo-N-acetylneuraminidase Proteins 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 241000607534 Aeromonas Species 0.000 description 9
- 239000006142 Luria-Bertani Agar Substances 0.000 description 9
- 229960005091 chloramphenicol Drugs 0.000 description 9
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 241000186660 Lactobacillus Species 0.000 description 8
- 102000005431 Molecular Chaperones Human genes 0.000 description 8
- 102100036034 Thrombospondin-1 Human genes 0.000 description 8
- 230000002950 deficient Effects 0.000 description 8
- 241000589291 Acinetobacter Species 0.000 description 7
- 241001453380 Burkholderia Species 0.000 description 7
- 241000588698 Erwinia Species 0.000 description 7
- 241000186781 Listeria Species 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 229960001225 rifampicin Drugs 0.000 description 7
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 241000179039 Paenibacillus Species 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 241000607734 Yersinia <bacteria> Species 0.000 description 6
- 210000000234 capsid Anatomy 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 101150028191 stf gene Proteins 0.000 description 6
- 241000863012 Caulobacter Species 0.000 description 5
- 241000193403 Clostridium Species 0.000 description 5
- 101100208245 Danio rerio thbs4b gene Proteins 0.000 description 5
- 241000588914 Enterobacter Species 0.000 description 5
- 241000589989 Helicobacter Species 0.000 description 5
- 101150053966 THBS4 gene Proteins 0.000 description 5
- 101710159964 Tail sheath protein Proteins 0.000 description 5
- 101710168563 Tail spike protein Proteins 0.000 description 5
- 102100029219 Thrombospondin-4 Human genes 0.000 description 5
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 235000019801 trisodium phosphate Nutrition 0.000 description 5
- 241000590020 Achromobacter Species 0.000 description 4
- 241000193738 Bacillus anthracis Species 0.000 description 4
- 241000606124 Bacteroides fragilis Species 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 4
- 241000589876 Campylobacter Species 0.000 description 4
- 241000606161 Chlamydia Species 0.000 description 4
- 241000588923 Citrobacter Species 0.000 description 4
- 241000186216 Corynebacterium Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000588747 Klebsiella pneumoniae Species 0.000 description 4
- 208000016604 Lyme disease Diseases 0.000 description 4
- 201000009906 Meningitis Diseases 0.000 description 4
- 241000736262 Microbiota Species 0.000 description 4
- 241000588653 Neisseria Species 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 108010001267 Protein Subunits Proteins 0.000 description 4
- 102000002067 Protein Subunits Human genes 0.000 description 4
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 4
- 241000606701 Rickettsia Species 0.000 description 4
- 241000607720 Serratia Species 0.000 description 4
- 241000589634 Xanthomonas Species 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 230000008827 biological function Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 229940037201 oris Drugs 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 108700026220 vif Genes Proteins 0.000 description 4
- 241000588626 Acinetobacter baumannii Species 0.000 description 3
- 241000186046 Actinomyces Species 0.000 description 3
- 231100000699 Bacterial toxin Toxicity 0.000 description 3
- 241000589562 Brucella Species 0.000 description 3
- 241001137855 Caudovirales Species 0.000 description 3
- 241001496942 Cellulophaga Species 0.000 description 3
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
- 108010054814 DNA Gyrase Proteins 0.000 description 3
- 101100434045 Danio rerio acp7 gene Proteins 0.000 description 3
- 101100208241 Danio rerio thbs3a gene Proteins 0.000 description 3
- 241000701959 Escherichia virus Lambda Species 0.000 description 3
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 description 3
- 101000633605 Homo sapiens Thrombospondin-2 Proteins 0.000 description 3
- 235000019687 Lamb Nutrition 0.000 description 3
- 108090000856 Lyases Proteins 0.000 description 3
- 102000004317 Lyases Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 101100434047 Mus musculus Acp7 gene Proteins 0.000 description 3
- 101100115705 Mus musculus Stfa1 gene Proteins 0.000 description 3
- 101100115709 Mus musculus Stfa2 gene Proteins 0.000 description 3
- 241000204031 Mycoplasma Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241000187654 Nocardia Species 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 241000206220 Roseobacter Species 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 241000193996 Streptococcus pyogenes Species 0.000 description 3
- 101710166729 Tail fiber protein Proteins 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 101150116166 Thbs3 gene Proteins 0.000 description 3
- 102100029529 Thrombospondin-2 Human genes 0.000 description 3
- 102100029524 Thrombospondin-3 Human genes 0.000 description 3
- 241000589886 Treponema Species 0.000 description 3
- 241000204066 Tsukamurella Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000688 bacterial toxin Substances 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 229940124307 fluoroquinolone Drugs 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 208000019206 urinary tract infection Diseases 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IXXFZUPTQVDPPK-ZAWHAJPISA-N (1r,2r,4r,6r,7r,8r,10s,13r,14s)-17-[4-[4-(3-aminophenyl)triazol-1-yl]butyl]-7-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-10-fluoro-6-methoxy-2,4,6,8,10,14-hexamethyl-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tet Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@](C)(F)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3N=NC(=C3)C=3C=C(N)C=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O IXXFZUPTQVDPPK-ZAWHAJPISA-N 0.000 description 2
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 2
- 102220560681 ATP-binding cassette sub-family C member 8_F27S_mutation Human genes 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 241000606750 Actinobacillus Species 0.000 description 2
- 101100214874 Autographa californica nuclear polyhedrosis virus AC81 gene Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 108700023313 Bacteriophage Receptors Proteins 0.000 description 2
- 241001148536 Bacteroides sp. Species 0.000 description 2
- 241000588807 Bordetella Species 0.000 description 2
- 241000589968 Borrelia Species 0.000 description 2
- 101001005165 Bos taurus Lens fiber membrane intrinsic protein Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 101100189913 Caenorhabditis elegans pept-1 gene Proteins 0.000 description 2
- 241000589875 Campylobacter jejuni Species 0.000 description 2
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 241000989055 Cronobacter Species 0.000 description 2
- 206010011409 Cross infection Diseases 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- 241000588697 Enterobacter cloacae Species 0.000 description 2
- 241000194031 Enterococcus faecium Species 0.000 description 2
- 241000186811 Erysipelothrix Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 101000763865 Escherichia phage lambda Tip attachment protein J Proteins 0.000 description 2
- 102220511796 F-actin-capping protein subunit beta_F26S_mutation Human genes 0.000 description 2
- 241000589602 Francisella tularensis Species 0.000 description 2
- 241000589599 Francisella tularensis subsp. novicida Species 0.000 description 2
- 241000605909 Fusobacterium Species 0.000 description 2
- 241000605986 Fusobacterium nucleatum Species 0.000 description 2
- 201000000628 Gas Gangrene Diseases 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000626621 Geobacillus Species 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 101000760620 Homo sapiens Cell adhesion molecule 1 Proteins 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000588915 Klebsiella aerogenes Species 0.000 description 2
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 241000588771 Morganella <proteobacterium> Species 0.000 description 2
- 101100494762 Mus musculus Nedd9 gene Proteins 0.000 description 2
- 101000740206 Mus musculus Sal-like protein 1 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010029803 Nosocomial infection Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 108700006385 OmpF Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 101150054516 PRD1 gene Proteins 0.000 description 2
- 241000192608 Phormidium Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 102100033073 Polypyrimidine tract-binding protein 1 Human genes 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 102000055027 Protein Methyltransferases Human genes 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- ZVGNESXIJDCBKN-WUIGKKEISA-N R-Tiacumicin B Natural products O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC1=CC=CC[C@H](O)C(C)=C[C@@H]([C@H](C(C)=CC(C)=CC[C@H](OC1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-WUIGKKEISA-N 0.000 description 2
- 241000191025 Rhodobacter Species 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 101100459905 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NCP1 gene Proteins 0.000 description 2
- 241000235342 Saccharomycetes Species 0.000 description 2
- 102100037205 Sal-like protein 2 Human genes 0.000 description 2
- 101710192308 Sal-like protein 2 Proteins 0.000 description 2
- 241000701835 Salmonella virus P22 Species 0.000 description 2
- 101100165188 Schizophyllum commune BBR1 gene Proteins 0.000 description 2
- 101100465903 Schizosaccharomyces pombe (strain 972 / ATCC 24843) psp3 gene Proteins 0.000 description 2
- 241000607764 Shigella dysenteriae Species 0.000 description 2
- 208000036379 Sigmoiditis Diseases 0.000 description 2
- 241000702202 Siphoviridae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241001186872 Staphylococcus virus 44AHJD Species 0.000 description 2
- 241000543700 Staphylococcus virus Twort Species 0.000 description 2
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 2
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 108020002494 acetyltransferase Proteins 0.000 description 2
- 102000005421 acetyltransferase Human genes 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229940065181 bacillus anthracis Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229960005495 cefotetan Drugs 0.000 description 2
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 2
- 229960002682 cefoxitin Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 229940092559 enterobacter aerogenes Drugs 0.000 description 2
- 229960000285 ethambutol Drugs 0.000 description 2
- 239000002095 exotoxin Substances 0.000 description 2
- 231100000776 exotoxin Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960000628 fidaxomicin Drugs 0.000 description 2
- ZVGNESXIJDCBKN-UUEYKCAUSA-N fidaxomicin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC\1=C/C=C/C[C@H](O)/C(C)=C/[C@@H]([C@H](/C(C)=C/C(/C)=C/C[C@H](OC/1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-UUEYKCAUSA-N 0.000 description 2
- 210000003495 flagella Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229940118764 francisella tularensis Drugs 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- 229960005287 lincomycin Drugs 0.000 description 2
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 2
- 229940041028 lincosamides Drugs 0.000 description 2
- 229960001977 loracarbef Drugs 0.000 description 2
- JAPHQRWPEGVNBT-UTUOFQBUSA-N loracarbef Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C([O-])=O)=O)[NH3+])=CC=CC=C1 JAPHQRWPEGVNBT-UTUOFQBUSA-N 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 102000035118 modified proteins Human genes 0.000 description 2
- 108091005573 modified proteins Proteins 0.000 description 2
- 101150021123 msrA gene Proteins 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- NYBZAGXTZXPYND-GBIKHYSHSA-N pyochelin I Chemical compound S1C[C@@H](C(O)=O)N(C)[C@H]1[C@@H]1N=C(C=2C(=CC=CC=2)O)SC1 NYBZAGXTZXPYND-GBIKHYSHSA-N 0.000 description 2
- 101710139639 rRNA methyltransferase Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 229960003040 rifaximin Drugs 0.000 description 2
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 2
- 229940007046 shigella dysenteriae Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 229950008588 solithromycin Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960004673 sulfadoxine Drugs 0.000 description 2
- 229960000654 sulfafurazole Drugs 0.000 description 2
- KXRZBTAEDBELFD-UHFFFAOYSA-N sulfamethopyrazine Chemical compound COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 KXRZBTAEDBELFD-UHFFFAOYSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 229960003250 telithromycin Drugs 0.000 description 2
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- HBJOXQRURQPDEX-MHXMMLMNSA-N (2s,4r)-n-[(1s,2s)-2-chloro-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-4-ethylpiperidine-2-carboxamide Chemical compound C1[C@H](CC)CCN[C@@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 HBJOXQRURQPDEX-MHXMMLMNSA-N 0.000 description 1
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 description 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
- HBUJYEUPIIJJOS-PBHICJAKSA-N (5r)-3-[4-[1-[(2s)-2,3-dihydroxypropanoyl]-3,6-dihydro-2h-pyridin-4-yl]-3,5-difluorophenyl]-5-(1,2-oxazol-3-yloxymethyl)-1,3-oxazolidin-2-one Chemical compound C1N(C(=O)[C@@H](O)CO)CCC(C=2C(=CC(=CC=2F)N2C(O[C@@H](COC3=NOC=C3)C2)=O)F)=C1 HBUJYEUPIIJJOS-PBHICJAKSA-N 0.000 description 1
- MMQXRUYUBYWTDP-KEIGCJKLSA-N (5s,6r,7r)-3-(acetyloxymethyl)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-5,8-dioxo-5$l^{4}-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2[C@@H]1[S@](CC(COC(C)=O)=C2C(O)=O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 MMQXRUYUBYWTDP-KEIGCJKLSA-N 0.000 description 1
- FMZXNVLFJHCSAF-DNVCBOLYSA-N (6R,7R)-3-[(4-carbamoyl-1-pyridin-1-iumyl)methyl]-8-oxo-7-[(1-oxo-2-thiophen-2-ylethyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CC=3SC=CC=3)[C@H]2SC1 FMZXNVLFJHCSAF-DNVCBOLYSA-N 0.000 description 1
- YBHZVPYSEUQIII-DYJQDLSISA-N (6r,7r)-3-(acetyloxymethyl)-7-[[(2z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 YBHZVPYSEUQIII-DYJQDLSISA-N 0.000 description 1
- OCLRGULJISNUQS-OXQOHEQNSA-N (6r,7r)-3-(acetyloxymethyl)-7-[[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl OCLRGULJISNUQS-OXQOHEQNSA-N 0.000 description 1
- LHNIIDJCEODSHA-OQRUQETBSA-N (6r,7r)-3-[(e)-2-(2,4-dinitrophenyl)ethenyl]-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)O)\C=C\C=1C(=CC(=CC=1)[N+]([O-])=O)[N+]([O-])=O)C(=O)CC1=CC=CS1 LHNIIDJCEODSHA-OQRUQETBSA-N 0.000 description 1
- QFTZCQVZVRVDTD-DNVCBOLYSA-N (6r,7r)-3-methyl-8-oxo-7-[[2-[4-(1,4,5,6-tetrahydropyrimidin-2-yl)phenyl]acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)C)C(O)=O)C(=O)CC(C=C1)=CC=C1C1=NCCCN1 QFTZCQVZVRVDTD-DNVCBOLYSA-N 0.000 description 1
- XSPUSVIQHBDITA-KXDGEKGBSA-N (6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(5-methyltetrazol-2-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CN1N=NC(C)=N1 XSPUSVIQHBDITA-KXDGEKGBSA-N 0.000 description 1
- RULITNAIJFZYLO-UEKVPHQBSA-N (6r,7r)-7-[[(2r)-2-amino-2-(3-chloro-4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C(Cl)=C1 RULITNAIJFZYLO-UEKVPHQBSA-N 0.000 description 1
- SBUCDZYLTRYMFG-PBFPGSCMSA-N (6r,7r)-7-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](N)C=3C=CC(O)=CC=3)[C@H]2SC1 SBUCDZYLTRYMFG-PBFPGSCMSA-N 0.000 description 1
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
- VDFFPBOAOLQAJV-SUYBPPKGSA-N (6r,7r)-7-[[(2r)-2-hydroxy-2-phenylacetyl]amino]-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 VDFFPBOAOLQAJV-SUYBPPKGSA-N 0.000 description 1
- MMRINLZOZVAPDZ-LSGRDSQZSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 MMRINLZOZVAPDZ-LSGRDSQZSA-N 0.000 description 1
- YWKJNRNSJKEFMK-PQFQYKRASA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 YWKJNRNSJKEFMK-PQFQYKRASA-N 0.000 description 1
- CUCFRCCRYQDMNM-PXIRVSTKSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-5-yl)-2-(2-oxopyrrolidin-3-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound S1C(N)=NC=C1C(\C(=O)N[C@@H]1C(N2C(=C(C[N+]=3C=CC=CC=3)CS[C@@H]21)C([O-])=O)=O)=N\OC1C(=O)NCC1 CUCFRCCRYQDMNM-PXIRVSTKSA-N 0.000 description 1
- JXHWKLWIYBATLL-GMIKGCRTSA-N (6r,7r)-7-[[2-[(z)-2-cyanoethenyl]sulfanylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CS\C=C/C#N)[C@H]2SC1 JXHWKLWIYBATLL-GMIKGCRTSA-N 0.000 description 1
- UQWYUAURRDNBKR-BXUZGUMPSA-N (6r,7r)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-3-(1h-1,2,4-triazol-5-ylsulfanylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)O)=C2CSC1=NC=NN1 UQWYUAURRDNBKR-BXUZGUMPSA-N 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- QKDHBVNJCZBTMR-LLVKDONJSA-N (R)-temafloxacin Chemical compound C1CN[C@H](C)CN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F QKDHBVNJCZBTMR-LLVKDONJSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- CNIGTNPXWSLRPH-UHFFFAOYSA-N 2,2,4-trimethyl-1-oxidoimidazol-1-ium Chemical compound CC1=NC(C)(C)[N+]([O-])=C1 CNIGTNPXWSLRPH-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- STMIIPIFODONDC-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)-1-(1H-1,2,4-triazol-1-yl)hexan-2-ol Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(O)(CCCC)CN1C=NC=N1 STMIIPIFODONDC-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
- FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 description 1
- 101710171217 30S ribosomal protein S15 Proteins 0.000 description 1
- 108050001922 30S ribosomal protein S17 Proteins 0.000 description 1
- 101710171225 30S ribosomal protein S18 Proteins 0.000 description 1
- 101710171204 30S ribosomal protein S20 Proteins 0.000 description 1
- 101710192522 30S ribosomal protein S8 Proteins 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- XHCNINMOALIGKM-UHFFFAOYSA-N 5,5,7,12,12,14-hexamethyl-1,4,8,11-tetrazacyclotetradecane Chemical compound CC1CC(C)(C)NCCNC(C)CC(C)(C)NCCN1 XHCNINMOALIGKM-UHFFFAOYSA-N 0.000 description 1
- 101710115003 50S ribosomal protein L31, chloroplastic Proteins 0.000 description 1
- WUWFMDMBOJLQIV-UHFFFAOYSA-N 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid Chemical compound C1C(N)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F WUWFMDMBOJLQIV-UHFFFAOYSA-N 0.000 description 1
- MPORYQCGWFQFLA-ONPDANIMSA-N 7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid;trihydrate Chemical compound O.O.O.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 MPORYQCGWFQFLA-ONPDANIMSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 108010049290 ADP Ribose Transferases Proteins 0.000 description 1
- 102000009062 ADP Ribose Transferases Human genes 0.000 description 1
- 102100031315 AP-2 complex subunit mu Human genes 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000195488 Abouovirus Species 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000203024 Acholeplasma Species 0.000 description 1
- 241000201372 Acholeplasma virus L2 Species 0.000 description 1
- 241000604451 Acidaminococcus Species 0.000 description 1
- 241000994363 Acinetobacter virus AB1 Species 0.000 description 1
- 241000994358 Acinetobacter virus AB2 Species 0.000 description 1
- 241000191499 Acinetobacter virus AB3 Species 0.000 description 1
- 241000994359 Acinetobacter virus AbC62 Species 0.000 description 1
- 241000191504 Acinetobacter virus IME200 Species 0.000 description 1
- 241000191501 Acinetobacter virus PD6A3 Species 0.000 description 1
- 241000191500 Acinetobacter virus PDAB9 Species 0.000 description 1
- 241000186041 Actinomyces israelii Species 0.000 description 1
- 101710168439 Acylamino-acid-releasing enzyme Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 101100335435 Aedes aegypti FERH gene Proteins 0.000 description 1
- 241000607516 Aeromonas caviae Species 0.000 description 1
- 241000607528 Aeromonas hydrophila Species 0.000 description 1
- 241000632298 Aeromonas virus 25 Species 0.000 description 1
- 241001619560 Aeromonas virus 31 Species 0.000 description 1
- 241001286171 Aeromonas virus AS4 Species 0.000 description 1
- 241001285983 Aeromonas virus Aes508 Species 0.000 description 1
- 241000889758 Agatevirus Species 0.000 description 1
- 241000195485 Agrican357virus Species 0.000 description 1
- 241000709770 Allolevivirus Species 0.000 description 1
- 241001093575 Alma Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101710092462 Alpha-hemolysin Proteins 0.000 description 1
- 101710197219 Alpha-toxin Proteins 0.000 description 1
- 241000889790 Alpha3microvirus Species 0.000 description 1
- 241001135756 Alphaproteobacteria Species 0.000 description 1
- 241000170181 Amigovirus Species 0.000 description 1
- 241001206546 Ampullaviridae Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000372033 Andromeda Species 0.000 description 1
- 241000505456 Andromedavirus Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 241000994387 Ap22virus Species 0.000 description 1
- 101100059544 Arabidopsis thaliana CDC5 gene Proteins 0.000 description 1
- 101100454361 Arabidopsis thaliana LCB1 gene Proteins 0.000 description 1
- 101100455985 Arabidopsis thaliana MAM3 gene Proteins 0.000 description 1
- 101100082447 Arabidopsis thaliana PBL1 gene Proteins 0.000 description 1
- 101100028789 Arabidopsis thaliana PBS1 gene Proteins 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241001123248 Arma Species 0.000 description 1
- 241000169860 Arthrobacter virus Amigo Species 0.000 description 1
- 241000148522 Arthrobacter virus Brent Species 0.000 description 1
- 241000171051 Arthrobacter virus Captnmurica Species 0.000 description 1
- 241000169864 Arthrobacter virus Decurro Species 0.000 description 1
- 241000171048 Arthrobacter virus Gordon Species 0.000 description 1
- 241000148524 Arthrobacter virus Jawnski Species 0.000 description 1
- 241000148530 Arthrobacter virus Martha Species 0.000 description 1
- 241000148529 Arthrobacter virus Sonny Species 0.000 description 1
- 241000195507 Arthrobacter virus Trina Species 0.000 description 1
- 101100162206 Aspergillus parasiticus (strain ATCC 56775 / NRRL 5862 / SRRC 143 / SU-1) aflJ gene Proteins 0.000 description 1
- 241001018157 B4virus Species 0.000 description 1
- 101150068401 BSL1 gene Proteins 0.000 description 1
- 101150011571 BSL2 gene Proteins 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101000862550 Bacillus subtilis (strain 168) 30S ribosomal protein S2 Proteins 0.000 description 1
- 101000622947 Bacillus subtilis (strain 168) 30S ribosomal protein S3 Proteins 0.000 description 1
- 101000964198 Bacillus subtilis (strain 168) Aminoglycoside 6-adenylyltransferase Proteins 0.000 description 1
- 101100054919 Bacillus subtilis (strain 168) adeR gene Proteins 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 241000914271 Bacillus virus 1 Species 0.000 description 1
- 241001378428 Bacillus virus 250 Species 0.000 description 1
- 241000689033 Bacillus virus AP50 Species 0.000 description 1
- 241000889763 Bacillus virus Agate Species 0.000 description 1
- 241000701897 Bacillus virus B103 Species 0.000 description 1
- 241001011699 Bacillus virus B4 Species 0.000 description 1
- 241000192220 Bacillus virus BCP78 Species 0.000 description 1
- 241000192217 Bacillus virus BCP82 Species 0.000 description 1
- 241000192216 Bacillus virus BM15 Species 0.000 description 1
- 241000220039 Bacillus virus BPS13 Species 0.000 description 1
- 241000682932 Bacillus virus Bam35 Species 0.000 description 1
- 241001011614 Bacillus virus Bastille Species 0.000 description 1
- 241000192205 Bacillus virus Bc431 Species 0.000 description 1
- 241001011700 Bacillus virus Bigbertha Species 0.000 description 1
- 241000426174 Bacillus virus Blastoid Species 0.000 description 1
- 241000889765 Bacillus virus Bobb Species 0.000 description 1
- 241000889759 Bacillus virus Bp8pC Species 0.000 description 1
- 241001013825 Bacillus virus CP51 Species 0.000 description 1
- 241000229294 Bacillus virus Camphawk Species 0.000 description 1
- 241000157329 Bacillus virus Curly Species 0.000 description 1
- 241000192215 Bacillus virus Deepblue Species 0.000 description 1
- 241000157322 Bacillus virus Finn Species 0.000 description 1
- 241001120469 Bacillus virus G Species 0.000 description 1
- 241000724210 Bacillus virus GA1 Species 0.000 description 1
- 241001288241 Bacillus virus Grass Species 0.000 description 1
- 241000220043 Bacillus virus Hakuna Species 0.000 description 1
- 241000482509 Bacillus virus IEBH Species 0.000 description 1
- 241000192222 Bacillus virus JBP901 Species 0.000 description 1
- 241001013826 Bacillus virus JL Species 0.000 description 1
- 241000220041 Bacillus virus Megatron Species 0.000 description 1
- 241001288247 Bacillus virus NIT1 Species 0.000 description 1
- 241000702198 Bacillus virus PBS1 Species 0.000 description 1
- 241001287918 Bacillus virus Page Species 0.000 description 1
- 241001287921 Bacillus virus Palmer Species 0.000 description 1
- 241001287920 Bacillus virus Pascal Species 0.000 description 1
- 241001287923 Bacillus virus Pony Species 0.000 description 1
- 241001287922 Bacillus virus Pookie Species 0.000 description 1
- 241000426199 Bacillus virus Riggi Species 0.000 description 1
- 241001011697 Bacillus virus Riley Species 0.000 description 1
- 241001288245 Bacillus virus SPG24 Species 0.000 description 1
- 241001013823 Bacillus virus Shanette Species 0.000 description 1
- 241001011698 Bacillus virus Spock Species 0.000 description 1
- 241000192219 Bacillus virus TsarBomba Species 0.000 description 1
- 241001272665 Bacillus virus WPh Species 0.000 description 1
- 241001130670 Bacillus virus Wbeta Species 0.000 description 1
- 241000701844 Bacillus virus phi29 Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 108020004513 Bacterial RNA Proteins 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 description 1
- 241000606215 Bacteroides vulgatus Species 0.000 description 1
- MGQLHRYJBWGORO-LLVKDONJSA-N Balofloxacin Chemical compound C1[C@H](NC)CCCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC MGQLHRYJBWGORO-LLVKDONJSA-N 0.000 description 1
- 241000606660 Bartonella Species 0.000 description 1
- 241001518086 Bartonella henselae Species 0.000 description 1
- 241000606108 Bartonella quintana Species 0.000 description 1
- 241001011613 Bastillevirus Species 0.000 description 1
- 241000936098 Bc431virus Species 0.000 description 1
- 241000206770 Bcep22virus Species 0.000 description 1
- 241001258325 Bcep78virus Species 0.000 description 1
- 241001258328 Bcepmuvirus Species 0.000 description 1
- 241000702355 Bdellomicrovirus Species 0.000 description 1
- 241000604933 Bdellovibrio Species 0.000 description 1
- 241000229334 Bdellovibrio virus MH2K Species 0.000 description 1
- 241001589086 Bellapiscis medius Species 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 241001340646 Bicaudaviridae Species 0.000 description 1
- 241000505484 Bignuzvirus Species 0.000 description 1
- 241000929484 Biquartavirus Species 0.000 description 1
- 241000186560 Blautia coccoides Species 0.000 description 1
- 241000157816 Bongovirus Species 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000180135 Borrelia recurrentis Species 0.000 description 1
- 241001148604 Borreliella afzelii Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241001148605 Borreliella garinii Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 208000004020 Brain Abscess Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241000555281 Brevibacillus Species 0.000 description 1
- 241000195487 Brevibacillus virus Abouo Species 0.000 description 1
- 241000195486 Brevibacillus virus Davies Species 0.000 description 1
- 241000195511 Brevibacillus virus Jimmer Species 0.000 description 1
- 241000195512 Brevibacillus virus Osiris Species 0.000 description 1
- 241000186146 Brevibacterium Species 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- 241001509299 Brucella canis Species 0.000 description 1
- 241001148106 Brucella melitensis Species 0.000 description 1
- 241001148111 Brucella suis Species 0.000 description 1
- 241000196268 Brucella virus Tb Species 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 241000986460 Burkholderia virus Bcep22 Species 0.000 description 1
- 241001247370 Burkholderia virus Bcep781 Species 0.000 description 1
- 241000496325 Burkholderia virus BcepC6B Species 0.000 description 1
- 241000078137 Burkholderia virus BcepMu Species 0.000 description 1
- 241001520050 Burkholderia virus Bcepil02 Species 0.000 description 1
- 241001190450 Burkholderia virus Bcepmigl Species 0.000 description 1
- 241000683792 Burkholderia virus DC1 Species 0.000 description 1
- 241000328462 Burkholderia virus phi52237 Species 0.000 description 1
- 241000023373 Burkholderia virus phi6442 Species 0.000 description 1
- 241000023374 Burkholderia virus phiE122 Species 0.000 description 1
- 241001048937 Burkholderia virus phiE125 Species 0.000 description 1
- 241000023375 Burkholderia virus phiE202 Species 0.000 description 1
- 241000023376 Burkholderia virus phiE255 Species 0.000 description 1
- 241001115397 C2virus Species 0.000 description 1
- 108010040467 CRISPR-Associated Proteins Proteins 0.000 description 1
- 101150018129 CSF2 gene Proteins 0.000 description 1
- 101150069031 CSN2 gene Proteins 0.000 description 1
- 102100022511 Cadherin-like protein 26 Human genes 0.000 description 1
- 101100011375 Caenorhabditis elegans egl-4 gene Proteins 0.000 description 1
- 241000589874 Campylobacter fetus Species 0.000 description 1
- 241001146530 Campylobacter virus CP21 Species 0.000 description 1
- 241000462745 Campylobacter virus CP220 Species 0.000 description 1
- 241000148536 Campylobacter virus CP30A Species 0.000 description 1
- 241000756229 Campylobacter virus CP81 Species 0.000 description 1
- 241001591624 Campylobacter virus CPX Species 0.000 description 1
- 241001547418 Campylobacter virus IBB35 Species 0.000 description 1
- 241000277039 Campylobacter virus NCTC12673 Species 0.000 description 1
- 241000173351 Camvirus Species 0.000 description 1
- 241000918666 Candidatus Hamiltonella Species 0.000 description 1
- 108010065839 Capreomycin Proteins 0.000 description 1
- UKXFZNMZXWBSGH-UHFFFAOYSA-N Carbomycin A Natural products COC1C(OC2OC(C)C(OC3CC(C)(O)C(OC(=O)CC(C)C)C(C)O3)C(C2O)N(C)C)C(CC=O)CC(C)C(=O)C=CC4OC4CC(C)OC(=O)CC1C(=O)C UKXFZNMZXWBSGH-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000032840 Catheter-Related Infections Diseases 0.000 description 1
- 241001016057 Cba41virus Species 0.000 description 1
- 241000972271 Cc31virus Species 0.000 description 1
- 241000505491 Cecivirus Species 0.000 description 1
- UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 description 1
- QYQDKDWGWDOFFU-IUODEOHRSA-N Cefotiam Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 241001013827 Cellulophaga virus ST Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000505475 Charlievirus Species 0.000 description 1
- 241000505474 Che8virus Species 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 108091092236 Chimeric RNA Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000505472 Chivirus Species 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 241000229337 Chlamydia virus CPAR39 Species 0.000 description 1
- 241000839428 Chlamydia virus CPG1 Species 0.000 description 1
- 241000839427 Chlamydia virus Chp2 Species 0.000 description 1
- 241000122131 Chlamydiamicrovirus Species 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 102100029297 Cholinephosphotransferase 1 Human genes 0.000 description 1
- 208000008158 Chorioamnionitis Diseases 0.000 description 1
- 241000588919 Citrobacter freundii Species 0.000 description 1
- 241000193497 Citrobacter virus Moogle Species 0.000 description 1
- 241000193495 Citrobacter virus Mordin Species 0.000 description 1
- 102100038445 Claudin-2 Human genes 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000051660 Clostridium virus phiC2 Species 0.000 description 1
- 241001605829 Clostridium virus phiCD119 Species 0.000 description 1
- 241000551684 Clostridium virus phiCD27 Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 101001023092 Condylactis gigantea Delta-actitoxin-Cps1a Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000173393 Coopervirus Species 0.000 description 1
- 241000701520 Corticoviridae Species 0.000 description 1
- 241000701558 Corticovirus Species 0.000 description 1
- 241000186226 Corynebacterium glutamicum Species 0.000 description 1
- 241000186245 Corynebacterium xerosis Species 0.000 description 1
- 241000945802 Cp220virus Species 0.000 description 1
- 241001013828 Cp51virus Species 0.000 description 1
- 241000945800 Cp8virus Species 0.000 description 1
- 241000956381 Cr3virus Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000956624 Cronobacter virus CR3 Species 0.000 description 1
- 241000956601 Cronobacter virus CR8 Species 0.000 description 1
- 241000956602 Cronobacter virus CR9 Species 0.000 description 1
- 241000776098 Cronobacter virus Esp2949-1 Species 0.000 description 1
- 241000871931 Cronusvirus Species 0.000 description 1
- 241000928573 Cutibacterium Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000702221 Cystoviridae Species 0.000 description 1
- 241000702216 Cystovirus Species 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 101150115013 DSP1 gene Proteins 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 241001187099 Dickeya Species 0.000 description 1
- 241001470217 Dickeya virus Limestone Species 0.000 description 1
- 101100447194 Dictyostelium discoideum fslA gene Proteins 0.000 description 1
- 241000983824 Dinoroseobacter Species 0.000 description 1
- JWCSIUVGFCSJCK-CAVRMKNVSA-N Disodium Moxalactam Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CO[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C1=CC=C(O)C=C1 JWCSIUVGFCSJCK-CAVRMKNVSA-N 0.000 description 1
- 101100234002 Drosophila melanogaster Shal gene Proteins 0.000 description 1
- 101100322244 Drosophila melanogaster nAChRbeta1 gene Proteins 0.000 description 1
- 101100116914 Drosophila melanogaster shv gene Proteins 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 241000194096 Ea214virus Species 0.000 description 1
- 241000168445 Ea92virus Species 0.000 description 1
- 241000148521 Edwardsiella virus MSW3 Species 0.000 description 1
- 241000148520 Edwardsiella virus PEi21 Species 0.000 description 1
- 241000169868 Edwardsiella virus eiAU Species 0.000 description 1
- 241000605314 Ehrlichia Species 0.000 description 1
- 241000605312 Ehrlichia canis Species 0.000 description 1
- 241000605310 Ehrlichia chaffeensis Species 0.000 description 1
- 241000169871 Eiauvirus Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000195505 Elvirus Species 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000972363 Enterobacter virus PG7 Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241001074631 Enterococcus virus phiEC24C Species 0.000 description 1
- 241000195484 Erwinia virus Deimos Species 0.000 description 1
- 241001124525 Erwinia virus Ea214 Species 0.000 description 1
- 241000168447 Erwinia virus Ea9-2 Species 0.000 description 1
- 241000191545 Erwinia virus Era103 Species 0.000 description 1
- 241000168465 Erwinia virus Frozen Species 0.000 description 1
- 241000193517 Erwinia virus M7 Species 0.000 description 1
- 241000195502 Erwinia virus Simmy50 Species 0.000 description 1
- 101100218161 Escherichia coli (strain K12) atpG gene Proteins 0.000 description 1
- 101100394050 Escherichia coli (strain K12) gyrB gene Proteins 0.000 description 1
- 101100053236 Escherichia coli (strain K12) ymcE gene Proteins 0.000 description 1
- 101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 description 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
- 241001618099 Escherichia coli S88 Species 0.000 description 1
- 241001446387 Escherichia coli UTI89 Species 0.000 description 1
- 101100434464 Escherichia coli afaD gene Proteins 0.000 description 1
- 101100186924 Escherichia coli neuC gene Proteins 0.000 description 1
- 101100242761 Escherichia coli papGI gene Proteins 0.000 description 1
- 101100242764 Escherichia coli papGIII gene Proteins 0.000 description 1
- 101100540144 Escherichia phage 186 apl gene Proteins 0.000 description 1
- 241000935963 Escherichia phage AR1 Species 0.000 description 1
- 241000220975 Escherichia virus 172-1 Species 0.000 description 1
- 241001147440 Escherichia virus 186 Species 0.000 description 1
- 241000130352 Escherichia virus 191 Species 0.000 description 1
- 241000130350 Escherichia virus 24B Species 0.000 description 1
- 241000956622 Escherichia virus 4MG Species 0.000 description 1
- 241000130349 Escherichia virus 933W Species 0.000 description 1
- 241000414630 Escherichia virus ACGM12 Species 0.000 description 1
- 241001243067 Escherichia virus AHP42 Species 0.000 description 1
- 241001243073 Escherichia virus AKS96 Species 0.000 description 1
- 241001246369 Escherichia virus APEC5 Species 0.000 description 1
- 241001246367 Escherichia virus APEC7 Species 0.000 description 1
- 241000047486 Escherichia virus BZ13 Species 0.000 description 1
- 241001246371 Escherichia virus Bp4 Species 0.000 description 1
- 241000954095 Escherichia virus Bp7 Species 0.000 description 1
- 241000216961 Escherichia virus CBA120 Species 0.000 description 1
- 241000972364 Escherichia virus CC31 Species 0.000 description 1
- 241001013661 Escherichia virus CVM10 Species 0.000 description 1
- 241001243076 Escherichia virus E41c Species 0.000 description 1
- 241001124784 Escherichia virus EC6 Species 0.000 description 1
- 241000220976 Escherichia virus ECB2 Species 0.000 description 1
- 241001246373 Escherichia virus ECBP1 Species 0.000 description 1
- 241000217363 Escherichia virus ECML4 Species 0.000 description 1
- 241000132101 Escherichia virus EK99P1 Species 0.000 description 1
- 241001243079 Escherichia virus Eb49 Species 0.000 description 1
- 241000956367 Escherichia virus FFH2 Species 0.000 description 1
- 241001534152 Escherichia virus FI Species 0.000 description 1
- 241000956366 Escherichia virus FV3 Species 0.000 description 1
- 241000229352 Escherichia virus G4 Species 0.000 description 1
- 241001246365 Escherichia virus G7C Species 0.000 description 1
- 241000731869 Escherichia virus HK578 Species 0.000 description 1
- 241000193515 Escherichia virus HY02 Species 0.000 description 1
- 241000414565 Escherichia virus ID21 Species 0.000 description 1
- 241000414561 Escherichia virus ID32 Species 0.000 description 1
- 241000890077 Escherichia virus ID52 Species 0.000 description 1
- 241000414597 Escherichia virus ID62 Species 0.000 description 1
- 241000954099 Escherichia virus IME08 Species 0.000 description 1
- 241001246375 Escherichia virus IME11 Species 0.000 description 1
- 241001124515 Escherichia virus JH2 Species 0.000 description 1
- 241000773343 Escherichia virus JL1 Species 0.000 description 1
- 241000708448 Escherichia virus JMPW1 Species 0.000 description 1
- 241000708447 Escherichia virus JMPW2 Species 0.000 description 1
- 241000954096 Escherichia virus JS10 Species 0.000 description 1
- 241001287791 Escherichia virus JenP2 Species 0.000 description 1
- 241000712697 Escherichia virus K1E Species 0.000 description 1
- 241000945638 Escherichia virus K1H Species 0.000 description 1
- 241000191512 Escherichia virus K30 Species 0.000 description 1
- 241000567137 Escherichia virus K5 Species 0.000 description 1
- 241001243084 Escherichia virus KP26 Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 241000047479 Escherichia virus MS2 Species 0.000 description 1
- 241000130359 Escherichia virus Min27 Species 0.000 description 1
- 241000702189 Escherichia virus Mu Species 0.000 description 1
- 241000124092 Escherichia virus N15 Species 0.000 description 1
- 241000701838 Escherichia virus N4 Species 0.000 description 1
- 241000414564 Escherichia virus NC28 Species 0.000 description 1
- 241000414563 Escherichia virus NC29 Species 0.000 description 1
- 241000414566 Escherichia virus NC35 Species 0.000 description 1
- 241000702192 Escherichia virus P2 Species 0.000 description 1
- 241000130357 Escherichia virus PA2 Species 0.000 description 1
- 241000130358 Escherichia virus PA28 Species 0.000 description 1
- 241001534160 Escherichia virus Qbeta Species 0.000 description 1
- 241001288375 Escherichia virus Rogue1 Species 0.000 description 1
- 241001080512 Escherichia virus Rtp Species 0.000 description 1
- 241000779477 Escherichia virus SSL2009a Species 0.000 description 1
- 241000194099 Escherichia virus SUSP1 Species 0.000 description 1
- 241000194098 Escherichia virus SUSP2 Species 0.000 description 1
- 241000130361 Escherichia virus Stx2 II Species 0.000 description 1
- 241000191543 Escherichia virus T7 Species 0.000 description 1
- 241000130355 Escherichia virus TL2011 Species 0.000 description 1
- 241000193513 Escherichia virus TP1 Species 0.000 description 1
- 241000890078 Escherichia virus Talmos Species 0.000 description 1
- 241000956384 Escherichia virus V5 Species 0.000 description 1
- 241000414567 Escherichia virus WA45 Species 0.000 description 1
- 241001477104 Escherichia virus Wphi Species 0.000 description 1
- 241000132083 Escherichia virus YD2008s Species 0.000 description 1
- 241000414595 Escherichia virus alpha3 Species 0.000 description 1
- 241001013662 Escherichia virus ep3 Species 0.000 description 1
- 241000702317 Escherichia virus phiK Species 0.000 description 1
- 241000702315 Escherichia virus phiX174 Species 0.000 description 1
- 241001124524 Escherichia virus wV8 Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 241000272186 Falco columbarius Species 0.000 description 1
- 102100021064 Fibroblast growth factor receptor substrate 3 Human genes 0.000 description 1
- 101710126873 Fibroblast growth factor receptor substrate 3 Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241001530491 Fibrovirus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000157778 Fishburnevirus Species 0.000 description 1
- 101710163168 Flavin-dependent monooxygenase Proteins 0.000 description 1
- 101150031761 Flnc gene Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000701367 Fuselloviridae Species 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 241000889791 G4microvirus Species 0.000 description 1
- 241000169869 Gaiavirus Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 101000722833 Geobacillus stearothermophilus 30S ribosomal protein S16 Proteins 0.000 description 1
- 241000171042 Gilesvirus Species 0.000 description 1
- 241001136687 Globuloviridae Species 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000169862 Gordonia virus Demosthenes Species 0.000 description 1
- 241000170813 Gordonia virus GordTnk2 Species 0.000 description 1
- 241000169289 Gordonia virus Hotorobo Species 0.000 description 1
- 241000169863 Gordonia virus Katyusha Species 0.000 description 1
- 241000169861 Gordonia virus Kvothe Species 0.000 description 1
- 241000169316 Gordonia virus Monty Species 0.000 description 1
- 241000708451 Gordonia virus Vendetta Species 0.000 description 1
- 241000169317 Gordonia virus Woes Species 0.000 description 1
- 241000171050 Gordonvirus Species 0.000 description 1
- AIJTTZAVMXIJGM-UHFFFAOYSA-N Grepafloxacin Chemical compound C1CNC(C)CN1C(C(=C1C)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 AIJTTZAVMXIJGM-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241001664989 Guttaviridae Species 0.000 description 1
- 241001530478 Habenivirus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000702204 Haemophilus virus HP1 Species 0.000 description 1
- 241000027040 Haemophilus virus HP2 Species 0.000 description 1
- 101100500479 Hafnia alvei eaeA gene Proteins 0.000 description 1
- 241000148516 Halobacterium virus phiH Species 0.000 description 1
- 241000658605 Halomonas virus HAP1 Species 0.000 description 1
- 241001261720 Hapunavirus Species 0.000 description 1
- 241000170824 Harrisonvirus Species 0.000 description 1
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 description 1
- 101710121697 Heat-stable enterotoxin Proteins 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000217351 Helicobacter virus KHP30 Species 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 101000796047 Homo sapiens AP-2 complex subunit mu Proteins 0.000 description 1
- 101000899450 Homo sapiens Cadherin-like protein 26 Proteins 0.000 description 1
- 101000859570 Homo sapiens Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 description 1
- 101000909313 Homo sapiens Carnitine O-palmitoyltransferase 2, mitochondrial Proteins 0.000 description 1
- 101000989606 Homo sapiens Cholinephosphotransferase 1 Proteins 0.000 description 1
- 101000882901 Homo sapiens Claudin-2 Proteins 0.000 description 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 1
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 description 1
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 description 1
- 101000588145 Homo sapiens Microtubule-associated tumor suppressor 1 Proteins 0.000 description 1
- 101001139122 Homo sapiens Nucleoporin NUP35 Proteins 0.000 description 1
- 101000983850 Homo sapiens Phosphatidate phosphatase LPIN3 Proteins 0.000 description 1
- 101001135344 Homo sapiens Polypyrimidine tract-binding protein 1 Proteins 0.000 description 1
- 101000710013 Homo sapiens Reversion-inducing cysteine-rich protein with Kazal motifs Proteins 0.000 description 1
- 101000820585 Homo sapiens SUN domain-containing ossification factor Proteins 0.000 description 1
- 101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 1
- 101000701440 Homo sapiens Stanniocalcin-1 Proteins 0.000 description 1
- 101000701446 Homo sapiens Stanniocalcin-2 Proteins 0.000 description 1
- 101000673946 Homo sapiens Synaptotagmin-like protein 1 Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 101000800312 Homo sapiens TERF1-interacting nuclear factor 2 Proteins 0.000 description 1
- 101000651211 Homo sapiens Transcription factor PU.1 Proteins 0.000 description 1
- 101000837866 Homo sapiens Transforming growth factor-beta receptor type 3-like protein Proteins 0.000 description 1
- 206010020429 Human ehrlichiosis Diseases 0.000 description 1
- 241000243251 Hydra Species 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 241000702394 Inoviridae Species 0.000 description 1
- 241000702377 Inovirus Species 0.000 description 1
- 102100039904 Integrin alpha-D Human genes 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 1
- MIFYHUACUWQUKT-UHFFFAOYSA-N Isopenicillin N Natural products OC(=O)C1C(C)(C)SC2C(NC(=O)CCCC(N)C(O)=O)C(=O)N21 MIFYHUACUWQUKT-UHFFFAOYSA-N 0.000 description 1
- 241000170821 Jenstvirus Species 0.000 description 1
- 241000890148 Jerseyvirus Species 0.000 description 1
- 241000195503 Jimmervirus Species 0.000 description 1
- 241000954196 Js98virus Species 0.000 description 1
- 241001070681 Kayvirus Species 0.000 description 1
- 101100123074 Klebsiella pneumoniae pulC gene Proteins 0.000 description 1
- 241001245866 Klebsiella virus 1513 Species 0.000 description 1
- 241001246636 Klebsiella virus F19 Species 0.000 description 1
- 241000193564 Klebsiella virus JD18 Species 0.000 description 1
- 241001246637 Klebsiella virus K244 Species 0.000 description 1
- 241000191511 Klebsiella virus K5 Species 0.000 description 1
- 241000191517 Klebsiella virus KP32 Species 0.000 description 1
- 241001246640 Klebsiella virus KP34 Species 0.000 description 1
- 241001245865 Klebsiella virus KP36 Species 0.000 description 1
- 241000148525 Klebsiella virus Kp2 Species 0.000 description 1
- 241000191516 Klebsiella virus KpV289 Species 0.000 description 1
- 241000148528 Klebsiella virus KpV41 Species 0.000 description 1
- 241000148534 Klebsiella virus KpV475 Species 0.000 description 1
- 241000148527 Klebsiella virus KpV71 Species 0.000 description 1
- 241001246642 Klebsiella virus SU503 Species 0.000 description 1
- 241001246644 Klebsiella virus SU552A Species 0.000 description 1
- 241000132140 Klebsiella virus Sushi Species 0.000 description 1
- 241000588752 Kluyvera Species 0.000 description 1
- 241000191514 Kp32virus Species 0.000 description 1
- 241001246639 Kp34virus Species 0.000 description 1
- 241001245864 Kp36virus Species 0.000 description 1
- 241000186809 Kurthia Species 0.000 description 1
- 241001112472 L5virus Species 0.000 description 1
- XAGMUUZPGZWTRP-ZETCQYMHSA-N LSM-5745 Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1C1(N)CC1 XAGMUUZPGZWTRP-ZETCQYMHSA-N 0.000 description 1
- 241001112693 Lachnospiraceae Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186685 Lactobacillus hilgardii Species 0.000 description 1
- 241000186684 Lactobacillus pentosus Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241001193631 Lactobacillus virus LLKu Species 0.000 description 1
- 241001208406 Lactobacillus virus LP65 Species 0.000 description 1
- 241001104871 Lactobacillus virus Lb338-1 Species 0.000 description 1
- 241000132078 Lactobacillus virus Ld25A Species 0.000 description 1
- 241000390350 Lactobacillus virus c5 Species 0.000 description 1
- 241000132088 Lactobacillus virus phiLdb Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 101710115990 Lens fiber membrane intrinsic protein Proteins 0.000 description 1
- 102100026038 Lens fiber membrane intrinsic protein Human genes 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241000589929 Leptospira interrogans Species 0.000 description 1
- 241001135196 Leptospira noguchii Species 0.000 description 1
- 241001135198 Leptospira santarosai Species 0.000 description 1
- 241001135200 Leptospira weilii Species 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 241000029590 Leptotrichia wadei Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000192129 Leuconostoc lactis Species 0.000 description 1
- 241000714210 Leviviridae Species 0.000 description 1
- 241000714216 Levivirus Species 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 241001530480 Lineavirus Species 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 241000701365 Lipothrixviridae Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 241000123769 Listeria virus A511 Species 0.000 description 1
- 241001287779 Listeria virus LP110 Species 0.000 description 1
- 241001287778 Listeria virus LP114 Species 0.000 description 1
- 241001287777 Listeria virus LP26 Species 0.000 description 1
- 241001287776 Listeria virus LP37 Species 0.000 description 1
- 241000310423 Listeria virus P100 Species 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 241001445982 Lithophragma glabrum Species 0.000 description 1
- 241000146522 Luz24virus Species 0.000 description 1
- 241000168506 Luz7virus Species 0.000 description 1
- 241000193386 Lysinibacillus sphaericus Species 0.000 description 1
- 241000148513 M12virus Species 0.000 description 1
- 101150115300 MAC1 gene Proteins 0.000 description 1
- 101150108881 MAM1 gene Proteins 0.000 description 1
- 101150031278 MP gene Proteins 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 108050005735 Maltoporin Proteins 0.000 description 1
- 241000168685 Mannheimia virus PHL101 Species 0.000 description 1
- 241001442495 Mantophasmatodea Species 0.000 description 1
- 241000148514 Marthavirus Species 0.000 description 1
- 102100025129 Mastermind-like protein 1 Human genes 0.000 description 1
- 102100025096 Mesothelin Human genes 0.000 description 1
- 241000202974 Methanobacterium Species 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 241000192701 Microcystis Species 0.000 description 1
- 241000702318 Microviridae Species 0.000 description 1
- DMUAPQTXSSNEDD-QALJCMCCSA-N Midecamycin Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C DMUAPQTXSSNEDD-QALJCMCCSA-N 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 241000193499 Mooglevirus Species 0.000 description 1
- 241000193587 Moonvirus Species 0.000 description 1
- 241000588772 Morganella morganii Species 0.000 description 1
- 241000148515 Msw3virus Species 0.000 description 1
- 101150082137 Mtrr gene Proteins 0.000 description 1
- 241000170159 Mudcatvirus Species 0.000 description 1
- 101100434972 Mus musculus Ankrd17 gene Proteins 0.000 description 1
- 101100385662 Mus musculus Cul9 gene Proteins 0.000 description 1
- 101001034321 Mus musculus Lactadherin Proteins 0.000 description 1
- 101100460976 Mus musculus Nrif1 gene Proteins 0.000 description 1
- 101001067830 Mus musculus Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 description 1
- 241001112536 Muvirus Species 0.000 description 1
- 241001502334 Mycobacterium avium complex bacterium Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000187917 Mycobacterium ulcerans Species 0.000 description 1
- 241000141165 Mycobacterium virus 244 Species 0.000 description 1
- 241000166738 Mycobacterium virus Adawi Species 0.000 description 1
- 241000173075 Mycobacterium virus Apizium Species 0.000 description 1
- 241001322469 Mycobacterium virus Ardmore Species 0.000 description 1
- 241001287232 Mycobacterium virus Arturo Species 0.000 description 1
- 241001190444 Mycobacterium virus Astro Species 0.000 description 1
- 241000173064 Mycobacterium virus Athena Species 0.000 description 1
- 241000176287 Mycobacterium virus Avani Species 0.000 description 1
- 241000995576 Mycobacterium virus BAKA Species 0.000 description 1
- 241001159571 Mycobacterium virus Babsiella Species 0.000 description 1
- 241000170607 Mycobacterium virus Barnyard Species 0.000 description 1
- 241000995081 Mycobacterium virus Bask21 Species 0.000 description 1
- 241000162176 Mycobacterium virus Boomer Species 0.000 description 1
- 241000166734 Mycobacterium virus BrownCNA Species 0.000 description 1
- 241000836824 Mycobacterium virus Brujita Species 0.000 description 1
- 241001208443 Mycobacterium virus Che8 Species 0.000 description 1
- 241001208561 Mycobacterium virus Che9c Species 0.000 description 1
- 241001208556 Mycobacterium virus Che9d Species 0.000 description 1
- 241000166451 Mycobacterium virus Chrisnmich Species 0.000 description 1
- 241001208457 Mycobacterium virus Cjw1 Species 0.000 description 1
- 241001159670 Mycobacterium virus DeadP Species 0.000 description 1
- 241001653331 Mycobacterium virus Doom Species 0.000 description 1
- 241000043795 Mycobacterium virus Dorothy Species 0.000 description 1
- 241001569753 Mycobacterium virus DotProduct Species 0.000 description 1
- 241000762725 Mycobacterium virus Drago Species 0.000 description 1
- 241001274761 Mycobacterium virus EricB Species 0.000 description 1
- 241000762706 Mycobacterium virus Eureka Species 0.000 description 1
- 241001246361 Mycobacterium virus Ff47 Species 0.000 description 1
- 241001159635 Mycobacterium virus Firecracker Species 0.000 description 1
- 241000157763 Mycobacterium virus Fishburne Species 0.000 description 1
- 241000852955 Mycobacterium virus Fruitloop Species 0.000 description 1
- 241000752601 Mycobacterium virus GUmbie Species 0.000 description 1
- 241000171041 Mycobacterium virus Gaia Species 0.000 description 1
- 241000995240 Mycobacterium virus George Species 0.000 description 1
- 241000171043 Mycobacterium virus Giles Species 0.000 description 1
- 241000141172 Mycobacterium virus Halo Species 0.000 description 1
- 241000995101 Mycobacterium virus Hammer Species 0.000 description 1
- 241000959828 Mycobacterium virus HelDan Species 0.000 description 1
- 241000995096 Mycobacterium virus Ibhubesi Species 0.000 description 1
- 241000091783 Mycobacterium virus Jasper Species 0.000 description 1
- 241000157800 Mycobacterium virus Jebeks Species 0.000 description 1
- 241000995253 Mycobacterium virus JoeDirt Species 0.000 description 1
- 241000995098 Mycobacterium virus KSSJEB Species 0.000 description 1
- 241000170608 Mycobacterium virus Konstantine Species 0.000 description 1
- 241000162177 Mycobacterium virus Kostya Species 0.000 description 1
- 241000995052 Mycobacterium virus Lesedi Species 0.000 description 1
- 241000141171 Mycobacterium virus Llij Species 0.000 description 1
- 241000157802 Mycobacterium virus Malithi Species 0.000 description 1
- 241001287352 Mycobacterium virus Marcell Species 0.000 description 1
- 241000995213 Mycobacterium virus Microwolf Species 0.000 description 1
- 241000995057 Mycobacterium virus Mozy Species 0.000 description 1
- 241001019737 Mycobacterium virus MrGordo Species 0.000 description 1
- 241001246362 Mycobacterium virus Muddy Species 0.000 description 1
- 241000995055 Mycobacterium virus Museum Species 0.000 description 1
- 241000959844 Mycobacterium virus Optimus Species 0.000 description 1
- 241000173082 Mycobacterium virus Osmaximus Species 0.000 description 1
- 241000141191 Mycobacterium virus PMC Species 0.000 description 1
- 241000852934 Mycobacterium virus Pacc40 Species 0.000 description 1
- 241000995216 Mycobacterium virus PackMan Species 0.000 description 1
- 241000794463 Mycobacterium virus Perseus Species 0.000 description 1
- 241000173062 Mycobacterium virus Pipefish Species 0.000 description 1
- 241000162175 Mycobacterium virus Porky Species 0.000 description 1
- 241000170605 Mycobacterium virus Predator Species 0.000 description 1
- 241000091792 Mycobacterium virus Pukovnik Species 0.000 description 1
- 241000557098 Mycobacterium virus Pumpkin Species 0.000 description 1
- 241000852935 Mycobacterium virus Ramsey Species 0.000 description 1
- 241000043801 Mycobacterium virus Rebeuca Species 0.000 description 1
- 241000173040 Mycobacterium virus Reprobate Species 0.000 description 1
- 241000838367 Mycobacterium virus Ridgecb Species 0.000 description 1
- 241000995212 Mycobacterium virus RockyHorror Species 0.000 description 1
- 241000856759 Mycobacterium virus Rosebush Species 0.000 description 1
- 241001144016 Mycobacterium virus Rumpelstiltskin Species 0.000 description 1
- 241001159633 Mycobacterium virus SG4 Species 0.000 description 1
- 241001569770 Mycobacterium virus Saintus Species 0.000 description 1
- 241000856772 Mycobacterium virus Sebata Species 0.000 description 1
- 241000522999 Mycobacterium virus Shilan Species 0.000 description 1
- 241000522998 Mycobacterium virus Sirduracell Species 0.000 description 1
- 241000522993 Mycobacterium virus Spartacus Species 0.000 description 1
- 241000237275 Mycobacterium virus Suffolk Species 0.000 description 1
- 241000522995 Mycobacterium virus Taj Species 0.000 description 1
- 241000522990 Mycobacterium virus Tiger Species 0.000 description 1
- 241000522983 Mycobacterium virus Toto Species 0.000 description 1
- 241000522979 Mycobacterium virus Tweety Species 0.000 description 1
- 241000522973 Mycobacterium virus Wee Species 0.000 description 1
- 241000522970 Mycobacterium virus Wildcat Species 0.000 description 1
- 241001621171 Mycobacterium virus Wonder Species 0.000 description 1
- 241000995177 Mycobacterium virus Yoshi Species 0.000 description 1
- 241000166475 Mycobacterium virus Zemanar Species 0.000 description 1
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 description 1
- 241000202936 Mycoplasma mycoides Species 0.000 description 1
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 description 1
- 241000438342 Myohalovirus Species 0.000 description 1
- 206010051458 Myometritis Diseases 0.000 description 1
- 241000701553 Myoviridae Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- GWBPFRGXNGPPMF-UHFFFAOYSA-N N-[4-[(4-nitrophenyl)sulfamoyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1S(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1 GWBPFRGXNGPPMF-UHFFFAOYSA-N 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- QSDSSSQWVNLFIG-UHFFFAOYSA-N Neosporin Natural products CC(O)CC1=C(OC)C(=O)C2=CC(O)=C3OCOC4=C(O)C=C5C6=C4C3=C2C1=C6C(CC(C)O)=C(OC)C5=O QSDSSSQWVNLFIG-UHFFFAOYSA-N 0.000 description 1
- 101100385413 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) csm-3 gene Proteins 0.000 description 1
- 101100462611 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) prr-1 gene Proteins 0.000 description 1
- 206010029443 Nocardia Infections Diseases 0.000 description 1
- 206010029444 Nocardiosis Diseases 0.000 description 1
- 241001431261 Nonlabens Species 0.000 description 1
- 241000170898 Nonlabens virus P12024S Species 0.000 description 1
- 102100020682 Nucleoporin NUP35 Human genes 0.000 description 1
- 108090000119 Nucleotidyltransferases Proteins 0.000 description 1
- 102000003832 Nucleotidyltransferases Human genes 0.000 description 1
- 241000192134 Oenococcus oeni Species 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 239000004104 Oleandomycin Substances 0.000 description 1
- RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 description 1
- 101100171146 Oryza sativa subsp. japonica DREB2C gene Proteins 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 241001112539 P22virus Species 0.000 description 1
- 241000505493 P23virus Species 0.000 description 1
- 241001234870 P2virus Species 0.000 description 1
- 241001643397 P2virus sp. Species 0.000 description 1
- 241001261955 P68virus Species 0.000 description 1
- 101150020457 PBC1 gene Proteins 0.000 description 1
- 241000170825 Paenibacillus virus Harrison Species 0.000 description 1
- 241000305433 Paenibacillus virus Vegas Species 0.000 description 1
- 241001287919 Pagevirus Species 0.000 description 1
- 241001286751 Pakpunavirus Species 0.000 description 1
- 241000170577 Pamx74virus Species 0.000 description 1
- 241000191515 Pantoea virus Limelight Species 0.000 description 1
- 241000191533 Pantoea virus Limezero Species 0.000 description 1
- 241000606210 Parabacteroides distasonis Species 0.000 description 1
- 206010033847 Parametritis Diseases 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- 241000122116 Parvimonas Species 0.000 description 1
- 241001464887 Parvimonas micra Species 0.000 description 1
- 241000697377 Pasteurella virus F108 Species 0.000 description 1
- 241000531155 Pectobacterium Species 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 101100082836 Pediococcus acidilactici pedC gene Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- XVASOOUVMJAZNJ-MBNYWOFBSA-N Penicillin K Chemical compound S1C(C)(C)[C@H](C(O)=O)N2C(=O)[C@@H](NC(=O)CCCCCCC)[C@H]21 XVASOOUVMJAZNJ-MBNYWOFBSA-N 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- 101710202686 Penicillin-sensitive transpeptidase Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 241000170602 Pepy6virus Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 241000157772 Phayoncevirus Species 0.000 description 1
- 241001261872 Phieco32virus Species 0.000 description 1
- 241000505511 Phifelvirus Species 0.000 description 1
- 102100025728 Phosphatidate phosphatase LPIN3 Human genes 0.000 description 1
- 101710124951 Phospholipase C Proteins 0.000 description 1
- 241000170630 Pis4avirus Species 0.000 description 1
- 241000701369 Plasmaviridae Species 0.000 description 1
- 241000701370 Plasmavirus Species 0.000 description 1
- 241000702210 Plectrovirus Species 0.000 description 1
- 241000935659 Pleolipoviridae Species 0.000 description 1
- 101000827750 Pleurodeles waltl Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 241000130324 Pocjvirus Species 0.000 description 1
- 241000702072 Podoviridae Species 0.000 description 1
- 241000512254 Polaribacter Species 0.000 description 1
- 241000170881 Polaribacter virus P12002L Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 241000985694 Polypodiopsida Species 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 241001135213 Porphyromonas endodontalis Species 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 241000191530 Pradovirus Species 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 241001135221 Prevotella intermedia Species 0.000 description 1
- 241001135225 Prevotella nigrescens Species 0.000 description 1
- 241000120981 Prochlorococcus virus PSSP7 Species 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 241000170915 Propionibacterium virus ATCC29399BC Species 0.000 description 1
- 241000170912 Propionibacterium virus ATCC29399BT Species 0.000 description 1
- 241000170913 Propionibacterium virus Attacne Species 0.000 description 1
- 241001524659 Propionibacterium virus B5 Species 0.000 description 1
- 241000170910 Propionibacterium virus Kubed Species 0.000 description 1
- 241000170905 Propionibacterium virus Lauchelly Species 0.000 description 1
- 241000170907 Propionibacterium virus MrAK Species 0.000 description 1
- 241000170927 Propionibacterium virus Ouroboros Species 0.000 description 1
- 241000170737 Propionibacterium virus P100D Species 0.000 description 1
- 241000170934 Propionibacterium virus P91 Species 0.000 description 1
- 241000170736 Propionibacterium virus PA6 Species 0.000 description 1
- 241000170744 Propionibacterium virus PAD20 Species 0.000 description 1
- 241000170752 Propionibacterium virus PHL009M11 Species 0.000 description 1
- 241000170753 Propionibacterium virus PHL025M00 Species 0.000 description 1
- 241000170750 Propionibacterium virus PHL037M02 Species 0.000 description 1
- 241000170751 Propionibacterium virus PHL041M10 Species 0.000 description 1
- 241000170749 Propionibacterium virus PHL067M01 Species 0.000 description 1
- 241000170754 Propionibacterium virus PHL092M00 Species 0.000 description 1
- 241000170755 Propionibacterium virus PHL095N00 Species 0.000 description 1
- 241000170762 Propionibacterium virus PHL111M01 Species 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000588768 Providencia Species 0.000 description 1
- PWNMXPDKBYZCOO-UHFFFAOYSA-N Prulifloxacin Chemical compound C1=C2N3C(C)SC3=C(C(O)=O)C(=O)C2=CC(F)=C1N(CC1)CCN1CC=1OC(=O)OC=1C PWNMXPDKBYZCOO-UHFFFAOYSA-N 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000701550 Pseudoalteromonas virus PM2 Species 0.000 description 1
- 101100280248 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) exoS gene Proteins 0.000 description 1
- 101100237386 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) mexR gene Proteins 0.000 description 1
- 101100135758 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) pchB gene Proteins 0.000 description 1
- 241000709748 Pseudomonas phage PRR1 Species 0.000 description 1
- 101100385759 Pseudomonas putida pchC gene Proteins 0.000 description 1
- 241000754449 Pseudomonas virus 119X Species 0.000 description 1
- 241000856794 Pseudomonas virus 141 Species 0.000 description 1
- 241001348709 Pseudomonas virus Ab03 Species 0.000 description 1
- 241001246670 Pseudomonas virus Ab09 Species 0.000 description 1
- 241000607111 Pseudomonas virus Ab22 Species 0.000 description 1
- 241000856791 Pseudomonas virus Ab28 Species 0.000 description 1
- 241001286754 Pseudomonas virus CAb02 Species 0.000 description 1
- 241000607112 Pseudomonas virus CHU Species 0.000 description 1
- 241001428540 Pseudomonas virus D3 Species 0.000 description 1
- 241000702136 Pseudomonas virus D3112 Species 0.000 description 1
- 241000856778 Pseudomonas virus DL60 Species 0.000 description 1
- 241000856790 Pseudomonas virus DL68 Species 0.000 description 1
- 241000572044 Pseudomonas virus DMS3 Species 0.000 description 1
- 241000195504 Pseudomonas virus EL Species 0.000 description 1
- 241000856793 Pseudomonas virus F8 Species 0.000 description 1
- 241001512094 Pseudomonas virus FHA0480 Species 0.000 description 1
- 241000157706 Pseudomonas virus H66 Species 0.000 description 1
- 241001286578 Pseudomonas virus JG004 Species 0.000 description 1
- 241000856789 Pseudomonas virus JG024 Species 0.000 description 1
- 241001348708 Pseudomonas virus KPP10 Species 0.000 description 1
- 241000856792 Pseudomonas virus KPP12 Species 0.000 description 1
- 241000168507 Pseudomonas virus KPP21 Species 0.000 description 1
- 241000168501 Pseudomonas virus KPP25 Species 0.000 description 1
- 241000856812 Pseudomonas virus LBL3 Species 0.000 description 1
- 241001246668 Pseudomonas virus LIT1 Species 0.000 description 1
- 241000191532 Pseudomonas virus LKA1 Species 0.000 description 1
- 241000856814 Pseudomonas virus LMA2 Species 0.000 description 1
- 241001471649 Pseudomonas virus LPB1 Species 0.000 description 1
- 241000222627 Pseudomonas virus LUZ24 Species 0.000 description 1
- 241000168504 Pseudomonas virus LUZ7 Species 0.000 description 1
- 241000754455 Pseudomonas virus M6 Species 0.000 description 1
- 241000132149 Pseudomonas virus MP1412 Species 0.000 description 1
- 241000928733 Pseudomonas virus MP22 Species 0.000 description 1
- 241000347288 Pseudomonas virus MP29 Species 0.000 description 1
- 241000347287 Pseudomonas virus MP38 Species 0.000 description 1
- 241000170884 Pseudomonas virus NP1 Species 0.000 description 1
- 241000314836 Pseudomonas virus PA1KOR Species 0.000 description 1
- 241001246669 Pseudomonas virus PA26 Species 0.000 description 1
- 241000980335 Pseudomonas virus PA7 Species 0.000 description 1
- 241000607110 Pseudomonas virus PAA2 Species 0.000 description 1
- 241000132132 Pseudomonas virus PAE1 Species 0.000 description 1
- 241001286576 Pseudomonas virus PAKP1 Species 0.000 description 1
- 241001348707 Pseudomonas virus PAKP3 Species 0.000 description 1
- 241001286582 Pseudomonas virus PAKP4 Species 0.000 description 1
- 241000856813 Pseudomonas virus PB1 Species 0.000 description 1
- 241000398389 Pseudomonas virus PMG1 Species 0.000 description 1
- 241001131732 Pseudomonas virus PaP3 Species 0.000 description 1
- 241000607108 Pseudomonas virus PaP4 Species 0.000 description 1
- 241000168508 Pseudomonas virus R18 Species 0.000 description 1
- 241000856815 Pseudomonas virus SN Species 0.000 description 1
- 241000607109 Pseudomonas virus TL Species 0.000 description 1
- 241001123776 Pseudomonas virus Yua Species 0.000 description 1
- 241000702217 Pseudomonas virus phi6 Species 0.000 description 1
- 241001493116 Pseudomonas virus phiCTX Species 0.000 description 1
- 241000191531 Pseudomonas virus phiKMV Species 0.000 description 1
- 241000438345 Pseudomonas virus phiKZ Species 0.000 description 1
- 241001113245 Psimunavirus Species 0.000 description 1
- NYBZAGXTZXPYND-UHFFFAOYSA-N Pyochelin I Natural products S1CC(C(O)=O)N(C)C1C1N=C(C=2C(=CC=CC=2)O)SC1 NYBZAGXTZXPYND-UHFFFAOYSA-N 0.000 description 1
- 241000205160 Pyrococcus Species 0.000 description 1
- 241001148023 Pyrococcus abyssi Species 0.000 description 1
- 101150004182 RER2 gene Proteins 0.000 description 1
- 230000007022 RNA scission Effects 0.000 description 1
- 241001162422 Ralstonia virus PE226 Species 0.000 description 1
- 241001532445 Ralstonia virus RS603 Species 0.000 description 1
- 241000651549 Ralstonia virus RSA1 Species 0.000 description 1
- 241000148503 Ralstonia virus RSF1 Species 0.000 description 1
- 241000148501 Ralstonia virus RSL1 Species 0.000 description 1
- 241000148504 Ralstonia virus RSL2 Species 0.000 description 1
- 241001532446 Ralstonia virus RSM1 Species 0.000 description 1
- 241001532447 Ralstonia virus RSM3 Species 0.000 description 1
- 241001162385 Ralstonia virus RSS1 Species 0.000 description 1
- 101000836070 Rattus norvegicus Serine protease inhibitor A3L Proteins 0.000 description 1
- 241000972264 Rb49virus Species 0.000 description 1
- 241000972265 Rb69virus Species 0.000 description 1
- 241000170640 Rdjlvirus Species 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 1
- 241000170639 Rer2virus Species 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000505885 Reyvirus Species 0.000 description 1
- 241001286161 Rheph4virus Species 0.000 description 1
- 101100327931 Rhizobium meliloti (strain 1021) chvG gene Proteins 0.000 description 1
- 101100280251 Rhizobium meliloti (strain 1021) exoU gene Proteins 0.000 description 1
- 241001286167 Rhizobium virus RHEph4 Species 0.000 description 1
- 241000871959 Rhodobacter virus RcCronus Species 0.000 description 1
- 241001317442 Rhodococcus virus RGL3 Species 0.000 description 1
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 description 1
- 206010039207 Rocky Mountain Spotted Fever Diseases 0.000 description 1
- 241000173044 Rosebushvirus Species 0.000 description 1
- 108700043532 RpoB Proteins 0.000 description 1
- 241000148499 Rslunavirus Species 0.000 description 1
- 241000040592 Rudiviridae Species 0.000 description 1
- NJCJBUHJQLFDSW-UHFFFAOYSA-N Rufloxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 NJCJBUHJQLFDSW-UHFFFAOYSA-N 0.000 description 1
- 241000134861 Ruminococcus sp. Species 0.000 description 1
- 241000972266 S16virus Species 0.000 description 1
- 101150071725 SMDT1 gene Proteins 0.000 description 1
- 102100021651 SUN domain-containing ossification factor Human genes 0.000 description 1
- 241001530486 Saetivirus Species 0.000 description 1
- 102100037204 Sal-like protein 1 Human genes 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241001287793 Salmonella virus 9NA Species 0.000 description 1
- 241000868024 Salmonella virus AG11 Species 0.000 description 1
- 241000010174 Salmonella virus BTP1 Species 0.000 description 1
- 241001541326 Salmonella virus Chi Species 0.000 description 1
- 241000216957 Salmonella virus Det7 Species 0.000 description 1
- 241000456882 Salmonella virus FSLSP030 Species 0.000 description 1
- 241000456873 Salmonella virus FSLSP088 Species 0.000 description 1
- 241001466751 Salmonella virus Fels2 Species 0.000 description 1
- 241001124517 Salmonella virus HB2014 Species 0.000 description 1
- 241000011473 Salmonella virus HK620 Species 0.000 description 1
- 241001532392 Salmonella virus IKe Species 0.000 description 1
- 241000867984 Salmonella virus L13 Species 0.000 description 1
- 241000217365 Salmonella virus Marshall Species 0.000 description 1
- 241000217373 Salmonella virus Maynard Species 0.000 description 1
- 241001124521 Salmonella virus Mushroom Species 0.000 description 1
- 241000724851 Salmonella virus PsP3 Species 0.000 description 1
- 241000956628 Salmonella virus SE1 Species 0.000 description 1
- 241000867983 Salmonella virus SETP13 Species 0.000 description 1
- 241000220886 Salmonella virus SFP10 Species 0.000 description 1
- 241000220887 Salmonella virus SH19 Species 0.000 description 1
- 241000216959 Salmonella virus SJ2 Species 0.000 description 1
- 241000217370 Salmonella virus SJ3 Species 0.000 description 1
- 241001287775 Salmonella virus SP069 Species 0.000 description 1
- 241000867977 Salmonella virus SP101 Species 0.000 description 1
- 241000456843 Salmonella virus SP126 Species 0.000 description 1
- 241001468001 Salmonella virus SP6 Species 0.000 description 1
- 241001010516 Salmonella virus SPN19 Species 0.000 description 1
- 241000168480 Salmonella virus SPN1S Species 0.000 description 1
- 241000195515 Salmonella virus SPN3US Species 0.000 description 1
- 241000867149 Salmonella virus SS3e Species 0.000 description 1
- 241000956630 Salmonella virus SSE121 Species 0.000 description 1
- 241000719857 Salmonella virus ST64T Species 0.000 description 1
- 241000217367 Salmonella virus STML131 Species 0.000 description 1
- 241000986978 Salmonella virus SopEphi Species 0.000 description 1
- 241001124518 Salmonella virus UAB87 Species 0.000 description 1
- 241001558040 Salmonella virus iEPS5 Species 0.000 description 1
- 241000867152 Salmonella virus wksl3 Species 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 241001053778 Salterprovirus Species 0.000 description 1
- 241000505884 Sap6virus Species 0.000 description 1
- 108010084592 Saporins Proteins 0.000 description 1
- 229910017841 Sb—I Inorganic materials 0.000 description 1
- 101100351802 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pfl6 gene Proteins 0.000 description 1
- 101100478275 Schizosaccharomyces pombe (strain 972 / ATCC 24843) spt8 gene Proteins 0.000 description 1
- 241001258322 Schizot4virus Species 0.000 description 1
- 241001286165 Secunda5virus Species 0.000 description 1
- 241000605036 Selenomonas Species 0.000 description 1
- 241000168388 Send513virus Species 0.000 description 1
- 241001285958 Septima3virus Species 0.000 description 1
- 101710142113 Serine protease inhibitor A3K Proteins 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241001223867 Shewanella oneidensis Species 0.000 description 1
- 108010079723 Shiga Toxin Proteins 0.000 description 1
- 108010090763 Shiga Toxin 2 Proteins 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 241000130360 Shigella virus 7502Stx Species 0.000 description 1
- 241000220889 Shigella virus AG3 Species 0.000 description 1
- 241000130353 Shigella virus POCJ13 Species 0.000 description 1
- 241001288367 Shigella virus PSf2 Species 0.000 description 1
- 241000701869 Shigella virus Sf6 Species 0.000 description 1
- 241000148517 Shigella virus SfMu Species 0.000 description 1
- 241000130378 Shigella virus VASD Species 0.000 description 1
- 244000166071 Shorea robusta Species 0.000 description 1
- 235000015076 Shorea robusta Nutrition 0.000 description 1
- 239000000589 Siderophore Substances 0.000 description 1
- 241001070769 Silviavirus Species 0.000 description 1
- 241000148518 Sinorhizobium virus M12 Species 0.000 description 1
- 241000148519 Sinorhizobium virus M7 Species 0.000 description 1
- 241000148523 Sinorhizobium virus N3 Species 0.000 description 1
- 229930192786 Sisomicin Natural products 0.000 description 1
- 241001286904 Slashvirus Species 0.000 description 1
- 241001660101 Sodalis Species 0.000 description 1
- 101100497209 Solanum lycopersicum CPT4 gene Proteins 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 241000168417 Soupsvirus Species 0.000 description 1
- 241000118315 Sp6virus Species 0.000 description 1
- 241000399119 Spio Species 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 241000702345 Spiromicrovirus Species 0.000 description 1
- 241000202917 Spiroplasma Species 0.000 description 1
- 241001524676 Spiroplasma virus C74 Species 0.000 description 1
- 241001524674 Spiroplasma virus R8A2B Species 0.000 description 1
- 241001162393 Spiroplasma virus SVTS2 Species 0.000 description 1
- 241000702363 Spiroplasma virus SpV4 Species 0.000 description 1
- 241001287291 Ssp2virus Species 0.000 description 1
- 102100030511 Stanniocalcin-1 Human genes 0.000 description 1
- 102100030510 Stanniocalcin-2 Human genes 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- 241001399465 Staphylococcus virus 108PVL Species 0.000 description 1
- 241001586731 Staphylococcus virus 3a Species 0.000 description 1
- 241001613944 Staphylococcus virus 42e Species 0.000 description 1
- 241001435321 Staphylococcus virus 77 Species 0.000 description 1
- 241001307091 Staphylococcus virus G15 Species 0.000 description 1
- 241001232319 Staphylococcus virus IPLA35 Species 0.000 description 1
- 241000148511 Staphylococcus virus IPLAC1C Species 0.000 description 1
- 241001307131 Staphylococcus virus JD7 Species 0.000 description 1
- 241000239110 Staphylococcus virus K Species 0.000 description 1
- 241001307092 Staphylococcus virus MCE2014 Species 0.000 description 1
- 241001070773 Staphylococcus virus Remus Species 0.000 description 1
- 241000148537 Staphylococcus virus Rodi Species 0.000 description 1
- 241000148539 Staphylococcus virus S25-4 Species 0.000 description 1
- 241001307089 Staphylococcus virus S253 Species 0.000 description 1
- 241000954605 Staphylococcus virus SA11 Species 0.000 description 1
- 241001307117 Staphylococcus virus SA12 Species 0.000 description 1
- 241000148512 Staphylococcus virus SEP1 Species 0.000 description 1
- 241000641150 Staphylococcus virus Stau2 Species 0.000 description 1
- 241001105562 Staphylococcus virus phi12 Species 0.000 description 1
- 241000886175 Staphylococcus virus phiSLT Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241001286169 Stenotrophomonas virus IME13 Species 0.000 description 1
- 241001162421 Stenotrophomonas virus PSH1 Species 0.000 description 1
- 241001162387 Stenotrophomonas virus SMA6 Species 0.000 description 1
- 241001162380 Stenotrophomonas virus SMA7 Species 0.000 description 1
- 241001162399 Stenotrophomonas virus SMA9 Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 101000910035 Streptococcus pyogenes serotype M1 CRISPR-associated endonuclease Cas9/Csn1 Proteins 0.000 description 1
- 101100129180 Streptococcus pyogenes serotype M5 emm5 gene Proteins 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 101000910045 Streptococcus thermophilus (strain ATCC BAA-491 / LMD-9) CRISPR-associated endonuclease Cas9 2 Proteins 0.000 description 1
- 241001312524 Streptococcus viridans Species 0.000 description 1
- 241000168477 Streptococcus virus Cp7 Species 0.000 description 1
- 108010034396 Streptogramins Proteins 0.000 description 1
- 241000719745 Streptomyces phaechromogenes Species 0.000 description 1
- 101001091349 Streptomyces ribosidificus Aminoglycoside 3'-phosphotransferase Proteins 0.000 description 1
- 241000173357 Streptomyces virus Aaronocolus Species 0.000 description 1
- 241000173361 Streptomyces virus Amela Species 0.000 description 1
- 241000173359 Streptomyces virus Caliburn Species 0.000 description 1
- 241000173379 Streptomyces virus ELB20 Species 0.000 description 1
- 241000173370 Streptomyces virus Lannister Species 0.000 description 1
- 241000173387 Streptomyces virus Lika Species 0.000 description 1
- 241000169298 Streptomyces virus TP1604 Species 0.000 description 1
- 241000169292 Streptomyces virus YDN12 Species 0.000 description 1
- 206010042343 Subcutaneous abscess Diseases 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 101000870046 Sus scrofa Glutamate dehydrogenase 1, mitochondrial Proteins 0.000 description 1
- 241000194097 Suspvirus Species 0.000 description 1
- 241001641711 Synechococcus virus P60 Species 0.000 description 1
- 241000113207 Synechococcus virus Syn5 Species 0.000 description 1
- 241000192584 Synechocystis Species 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000143014 T7virus Species 0.000 description 1
- 102100035213 TATA box-binding protein-associated factor RNA polymerase I subunit C Human genes 0.000 description 1
- 102220538234 TATA box-binding protein-associated factor RNA polymerase I subunit C_P52A_mutation Human genes 0.000 description 1
- 102100033085 TERF1-interacting nuclear factor 2 Human genes 0.000 description 1
- 241000168412 Tankvirus Species 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 241000701521 Tectiviridae Species 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- 101000870232 Tenebrio molitor Diuretic hormone 1 Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 241000589596 Thermus Species 0.000 description 1
- 241001166290 Thermus virus P23-45 Species 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- 241000168453 Titanvirus Species 0.000 description 1
- 241001245868 Tlsvirus Species 0.000 description 1
- 241000505887 Tm4virus Species 0.000 description 1
- 206010044314 Tracheobronchitis Diseases 0.000 description 1
- 241000982634 Tragelaphus eurycerus Species 0.000 description 1
- 102100027654 Transcription factor PU.1 Human genes 0.000 description 1
- 102100028568 Transforming growth factor-beta receptor type 3-like protein Human genes 0.000 description 1
- 101800000385 Transmembrane protein Proteins 0.000 description 1
- 241000589892 Treponema denticola Species 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000192221 Tsarbombavirus Species 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 241001070682 Twortvirus Species 0.000 description 1
- 239000004182 Tylosin Substances 0.000 description 1
- 229930194936 Tylosin Natural products 0.000 description 1
- 241001467018 Typhis Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000202898 Ureaplasma Species 0.000 description 1
- 241000202921 Ureaplasma urealyticum Species 0.000 description 1
- 241000956383 V5virus Species 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 241001530487 Vespertiliovirus Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 241001249853 Vibrio virus CTXphi Species 0.000 description 1
- 241001223301 Vibrio virus K139 Species 0.000 description 1
- 241001162389 Vibrio virus KSF1 Species 0.000 description 1
- 241000576600 Vibrio virus Kappa Species 0.000 description 1
- 241001282549 Vibrio virus MAR Species 0.000 description 1
- 241001162395 Vibrio virus VCY Species 0.000 description 1
- 241001532395 Vibrio virus VFJ Species 0.000 description 1
- 241001530482 Vibrio virus VGJ Species 0.000 description 1
- 241001282547 Vibrio virus VHML Species 0.000 description 1
- 241001282517 Vibrio virus VP585 Species 0.000 description 1
- 241000036036 Vibrio virus VP882 Species 0.000 description 1
- 241000593562 Vibrio virus Vf33 Species 0.000 description 1
- 241001467184 Vibrio virus VpV262 Species 0.000 description 1
- 241001532399 Vibrio virus fs2 Species 0.000 description 1
- 244000172533 Viola sororia Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 102100038968 WAP four-disulfide core domain protein 1 Human genes 0.000 description 1
- 241000505892 Wbetavirus Species 0.000 description 1
- 241000048138 Xanthomonas virus OP1 Species 0.000 description 1
- 241001469323 Xanthomonas virus Xop411 Species 0.000 description 1
- 241000191529 Xanthomonas virus f20 Species 0.000 description 1
- 241000191548 Xanthomonas virus f30 Species 0.000 description 1
- 241001476582 Xanthomonas virus phil7 Species 0.000 description 1
- 101001128833 Xenopus laevis Nuclear distribution protein nudE homolog 1-A Proteins 0.000 description 1
- 101100191375 Xenopus laevis prkra-b gene Proteins 0.000 description 1
- 241000191547 Xylella virus Prado Species 0.000 description 1
- 229920002000 Xyloglucan Polymers 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 101100395365 Yersinia enterocolitica serotype O:8 / biotype 1B (strain NCTC 13174 / 8081) irp2 gene Proteins 0.000 description 1
- 101100053619 Yersinia enterocolitica yscF gene Proteins 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- 241000316277 Yersinia virus L413C Species 0.000 description 1
- 241001286899 Yersinia virus R1RT Species 0.000 description 1
- 101100023962 Zea mays VP15 gene Proteins 0.000 description 1
- 241000588902 Zymomonas mobilis Species 0.000 description 1
- FQVHOULQCKDUCY-OGHXVOSASA-N [(2s,3s,4r,6s)-6-[(2r,3s,4r,5r,6s)-6-[[(1s,3r,7r,8s,9s,10r,12r,14e,16s)-7-acetyloxy-8-methoxy-3,12-dimethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2,4-dimeth Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@H]1[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/[C@@H]2O[C@H]2C[C@@H](C)OC(=O)C[C@H]([C@@H]1OC)OC(C)=O)[C@H]1C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O1 FQVHOULQCKDUCY-OGHXVOSASA-N 0.000 description 1
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 1
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 description 1
- 241000186569 [Clostridium] leptum Species 0.000 description 1
- 241001531189 [Eubacterium] siraeum Species 0.000 description 1
- 101150116772 aatA gene Proteins 0.000 description 1
- PENDGIOBPJLVBT-HMMOOPTJSA-N abt-773 Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@]1(C)OC\C=C\C=1C=C2C=CC=CC2=NC=1)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O PENDGIOBPJLVBT-HMMOOPTJSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 101150066706 acrA gene Proteins 0.000 description 1
- 101150004068 acrB gene Proteins 0.000 description 1
- 101150079343 acrR gene Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000013086 acute epiglottitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229950008644 adicillin Drugs 0.000 description 1
- 229960000919 alatrofloxacin Drugs 0.000 description 1
- UUZPPAMZDFLUHD-VUJLHGSVSA-N alatrofloxacin Chemical compound C([C@@H]1[C@H]([C@@H]1C1)NC(=O)[C@H](C)NC(=O)[C@@H](N)C)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F UUZPPAMZDFLUHD-VUJLHGSVSA-N 0.000 description 1
- 229950008560 almecillin Drugs 0.000 description 1
- 239000002776 alpha toxin Substances 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 108010082008 aminoglycoside 2''-phosphotransferase Proteins 0.000 description 1
- 108010002000 aminoglycoside 2'-N-acetyltransferase Proteins 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 101150015540 apxIIC gene Proteins 0.000 description 1
- 108010039311 arabinosyltransferase Proteins 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- VLAXZGHHBIJLAD-UHFFFAOYSA-N arsphenamine Chemical compound [Cl-].[Cl-].C1=C(O)C([NH3+])=CC([As]=[As]C=2C=C([NH3+])C(O)=CC=2)=C1 VLAXZGHHBIJLAD-UHFFFAOYSA-N 0.000 description 1
- 229940003446 arsphenamine Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 101150005925 aspC gene Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 229960002699 bacampicillin Drugs 0.000 description 1
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 201000007032 bacterial conjunctivitis Diseases 0.000 description 1
- 229950000805 balofloxacin Drugs 0.000 description 1
- 229940092524 bartonella henselae Drugs 0.000 description 1
- 229940092523 bartonella quintana Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 101150009149 bfpA gene Proteins 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 1
- 108010089894 bradykinin potentiating factors Proteins 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940056450 brucella abortus Drugs 0.000 description 1
- 229940038698 brucella melitensis Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 229960003972 cefacetrile Drugs 0.000 description 1
- RRYMAQUWDLIUPV-BXKDBHETSA-N cefacetrile Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC#N)[C@@H]12 RRYMAQUWDLIUPV-BXKDBHETSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229950004030 cefaloglycin Drugs 0.000 description 1
- FUBBGQLTSCSAON-PBFPGSCMSA-N cefaloglycin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)C)C(O)=O)=CC=CC=C1 FUBBGQLTSCSAON-PBFPGSCMSA-N 0.000 description 1
- 229950005258 cefalonium Drugs 0.000 description 1
- 229950001373 cefaloram Drugs 0.000 description 1
- GOFCPYKUMJBHBH-RHSMWYFYSA-N cefaloram Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CC=C1 GOFCPYKUMJBHBH-RHSMWYFYSA-N 0.000 description 1
- 229960003866 cefaloridine Drugs 0.000 description 1
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229950000042 cefaparole Drugs 0.000 description 1
- 229960004350 cefapirin Drugs 0.000 description 1
- 229960002420 cefatrizine Drugs 0.000 description 1
- ACXMTAJLYQCRGF-PBFPGSCMSA-N cefatrizine Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC1=CN=N[N]1 ACXMTAJLYQCRGF-PBFPGSCMSA-N 0.000 description 1
- 229950004359 cefazaflur Drugs 0.000 description 1
- HGXLJRWXCXSEJO-GMSGAONNSA-N cefazaflur Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CSC(F)(F)F)[C@H]2SC1 HGXLJRWXCXSEJO-GMSGAONNSA-N 0.000 description 1
- 229960005312 cefazedone Drugs 0.000 description 1
- VTLCNEGVSVJLDN-MLGOLLRUSA-N cefazedone Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3C=C(Cl)C(=O)C(Cl)=C3)[C@H]2SC1 VTLCNEGVSVJLDN-MLGOLLRUSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960001817 cefbuperazone Drugs 0.000 description 1
- SMSRCGPDNDCXFR-CYWZMYCQSA-N cefbuperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H]([C@H](C)O)C(=O)N[C@]1(OC)C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 SMSRCGPDNDCXFR-CYWZMYCQSA-N 0.000 description 1
- 229950002706 cefcanel Drugs 0.000 description 1
- 229960002966 cefcapene Drugs 0.000 description 1
- HJJRIJDTIPFROI-NVKITGPLSA-N cefcapene Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=C/CC)C1=CSC(N)=N1 HJJRIJDTIPFROI-NVKITGPLSA-N 0.000 description 1
- JUVHVMCKLDZLGN-TVNFHGJBSA-N cefclidin Chemical compound N([C@@H]1C(N2C(=C(C[N+]34CCC(CC3)(CC4)C(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=NSC(N)=N1 JUVHVMCKLDZLGN-TVNFHGJBSA-N 0.000 description 1
- 229950006550 cefdaloxime Drugs 0.000 description 1
- HOGISBSFFHDTRM-GHXIOONMSA-N cefdaloxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/O)\C1=CSC(N)=N1 HOGISBSFFHDTRM-GHXIOONMSA-N 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- 229960004069 cefditoren Drugs 0.000 description 1
- KMIPKYQIOVAHOP-YLGJWRNMSA-N cefditoren Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C KMIPKYQIOVAHOP-YLGJWRNMSA-N 0.000 description 1
- 229950007281 cefedrolor Drugs 0.000 description 1
- 229950009347 cefempidone Drugs 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- 229960004041 cefetamet Drugs 0.000 description 1
- MQLRYUCJDNBWMV-GHXIOONMSA-N cefetamet Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 MQLRYUCJDNBWMV-GHXIOONMSA-N 0.000 description 1
- 229950003098 cefetrizole Drugs 0.000 description 1
- 229950007546 cefivitril Drugs 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229950001334 cefluprenam Drugs 0.000 description 1
- XAKKNLNAJBNLPC-MAYKBZFQSA-N cefluprenam Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)/C=C/C[N+](C)(CC)CC(N)=O)C([O-])=O)C(=O)C(=N/OCF)\C1=NSC(N)=N1 XAKKNLNAJBNLPC-MAYKBZFQSA-N 0.000 description 1
- 229950008727 cefmatilen Drugs 0.000 description 1
- UEQVTKSAEXANEZ-YCRCPZNHSA-N cefmatilen Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(SCSC4=NNN=C4)CS[C@@H]32)C(O)=O)=O)=C1 UEQVTKSAEXANEZ-YCRCPZNHSA-N 0.000 description 1
- 229960003791 cefmenoxime Drugs 0.000 description 1
- HJJDBAOLQAWBMH-YCRCPZNHSA-N cefmenoxime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C HJJDBAOLQAWBMH-YCRCPZNHSA-N 0.000 description 1
- 229960003585 cefmetazole Drugs 0.000 description 1
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 description 1
- 229960002025 cefminox Drugs 0.000 description 1
- JSDXOWVAHXDYCU-VXSYNFHWSA-N cefminox Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSC[C@@H](N)C(O)=O)OC)CC=1CSC1=NN=NN1C JSDXOWVAHXDYCU-VXSYNFHWSA-N 0.000 description 1
- 229960001958 cefodizime Drugs 0.000 description 1
- XDZKBRJLTGRPSS-BGZQYGJUSA-N cefodizime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(C)=C(CC(O)=O)S1 XDZKBRJLTGRPSS-BGZQYGJUSA-N 0.000 description 1
- 229960004489 cefonicid Drugs 0.000 description 1
- DYAIAHUQIPBDIP-AXAPSJFSSA-N cefonicid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS(O)(=O)=O DYAIAHUQIPBDIP-AXAPSJFSSA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229950001580 cefoselis Drugs 0.000 description 1
- ZINFAXPQMLDEEJ-GFVOIPPFSA-N cefoselis Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CN1C=CC(=N)N1CCO ZINFAXPQMLDEEJ-GFVOIPPFSA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 229960001242 cefotiam Drugs 0.000 description 1
- 229960003391 cefovecin Drugs 0.000 description 1
- ZJGQFXVQDVCVOK-MSUXKOGISA-N cefovecin Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1[C@@H]1CCCO1 ZJGQFXVQDVCVOK-MSUXKOGISA-N 0.000 description 1
- 229950002823 cefoxazole Drugs 0.000 description 1
- QDUIJCOKQCCXQY-WHJQOFBOSA-N cefozopran Chemical compound N([C@@H]1C(N2C(=C(CN3C4=CC=CN=[N+]4C=C3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=NSC(N)=N1 QDUIJCOKQCCXQY-WHJQOFBOSA-N 0.000 description 1
- 229960002642 cefozopran Drugs 0.000 description 1
- 229950004036 cefpimizole Drugs 0.000 description 1
- LNZMRLHZGOBKAN-KAWPREARSA-N cefpimizole Chemical compound N1=CNC(C(=O)N[C@@H](C(=O)N[C@@H]2C(N3C(=C(C[N+]=4C=CC(CCS(O)(=O)=O)=CC=4)CS[C@@H]32)C([O-])=O)=O)C=2C=CC=CC=2)=C1C(=O)O LNZMRLHZGOBKAN-KAWPREARSA-N 0.000 description 1
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 description 1
- 229960000466 cefpirome Drugs 0.000 description 1
- 229960005090 cefpodoxime Drugs 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 229950009592 cefquinome Drugs 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- 229950003685 cefrotil Drugs 0.000 description 1
- 229960003844 cefroxadine Drugs 0.000 description 1
- RDMOROXKXONCAL-UEKVPHQBSA-N cefroxadine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)OC)C(O)=O)=CCC=CC1 RDMOROXKXONCAL-UEKVPHQBSA-N 0.000 description 1
- OFKRKCHCYWQZLY-XHBSWPGZSA-N cefsumide Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC(NS(C)(=O)=O)=C1 OFKRKCHCYWQZLY-XHBSWPGZSA-N 0.000 description 1
- 229950010594 cefsumide Drugs 0.000 description 1
- 229940036735 ceftaroline Drugs 0.000 description 1
- ZCCUWMICIWSJIX-NQJJCJBVSA-N ceftaroline fosamil Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OCC)C=2N=C(NP(O)(O)=O)SN=2)CC=1SC(SC=1)=NC=1C1=CC=[N+](C)C=C1 ZCCUWMICIWSJIX-NQJJCJBVSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 229950000679 cefteram Drugs 0.000 description 1
- 229960004366 ceftezole Drugs 0.000 description 1
- DZMVCVMFETWNIU-LDYMZIIASA-N ceftezole Chemical compound O=C([C@@H](NC(=O)CN1N=NN=C1)[C@H]1SC2)N1C(C(=O)O)=C2CSC1=NN=CS1 DZMVCVMFETWNIU-LDYMZIIASA-N 0.000 description 1
- 229960004086 ceftibuten Drugs 0.000 description 1
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 description 1
- 229960005229 ceftiofur Drugs 0.000 description 1
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 description 1
- WJXAHFZIHLTPFR-JLRJEBFFSA-N ceftiolene Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C\SC1=NNC(=O)C(=O)N1CC=O WJXAHFZIHLTPFR-JLRJEBFFSA-N 0.000 description 1
- 229950008880 ceftiolene Drugs 0.000 description 1
- 229950007152 ceftioxide Drugs 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- VOAZJEPQLGBXGO-SDAWRPRTSA-N ceftobiprole Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(\C=C/4C(N([C@H]5CNCC5)CC\4)=O)CS[C@@H]32)C(O)=O)=O)=N1 VOAZJEPQLGBXGO-SDAWRPRTSA-N 0.000 description 1
- 229950004259 ceftobiprole Drugs 0.000 description 1
- 229960002405 ceftolozane Drugs 0.000 description 1
- JHFNIHVVXRKLEF-DCZLAGFPSA-N ceftolozane Chemical compound CN1C(N)=C(NC(=O)NCCN)C=[N+]1CC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)C(=N/OC(C)(C)C([O-])=O)\C=3N=C(N)SN=3)[C@H]2SC1 JHFNIHVVXRKLEF-DCZLAGFPSA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229950010799 cefuracetime Drugs 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- CXHKZHZLDMQGFF-ZSDSSEDPSA-N cefuzonam Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=CN=NS1 CXHKZHZLDMQGFF-ZSDSSEDPSA-N 0.000 description 1
- 229950000807 cefuzonam Drugs 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 229950010329 cethromycin Drugs 0.000 description 1
- 201000004308 chancroid Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- DHSUYTOATWAVLW-WFVMDLQDSA-N cilastatin Chemical compound CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O DHSUYTOATWAVLW-WFVMDLQDSA-N 0.000 description 1
- 229960004912 cilastatin Drugs 0.000 description 1
- 229960004621 cinoxacin Drugs 0.000 description 1
- VDUWPHTZYNWKRN-UHFFFAOYSA-N cinoxacin Chemical compound C1=C2N(CC)N=C(C(O)=O)C(=O)C2=CC2=C1OCO2 VDUWPHTZYNWKRN-UHFFFAOYSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 239000009194 citrus pectin Substances 0.000 description 1
- 229940040387 citrus pectin Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229950001320 clinafloxacin Drugs 0.000 description 1
- QGPKADBNRMWEQR-UHFFFAOYSA-N clinafloxacin Chemical compound C1C(N)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl QGPKADBNRMWEQR-UHFFFAOYSA-N 0.000 description 1
- 229960004287 clofazimine Drugs 0.000 description 1
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 108010004171 colibactin Proteins 0.000 description 1
- ZWKHDAZPVITMAI-ROUUACIJSA-N colibactin Chemical compound C[C@H]1CCC(=N1)C1=C(CC(=O)NCC(=O)c2csc(n2)C(=O)C(=O)c2csc(CNC(=O)CC3=C(C(=O)NC33CC3)C3=N[C@@H](C)CC3)n2)C2(CC2)NC1=O ZWKHDAZPVITMAI-ROUUACIJSA-N 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 101150055601 cops2 gene Proteins 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 101150112550 csgA gene Proteins 0.000 description 1
- 101150055700 csgB gene Proteins 0.000 description 1
- 101150095724 csgC gene Proteins 0.000 description 1
- 101150031345 csgD gene Proteins 0.000 description 1
- 101150101046 csgE gene Proteins 0.000 description 1
- 101150044423 csgF gene Proteins 0.000 description 1
- 101150099331 csgG gene Proteins 0.000 description 1
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 1
- 101150028842 ctxA gene Proteins 0.000 description 1
- 101150087320 ctxB gene Proteins 0.000 description 1
- 101150096136 cyaC gene Proteins 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 229960002488 dalbavancin Drugs 0.000 description 1
- 108700009376 dalbavancin Proteins 0.000 description 1
- 229960002615 dalfopristin Drugs 0.000 description 1
- 108700028430 dalfopristin Proteins 0.000 description 1
- SUYRLXYYZQTJHF-VMBLUXKRSA-N dalfopristin Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1 SUYRLXYYZQTJHF-VMBLUXKRSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 229960005484 daptomycin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229950006412 delafloxacin Drugs 0.000 description 1
- DYDCPNMLZGFQTM-UHFFFAOYSA-N delafloxacin Chemical compound C1=C(F)C(N)=NC(N2C3=C(Cl)C(N4CC(O)C4)=C(F)C=C3C(=O)C(C(O)=O)=C2)=C1F DYDCPNMLZGFQTM-UHFFFAOYSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- RWYFURDDADFSHT-RBBHPAOJSA-N diane Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1=C(Cl)C2=CC(=O)[C@@H]3CC3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RWYFURDDADFSHT-RBBHPAOJSA-N 0.000 description 1
- 229960003807 dibekacin Drugs 0.000 description 1
- JJCQSGDBDPYCEO-XVZSLQNASA-N dibekacin Chemical compound O1[C@H](CN)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N JJCQSGDBDPYCEO-XVZSLQNASA-N 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960000895 doripenem Drugs 0.000 description 1
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 108010046161 drug combination polymyxin B neomycin sulfate bacitracin zinc Proteins 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 101150107911 eae gene Proteins 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 229940051998 ehrlichia canis Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 101150094741 eltB gene Proteins 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 229960002457 epicillin Drugs 0.000 description 1
- RPBAFSBGYDKNRG-NJBDSQKTSA-N epicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CCC=CC1 RPBAFSBGYDKNRG-NJBDSQKTSA-N 0.000 description 1
- 208000001606 epiglottitis Diseases 0.000 description 1
- 101150055072 epsA gene Proteins 0.000 description 1
- 229960002770 ertapenem Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 101150055155 espA gene Proteins 0.000 description 1
- 101150006505 estA gene Proteins 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 229960002001 ethionamide Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 101150115756 exoT gene Proteins 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 101150043770 fimA gene Proteins 0.000 description 1
- 101150028805 fimF gene Proteins 0.000 description 1
- 101150015947 fimH gene Proteins 0.000 description 1
- 229960003306 fleroxacin Drugs 0.000 description 1
- XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 description 1
- 229960002878 flomoxef Drugs 0.000 description 1
- UHRBTBZOWWGKMK-DOMZBBRYSA-N flomoxef Chemical compound O([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSC(F)F)OC)CC=1CSC1=NN=NN1CCO UHRBTBZOWWGKMK-DOMZBBRYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 101150064107 fosB gene Proteins 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 101150002737 fyuA gene Proteins 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- XZUIIFPVEPUATO-QXZMDWRJSA-N gap31 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)NCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=C(O)C=C1 XZUIIFPVEPUATO-QXZMDWRJSA-N 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 229960003170 gemifloxacin Drugs 0.000 description 1
- ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960000642 grepafloxacin Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- MCAHMSDENAOJFZ-BVXDHVRPSA-N herbimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-BVXDHVRPSA-N 0.000 description 1
- 229930193320 herbimycin Natural products 0.000 description 1
- 229960003884 hetacillin Drugs 0.000 description 1
- DXVUYOAEDJXBPY-NFFDBFGFSA-N hetacillin Chemical compound C1([C@@H]2C(=O)N(C(N2)(C)C)[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 DXVUYOAEDJXBPY-NFFDBFGFSA-N 0.000 description 1
- 101150039987 hlyC gene Proteins 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000530 impalefection Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 108090000237 interleukin-24 Proteins 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- JYJVVHFRSFVEJM-UHFFFAOYSA-N iodosobenzene Chemical compound O=IC1=CC=CC=C1 JYJVVHFRSFVEJM-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- 229960004144 josamycin Drugs 0.000 description 1
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- 239000003835 ketolide antibiotic agent Substances 0.000 description 1
- 229950007634 kitasamycin Drugs 0.000 description 1
- 101150023351 kpsE gene Proteins 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 229960000433 latamoxef Drugs 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- XYJOGTQLTFNMQG-KJHBSLKPSA-N leucomycin V Chemical compound CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1 XYJOGTQLTFNMQG-KJHBSLKPSA-N 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000001320 lysogenic effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 101150099153 malX gene Proteins 0.000 description 1
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960003806 metampicillin Drugs 0.000 description 1
- FZECHKJQHUVANE-MCYUEQNJSA-N metampicillin Chemical compound C1([C@@H](N=C)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 FZECHKJQHUVANE-MCYUEQNJSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
- 229960002757 midecamycin Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229940041009 monobactams Drugs 0.000 description 1
- 229940076266 morganella morganii Drugs 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 206010028320 muscle necrosis Diseases 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Polymers CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- YKQOSKADJPQZHB-YNWHQGOSSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1s)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Polymers CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O YKQOSKADJPQZHB-YNWHQGOSSA-N 0.000 description 1
- 229960003808 nadifloxacin Drugs 0.000 description 1
- JYJTVFIEFKZWCJ-UHFFFAOYSA-N nadifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)CCC3=C1N1CCC(O)CC1 JYJTVFIEFKZWCJ-UHFFFAOYSA-N 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 229960002353 nemonoxacin Drugs 0.000 description 1
- AVPQPGFLVZTJOR-RYUDHWBXSA-N nemonoxacin Chemical compound COC1=C(N2C[C@@H](N)C[C@H](C)C2)C=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 AVPQPGFLVZTJOR-RYUDHWBXSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229940049337 neosporin Drugs 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000019895 oat fiber Nutrition 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960002351 oleandomycin Drugs 0.000 description 1
- 235000019367 oleandomycin Nutrition 0.000 description 1
- RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 description 1
- 101150093139 ompT gene Proteins 0.000 description 1
- 208000005963 oophoritis Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960001607 oritavancin Drugs 0.000 description 1
- 108010006945 oritavancin Proteins 0.000 description 1
- VHFGEBVPHAGQPI-MYYQHNLBSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-MYYQHNLBSA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960000321 oxolinic acid Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 101150061305 papC gene Proteins 0.000 description 1
- 101150040891 papGII gene Proteins 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 230000007110 pathogen host interaction Effects 0.000 description 1
- 229960002625 pazufloxacin Drugs 0.000 description 1
- 101150098891 pchA gene Proteins 0.000 description 1
- 101150075787 pchD gene Proteins 0.000 description 1
- 101150020987 pchE gene Proteins 0.000 description 1
- 101150084964 pchF gene Proteins 0.000 description 1
- 229960004236 pefloxacin Drugs 0.000 description 1
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- MIFYHUACUWQUKT-GPUHXXMPSA-N penicillin N Chemical compound OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)CCC[C@@H](N)C(O)=O)C(=O)N21 MIFYHUACUWQUKT-GPUHXXMPSA-N 0.000 description 1
- QULKGELYPOJSLP-WCABBAIRSA-N penicillin O Chemical compound OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)CSCC=C)C(=O)N21 QULKGELYPOJSLP-WCABBAIRSA-N 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 238000001066 phage therapy Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 101150014100 pilA gene Proteins 0.000 description 1
- 229960001732 pipemidic acid Drugs 0.000 description 1
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 229960001635 pirlimycin Drugs 0.000 description 1
- 229960004444 piromidic acid Drugs 0.000 description 1
- RCIMBBZXSXFZBV-UHFFFAOYSA-N piromidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCCC1 RCIMBBZXSXFZBV-UHFFFAOYSA-N 0.000 description 1
- 229960003342 pivampicillin Drugs 0.000 description 1
- ZEMIJUDPLILVNQ-ZXFNITATSA-N pivampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OCOC(=O)C(C)(C)C)=CC=CC=C1 ZEMIJUDPLILVNQ-ZXFNITATSA-N 0.000 description 1
- CSOMAHTTWTVBFL-OFBLZTNGSA-N platensimycin Chemical compound C([C@]1([C@@H]2[C@@H]3C[C@@H]4C[C@@]2(C=CC1=O)C[C@@]4(O3)C)C)CC(=O)NC1=C(O)C=CC(C(O)=O)=C1O CSOMAHTTWTVBFL-OFBLZTNGSA-N 0.000 description 1
- CSOMAHTTWTVBFL-UHFFFAOYSA-N platensimycin Natural products O1C2(C)CC3(C=CC4=O)CC2CC1C3C4(C)CCC(=O)NC1=C(O)C=CC(C(O)=O)=C1O CSOMAHTTWTVBFL-UHFFFAOYSA-N 0.000 description 1
- 108010063723 poly-pyrimidine tract binding protein Proteins 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 108010046630 polymyxin B drug combination bacitracin Proteins 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229940041153 polymyxins Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940103255 polysporin Drugs 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229950004447 posizolid Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 229960001224 prulifloxacin Drugs 0.000 description 1
- 101150069622 pvdA gene Proteins 0.000 description 1
- 101150024179 pvdQ gene Proteins 0.000 description 1
- 108010025281 pyoverdin Proteins 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 229960005442 quinupristin Drugs 0.000 description 1
- WTHRRGMBUAHGNI-LCYNINFDSA-N quinupristin Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O WTHRRGMBUAHGNI-LCYNINFDSA-N 0.000 description 1
- 108700028429 quinupristin Proteins 0.000 description 1
- 229950009965 radezolid Drugs 0.000 description 1
- BTTNOGHPGJANSW-IBGZPJMESA-N radezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C1=CC=C(C=2C=CC(CNCC=3NN=NC=3)=CC=2)C(F)=C1 BTTNOGHPGJANSW-IBGZPJMESA-N 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000009754 rhamnogalacturonan I Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229960000885 rifabutin Drugs 0.000 description 1
- 229960002599 rifapentine Drugs 0.000 description 1
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229960003889 rosoxacin Drugs 0.000 description 1
- XBPZXDSZHPDXQU-UHFFFAOYSA-N rosoxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC=C1C1=CC=NC=C1 XBPZXDSZHPDXQU-UHFFFAOYSA-N 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 229960004062 rufloxacin Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229940115939 shigella sonnei Drugs 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 229960005456 sisomicin Drugs 0.000 description 1
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 description 1
- 229960003177 sitafloxacin Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 101150027996 smb1 gene Proteins 0.000 description 1
- 235000013570 smoothie Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 101150090484 stf3 gene Proteins 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 108010041757 streptomycin 6-kinase Proteins 0.000 description 1
- 108010015544 streptothricin acetyltransferase Proteins 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960000973 sulfadimethoxine Drugs 0.000 description 1
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 1
- 229960002135 sulfadimidine Drugs 0.000 description 1
- 229960000468 sulfalene Drugs 0.000 description 1
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- GPTONYMQFTZPKC-UHFFFAOYSA-N sulfamethoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 description 1
- 229960004936 sulfamethoxypyridazine Drugs 0.000 description 1
- VLYWMPOKSSWJAL-UHFFFAOYSA-N sulfamethoxypyridazine Chemical compound N1=NC(OC)=CC=C1NS(=O)(=O)C1=CC=C(N)C=C1 VLYWMPOKSSWJAL-UHFFFAOYSA-N 0.000 description 1
- 229960002229 sulfametoxydiazine Drugs 0.000 description 1
- 229960001363 sulfamoxole Drugs 0.000 description 1
- CYFLXLSBHQBMFT-UHFFFAOYSA-N sulfamoxole Chemical compound O1C(C)=C(C)N=C1NS(=O)(=O)C1=CC=C(N)C=C1 CYFLXLSBHQBMFT-UHFFFAOYSA-N 0.000 description 1
- 229950004215 sulfanitran Drugs 0.000 description 1
- 229960001975 sulfisomidine Drugs 0.000 description 1
- YZMCKZRAOLZXAZ-UHFFFAOYSA-N sulfisomidine Chemical compound CC1=NC(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 YZMCKZRAOLZXAZ-UHFFFAOYSA-N 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960002780 talampicillin Drugs 0.000 description 1
- SOROUYSPFADXSN-SUWVAFIASA-N talampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)OC2C3=CC=CC=C3C(=O)O2)(C)C)=CC=CC=C1 SOROUYSPFADXSN-SUWVAFIASA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 101150065777 tcpN gene Proteins 0.000 description 1
- XFALPSLJIHVRKE-GFCCVEGCSA-N tedizolid Chemical compound CN1N=NC(C=2N=CC(=CC=2)C=2C(=CC(=CC=2)N2C(O[C@@H](CO)C2)=O)F)=N1 XFALPSLJIHVRKE-GFCCVEGCSA-N 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 108010041283 teixobactin Proteins 0.000 description 1
- 229960005240 telavancin Drugs 0.000 description 1
- 108010089019 telavancin Proteins 0.000 description 1
- ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 description 1
- 229960004576 temafloxacin Drugs 0.000 description 1
- 229960001114 temocillin Drugs 0.000 description 1
- BVCKFLJARNKCSS-DWPRYXJFSA-N temocillin Chemical compound N([C@]1(OC)C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C=1C=CSC=1 BVCKFLJARNKCSS-DWPRYXJFSA-N 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- BSMKSTAEJFRBHA-UHFFFAOYSA-N tgl-4 Chemical compound O1C(C2=3)=C(O4)C(O)=CC=3CCNC2CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C1C4=C23 BSMKSTAEJFRBHA-UHFFFAOYSA-N 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 229960003053 thiamphenicol Drugs 0.000 description 1
- OTVAEFIXJLOWRX-NXEZZACHSA-N thiamphenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 101150071242 tolC gene Proteins 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229950008187 tosufloxacin Drugs 0.000 description 1
- 101150104391 traT gene Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 229960005041 troleandomycin Drugs 0.000 description 1
- LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 description 1
- 229960000497 trovafloxacin Drugs 0.000 description 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229960004059 tylosin Drugs 0.000 description 1
- 235000019375 tylosin Nutrition 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
- 229950005850 zabofloxacin Drugs 0.000 description 1
- ZNPOCLHDJCAZAH-UCQKPKSFSA-N zabofloxacin Chemical compound CO\N=C1\CN(C=2C(=CC=3C(=O)C(C(O)=O)=CN(C=3N=2)C2CC2)F)CC11CNC1 ZNPOCLHDJCAZAH-UCQKPKSFSA-N 0.000 description 1
- KGPGQDLTDHGEGT-JCIKCJKQSA-N zeven Chemical compound C=1C([C@@H]2C(=O)N[C@H](C(N[C@H](C3=CC(O)=C4)C(=O)NCCCN(C)C)=O)[C@H](O)C5=CC=C(C(=C5)Cl)OC=5C=C6C=C(C=5O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@H](O5)C(O)=O)NC(=O)CCCCCCCCC(C)C)OC5=CC=C(C=C5)C[C@@H]5C(=O)N[C@H](C(N[C@H]6C(=O)N2)=O)C=2C(Cl)=C(O)C=C(C=2)OC=2C(O)=CC=C(C=2)[C@H](C(N5)=O)NC)=CC=C(O)C=1C3=C4O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O KGPGQDLTDHGEGT-JCIKCJKQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10311—Siphoviridae
- C12N2795/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10311—Siphoviridae
- C12N2795/10341—Use of virus, viral particle or viral elements as a vector
- C12N2795/10342—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10311—Siphoviridae
- C12N2795/10341—Use of virus, viral particle or viral elements as a vector
- C12N2795/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present disclosure relates generally to bacterial delivery vehicles for use in efficient transfer of a desired payload into a target bacterial cell.
- Bacteriophages are parasites that infect and multiply in bacteria. In general, the infection process can be divided in several stages: (i) adsorption corresponding to recognition and binding to the bacterial cell; (ii) injection of the DNA genome into the bacterial cell cytoplasm; (iii) production of a set of viral proteins that can lead to insertion in the host target genome (lysogenic phages) or to the production of infective particles (lytic phages) and (iv) release of mature virions from the infected cell, usually by controlled lysis [1]
- a bacteriophage encodes two main sets of proteins that are involved in the recognition process.
- the first set is able to attach to the bacteriophage’s primary receptor on the cell surface, an event that triggers DNA ejection into the cytoplasm and is usually viewed as an“irreversible” binding process [3].
- Different bacteriophage genera differ in the organization of this set of proteins, and hence the naming can be different. In some Siphovirus, for example, they are called the “central tail fiber” or“tail tip”, which binds irreversibly to the LamB receptor in Escherichia coli.
- the“central tail fiber” or“tail tip” is composed of the protein gpj [4].
- a protein located at the very tip of the tail mediates this process.
- pb5 recognizes the FhuA receptor [5]. This type of protein can be found in many other bacteriophages.
- Myoviruses like T4, the irreversible binding to the primary receptor or to the cell surface in general is mediated by the“short tail fibers”, which are also located at the end of the tail tube [5].
- the second set of proteins in the bacteriophage (herein referred to as“receptor binding proteins”) encodes recognition and binding activities to the so-called“secondary receptor” on the bacterium.
- This secondary receptor allows for transient binding of the phage particle on the cell surface in order to scan the surface and position the first set of proteins in contact with the primary receptor. Since this binding is reversible, it allows the phage to“walk” on the cell surface until a primary receptor is found and the infection process starts.
- These protein complexes are sometimes referred to as“L-shape fibers”, such as in T5,“side tail fibers” such as in lambda,“long tail fibers” as in T4, or tailspikes such as in phage P22 [5]— [8] .
- the presence of this second set of proteins is necessary for the infection process to occur, such as T4 [5].
- this second set of proteins is not strictly necessary for the infection process to happen, but it may allow for a more efficient binding to the target cell [7].
- bacteria can develop multiple ways to avoid being recognized by a bacteriophage. For example, they can mutate the primary or secondary receptor to which the bacteriophage binds; they can mask this receptor by attaching proteins to it (receptor masking); or they can grow physical barriers around them in the form of bacterial capsules, thus blocking any access to the cell surface [9]. Bacteria can produce many different types of extracellular polymeric capsules [10]. In turn, bacteriophages have evolved different strategies to bypass these defense mechanisms. For instance, mutating the tail tip proteins allows them to use a different receptor [11].
- the host range of a packaged phagemid tends to be larger than that of the parental bacteriophage it derives from.
- novel bacterial delivery vehicles designed for the efficient delivery of exogenous DNA payload into target strains, it is of utmost importance to be able to engineer delivery vehicles with desired host ranges as well as the ability to bypass bacterial mechanisms that can lead to unsuccessful binding of the packaged phagemid to the bacterial cell surface.
- a bacteriophage encodes sets of proteins that are involved in the bacterial cell recognition process. Described herein are novel approaches to engineering synthetic bacterial delivery vehicles with desired target host ranges.
- synthetic bacterial delivery vehicles are provided that are characterized by a chimeric receptor binding protein (RBP), wherein the chimeric RBP comprises a fusion between an N-terminal domain of a RBP from a lambda-like bacteriophage, or lambda bacteriophage, and a C-terminal domain of a different bacteriophage RBP.
- RBP chimeric receptor binding protein
- Such bacteriophage RBPs include, for example, and depending on phages families,“L-shape fibers”,“side tail fibers (stfs)”,“long tail fibers” or“tailspikes.”
- a lambda-like bacteriophage receptor binding protein such as a stf protein
- RBP lambda-like bacteriophage receptor binding protein
- the disclosure relates to bacterial delivery vehicles with desired host ranges based on the presence of an engineered branched receptor binding multi-subunit protein complex (“branched- RBP”).
- branched- RBP comprises two or more associated receptor binding proteins derived from bacteriophages, wherein said RBPs contain“interaction domains” (IDs) that mediate association of the different subunits.
- IDs “interaction domains”
- the association of one subunit to another can be non-covalent or covalent.
- the two or more associated RBPs include, but are not limited to, the chimeric receptor binding proteins (RBPs) described herein that comprise a fusion between the N-terminal domain of a RBP derived from a lambda-like, or lambda bacteriophage and the C- terminal domain of a different RBP.
- RBPs chimeric receptor binding proteins
- the chimeric receptor binding protein is one wherein the chimeric RBP comprises a fusion between an N-terminal domain of a RBP derived from a lambda-like bacteriophage, or lambda bacteriophage, and a C-terminal domain of a different RBP wherein said N-terminal domain of the RBP is fused to said C-terminal domain of a different RBP within one of the amino acids regions selected from positions 1-150, 320- 460, or 495-560 of the N-terminal RBP with reference to the lambda stf sequence (SEQ ID NO: 1) or a similar region of a RBP having homology with one or more of three amino acid regions ranging from positions 1-150, 320-460, and 495-560 of the RBP with reference to the lambda stf sequence.
- the different RBP domain of the chimeric receptor binding protein is derived from any bacteriophage or from any bacteriocin.
- the RBP from the lambda-like bacteriophage, or the lambda bacteriophage, or the different RBP contains homology in one or more of three amino acid regions ranging from positions 1-150, 320- 460, or 495-560 of the N-terminal RBP with reference to the lambda bacteriophage stf sequence (SEQ ID NO: 1).
- the homology between the lambda-like bacteriophage, the lambda bacteriophage, or the different RBP and the one or more of three amino acids regions is around 35% identity for 45 amino acids or more, around 50% identify for 30 amino acids or more, and around 90% identity for 18 amino acids or more with reference to the lambda bacteriophage stf sequence (SEQ ID NO:l). Determination of homology can be performed using alignment tools such as the Smith- Waterman algorithm (Smith et ah, 1981, J. Mol. Biol 147:195-197) or EMBOSS Matcher (Rice, Longden, Bleasby 2000 EMBOSS Trends in Genetics 16: 276-277),
- the chimeric RBP comprises the N-terminal domain of a RBP fused to the C-terminal domain of a different RBP within one of the amino acid regions selected from positions 80-150, 320-460, or 495-560 of the N- terminal RBP with reference to the lambda bacteriophage stf sequence (SEQ ID NO:l).
- the chimeric RBP comprises an N-terminal domain and a C-terminal domain fused within one of the amino acids regions selected from positions 1-150, 320-460 or 495-560 at an insertion site having at least 80%, preferably at least 85%, at least 90%, at least 95%, at least 98% or at least 99%, identity with an insertion site selected from the group consisting of amino acids SAGDAS (SEQ ID NO: 190), ADAKKS (SEQ ID NO: 191), MDETNR (SEQ ID NO: 192), S AS AAA (SEQ ID NO: 193), GAGENS (SEQ ID NO: 194), ATLKQI (SEQ ID NO: 195), IIQLED (SEQ ID NO: 196), GNIIDL (SEQ ID NO: 197), IATRV (SEQ ID NO: 198), TPGEL (SEQ ID NO: 199), GAIIN (SEQ ID NO:200), NQIID (SEQ ID NO:201), GQIVN
- the chimeric RBP comprises an N-terminal domain and a C-terminal domain fused within one of the amino acids regions selected from positions 1-150, 320-460 or 495-560 at an insertion site having at least 80%, preferably at least 85%, at least 90%, at least 95%, at least 98% or at least 99%, identity with an insertion site selected from the group consisting of amino acids SAGDAS (SEQ ID NO: 190), ADAKKS (SEQ ID NO: 191), MDETNR (SEQ ID NO: 192), S AS AAA (SEQ ID NO: 193) and GAGENS (SEQ ID NO: 194)
- SAGDAS SEQ ID NO: 190
- ADAKKS SEQ ID NO: 191
- MDETNR SEQ ID NO: 192
- S AS AAA SEQ ID NO: 193
- GAGENS SEQ ID NO: 194
- the chimeric RBP comprises the N-terminal domain of a RBP fused to the C-terminal domain of different RBP wherein the different RBP is a protein or group a different proteins that confers an altered host range.
- the different RBP is a T4-like or T4 long tail fiber composed of a proximal tail fiber and a distal tail fiber (DTF), and the C-terminal domain of a T4-like or T4 RBP is the distal tail fiber (DTF).
- the N-terminal domain of a RBP is fused to the T4-like or T4 distal tail fiber at an insertion site within the T4-like or T4 DTF having at least 80%, preferably at least 85%, at least 90%, at least 95%, at least 98% or at least 99%, identity with an insertion site selected from the group consisting of amino acids ATLKQI (SEQ ID NO: 195), IIQLED (SEQ ID NO: 196), GNIIDL (SEQ ID NO: 197), IATRV (SEQ ID NO: 198), TPGEL (SEQ ID NO: 199), GAIIN (SEQ ID NO:200), NQIID (SEQ ID NO:201), GQIVN (SEQ ID NO:202), and VDRAV (SEQ ID NO:203).
- the N-terminal domain of a RBP is fused to the T4-like or T4 distal tail fiber within a region from amino acid 1 to 90, with a preferred region from amino acids ATLKQI (S
- the disclosure provides specific chimeric RBPs.
- SEQ ID NOS 2-61, 135-165, 215-242, 271, 273, 282 and 283 disclose the amino acid sequences of such chimeric RBPs as well as, in some instances, their corresponding natural chaperone proteins (designated“AP”). Such AP proteins assist in the folding of the chimeric RBPs.
- the RBP comprises the amino acid sequence of SEQ ID NO: 2, 4, 7, 9, 12, 15, 17, 20, 23, 24, 25, 27, 29, 31, 33, 35, 37, 39, 41, 42, 44, 46, 47, 48, 49, 50, 51, 52, 53, 56, 59, 135 to 144, 147, 150, 151, 154, 157, 160, 163, 215, 216, 219, 221, 223, 225, 227, 229, 232, 325, 237, 239, 241, 282 or 283.
- the RBP comprises the amino acid sequence of SEQ ID NO: 2, 4, 7, 9, 12, 15, 17, 20, 23, 24, 25, 27, 29, 31, 33, 35, 37, 39, 41, 42, 44, 46, 47, 48, 49, 50, 51, 52, 53, 56 or 59.
- nucleotide sequences encoding for the chimeric RBPs disclosed herein are depicted in SEQ ID NOS 62-120, 166-189, 206-212, 243-270, 272, 274 and 284.
- the nucleic acids encoding such chimeric RBPs comprise the nucleotide sequence of SEQ ID NO: 62, 64, 67, 69, 72, 75, 77, 80, 83, 84, 85, 87, 89, 91, 93, 95, 97, 99, 101, 102, 104, 106, 107, 108, 109, 110, 111, 112, 113, 116, 119, 166, 167, 168, 171, 174, 175, 178, 181, 184, 187, 206, 207, 208, 209, 210, 211, 212, 243, 244, 247, 249, 251, 253, 255, 257, 260, 263, 265, 267, 269 or 284.
- the nucleic acids encoding such chimeric RBPs comprise the nucleotide sequence of SEQ ID NO: 62, 64, 67, 69, 72, 75, 77, 80, 83, 84, 85, 87, 89, 91, 93, 95, 97, 99, 101, 102, 104, 106, 107, 108, 109, 110, 111, 112, 113, 116 or 119.
- the different RBP domain of the chimeric RBP comprises enzymatic activity such as depolymerase activity against an encapsulated bacterial strain.
- the depolymerase is an endosialidase such as, for example, a K1F or K5 endosialidase.
- the present disclosure provides for engineered branched-RBPs, as well as bacterial delivery vehicles, with desired host ranges and/or specific biological functions, based on the presence of an engineered branched receptor binding multi subunit protein complex (“branched-RBP”).
- the engineered branched-RBP comprises two or more associated receptor binding proteins, derived from bacteriophages that associated with one another based on the presence of interaction domains (IDs).
- IDs interaction domains
- Each of the protein complex subunits contain IDs that function as“anchors” for association of one subunit RBP with another.
- the association of one subunit with another can be non- covalent or covalent.
- the engineered branched RBP may comprise non-covalent association of the different subunits; in some instance, the engineered branched RBP may comprise covalent association of the different subunits; and in further instances, the engineered branched RBP may comprise both covalent and non-covalent associations of the different subunits.
- the protein subunits are assembled into the engineered branched-RBP as separate protein subunits each having their own ID.
- the engineered branched-RBP may exist as a single fusion protein comprising different protein domains of interest fused to two or more ID domains.
- the branched-RBP may comprise multiple RBP subunits, including, for example, two, three, four, etc. subunits.
- Each of the RBP subunits may bring different biological functions to the overall branched-RBP.
- Such functions include, but are not limited to, host recognition and enzymatic activity.
- enzymatic activity includes depolymerase activity.
- IDs amino acid sequences that are able to function as interaction domains (IDs).
- IDs are those amino acid sequences that provide for association of one subunit to another thereby providing for assembly of the engineered branched-RBPs.
- the IDs may be naturally occurring bacteriophage IDs, IDs derived from non-bacteriophage polypeptides, or recombinantly derived IDs.
- the two or more of the associated receptor binding proteins of the engineered branched-RBP may be any bacteriophage RBP, or a functional domain of a bacteriophage RBP, e.g.
- the associated receptor binding proteins may include, but are not limited to, chimeric receptor binding proteins (RBPs) described herein that comprise of a fusion between the N-terminal domain of a RBP derived from a lambda-like, or lambda bacteriophage and the C-terminal domain of a different RBP wherein said chimeric RBP also comprises an ID.
- RBPs chimeric receptor binding proteins
- nucleic acid molecules encoding the chimeric RBPs disclosed herein, as well as the two or more subunit RBPs of the engineered branched-RBP are provided.
- Such nucleic acids may be included in vectors such as bacteriophages, plasmids, phagemids, viruses, and other vehicles which enable transfer and expression of the chimeric RBP encoding nucleic acids.
- Bacterial delivery vehicles are provided which enable transfer of a nucleic acid payload, encoding a protein or nucleic acid of interest, into a desired target bacterial host cell.
- Such bacterial delivery vehicles are characterized by having a chimeric RBP comprising a fusion between the N-terminal domain of a RBP from a lambda- like bacteriophage, or lambda bacteriophage, and the C-terminal domain of a different RBP.
- the bacterial delivery vehicles contain a chimeric RBP comprising a fusion between an N-terminal domain of a RBP derived from a lambda-like bacteriophage, or lambda bacteriophage, and a C-terminal domain of a different RBP wherein said N-terminal domain of the chimeric RBP is fused to said C- terminal domain of a different RBP within one of the amino acids regions selected from positions 1-150, 320-460, or 495-560 of the N-terminal domain with reference to the lambda stf sequence (SEQ ID NO: 1).
- the RBP from the lambda-like bacteriophage, the lambda bacteriophage, and the different RBP contain homology in one or more of three amino acids regions ranging from positions 1-150, 320-460, and 495-560 of the RBP with reference to the lambda bacteriophage stf sequence (SEQ ID NO: 1).
- the homology is around 35% identity for 45 amino acids or more, around 50% identify for 30 amino acids or more, or around 90% identity for 18 amino acids or more within the one or more of three amino acids regions ranging from positions 1-150, 320-460, and 495-560 of the RBP with reference to the lambda bacteriophage stf sequence (SEQ ID NO:l).
- the different RBP domain of the chimeric receptor binding protein is derived from a bacteriophage or a bacteriocin.
- the chimeric RBP comprises an N-terminal domain of a RBP fused to a C-terminal domain of a RBP within one of the amino acids regions selected from positions 80-150, 320-460, or 495- 560 of the N-terminal RBP domain with reference to the lambda stf sequence (SEQ ID NO:l).
- the chimeric RBP comprises an N- terminal domain of a RBP and a C-terminal domain of a RBP fused within a site of the N-terminal RBP domain having at least 80%, preferably at least 85%, at least 90%, at least 95%, at least 98% or at least 99%, identity with a site selected from the group consisting of amino acids SAGDAS (SEQ ID NO: 190), ADAKKS (SEQ ID NO: 191), MDETNR (SEQ ID NO: 192), S AS AAA (SEQ ID NO: 193), GAGENS (SEQ ID NO: 194), ATLKQI (SEQ ID NO: 195), IIQLED (SEQ ID NO: 196), GNIIDL (SEQ ID NO: 197), IATRV (SEQ ID NO: 198), TPGEL (SEQ ID NO: 199), GAIIN (SEQ ID NO:200), NQIID (SEQ ID NO:201), GQIVN (SEQ ID NO:
- the disclosure provides a bacterial delivery vehicle comprising a chimeric RBP.
- SEQ ID NOS 2-61, 135-165, 215-242, 271, 273, 282 and 283 disclose the amino acid sequences of such chimeric RBPs and in addition, in some instances, their corresponding natural chaperone proteins (designated“AP”). Such AP proteins assist in the folding of the chimeric PBPs.
- the RBP comprises the amino acid sequence of SEQ ID NO: 2, 4, 7, 9, 12, 15, 17, 20, 23, 24, 25, 27, 29, 31, 33, 35, 37, 39, 41, 42, 44, 46, 47, 48, 49, 50, 51, 52, 53, 56, 59, 135 to 144, 147, 150, 151, 154, 157, 160, 163, 215, 216, 219, 221, 223, 225, 227, 229, 232, 325, 237, 239, 241, 282 or 283.
- the RBP comprises the amino acid sequence of SEQ ID NO: 2, 4, 7, 9, 12, 15, 17, 20, 23, 24, 25, 27, 29, 31, 33, 35, 37, 39, 41, 42, 44, 46, 47, 48, 49, 50, 51, 52, 53, 56 or 59.
- the present disclosure also provides nucleotide sequences encoding for the chimeric RBPs disclosed herein.
- nucleic acids encoding such chimeric RBPs, as well as corresponding AP proteins are depicted in SEQ ID NOS 62-120, 166-189, 206-212, 243-270, 272, 274 and 284.
- the nucleic acids encoding such chimeric RBPs comprise the nucleotide sequence of SEQ ID NO: 62, 64, 67, 69, 72, 75, 77, 80, 83, 84, 85, 87, 89, 91, 93, 95, 97, 99, 101, 102, 104, 106, 107, 108, 109, 110, 111, 112, 113, 116, 119, 166, 167, 168, 171, 174, 175, 178, 181, 184, 187, 206, 207, 208, 209, 210, 211, 212, 243, 244, 247, 249, 251, 253, 255, 257, 260, 263, 265, 267, 269 or 284.
- the nucleic acids encoding such chimeric RBPs comprise the nucleotide sequence of SEQ ID NO: 62, 64, 67, 69, 72, 75, 77, 80, 83, 84, 85, 87, 89, 91, 93, 95, 97, 99, 101, 102, 104, 106, 107, 108, 109, 110, 111, 112, 113, 116, or 119.
- the different RBP domain of the chimeric RBP comprises a domain having depolymerase activity against an encapsulated bacterial strain.
- the depolymerase is an endosialidase, such as for example, a K1F or K5 endosialidase.
- bacterial delivery vehicles which enable transfer of a nucleic acid payload, encoding a protein or nucleic acid of interest, into a desired target bacterial host cell wherein said bacterial delivery vehicles are characterized by having a branched-RBP as disclosed herein.
- the bacterial delivery vehicles provided herein enable transfer of a nucleic acid payload, encoding a protein or nucleic acid of interest, into a desired target bacterial host cell.
- the nucleic acid of interest is selected from the group consisting of a Cas nuclease gene, a Cas9 nuclease gene, a guide RNA, a CRISPR locus, a toxin gene, a gene expressing an enzyme such as a nuclease or a kinase, a TALEN, a ZFN, a meganuclease, a recombinase, a bacterial receptor, a membrane protein, a structural protein, a secreted protein, a gene expressing resistance to an antibiotic or to a drug in general, a gene expressing a toxic protein or a toxic factor, and a gene expressing a virulence protein or a virulence factor, or any of their combination.
- the bacterial delivery vehicle enables the transfer of a nucleic acid payload that encodes a nuclease that targets cleavage of a host bacterial cell genome or a host bacterial cell plasmid.
- the cleavage occurs in an antibiotic resistant gene.
- the nuclease mediated cleavage of the host bacterial cell genome is designed to stimulate a homologous recombination event for insertion of a nucleic acid of interest into the genome of the bacterial cell.
- the present invention also provides pharmaceutical or veterinary compositions comprising one or more of the bacterial delivery vehicles disclosed herein and a pharmaceutically-acceptable carrier. Also provided is a method for treating a disease or disorder caused by bacteria, preferably a bacterial infection, comprising administering to a subject having a disease or disorder caused by bacteria, preferably a bacterial infection, in need of treatment the provided pharmaceutical or veterinary composition.
- the present invention also relates to a pharmaceutical or veterinary composition as disclosed herein for use in the treatment of a disease or disorder caused by bacteria, preferably a bacterial infection. It further relates to the use of a pharmaceutical or veterinary composition as disclosed herein for the manufacture of a medicament for treating a disease or disorder caused by bacteria, preferably a bacterial infection.
- a method for reducing the amount of virulent and/or antibiotic resistant bacteria in a bacterial population comprising contacting the bacterial population with the bacterial delivery vehicles disclosed herein.
- the method may be an in vivo or in vitro method.
- the present invention also relates to a pharmaceutical or veterinary composition as disclosed herein for use in reducing the amount of virulent and/or antibiotic resistant bacteria in a bacterial population, in particular in a subject having a bacterial infection. It further relates to the use of a pharmaceutical or veterinary composition as disclosed herein for the manufacture of a medicament for reducing the amount of virulent and/or antibiotic resistant bacteria in a bacterial population, in particular in a subject having a bacterial infection.
- FIG. 1 demonstrates delivery in wild-type E. coli strains with lambda and OMPF-lambda packaged phagemids. Lambda packaged phagemids were diluted 1:5 in
- FIG. 2 depicts wild-type lambda and lambda-stf-KlF chimeric delivery vehicles on K1+ strains.
- Lambda packaged phagemids were sequentially diluted 10X in LB plus 5mM CaCh and 10 pL added in each well. Cells grown to an ODeoo of around 0.5 were then added to each phagemid dilution, incubated for 30 min at 37°C and 10 pL plated on LB supplemented with chloramphenicol. Top panel, strain UTI89; bottom panel, strain S88. Left plates, wild type lambda packaged phagemids; right plates, stf-KlF lambda packaged phagemids.
- FIG. 3 depicts wild-type lambda and lambda-stf-K5 chimeric delivery vehicles on a K5+ strain.
- Lambda packaged phagemids were sequentially diluted 10X in LB plus 5mM CaCh and 10 pL added in each well.
- ECOR55 grown to an ODeoo of around 0.5 were then added to each phagemid dilution, incubated for 30 min at 37°C and 10 pL plated on LB supplemented with chloramphenicol.
- Left panel wild type lambda packaged phagemids
- right panel stf-K15 lambda packaged phagemids.
- FIG. 4 depicts wild-type lambda, lambda-stf-AG22 and lambda-stf-SIEAl l chimeric delivery vehicles on a variety of encapsulated strains (O and K capsules).
- Lambda phagemids were diluted 1:5 in LB plus 5mM CaCh and 10 pL added in each well. 90 pL of cells grown to an ODeoo of around 0.5 were then added to each phagemid- containing well, incubated for 30 min at 37°C and 10 pL spotted on LB-agar supplemented with chloramphenicol. Left panel, wild type lambda phagemids; middle panel, lambda stf-SIEAl l variant; right panel, lambda-stf-AG22 variant. Circles show strains with modified delivery as compared to lambda wild-type.
- FIG. 5A-C demonstrates delivery of wild-type lambda and stf chimeras with different insertion sites on a variety of encapsulated strains (O and K capsules).
- Lambda packaged phagemids were diluted 1:5 in LB plus 5mM CaCh and 10 pL added in each well. 90 pL of cells grown to an ODeoo of around 0.5 were then added to each phagemid- containing well, incubated for 30 min at 37°C and 10 pL spotted on LB-agar supplemented with chloramphenicol.
- FIG. 5A demonstrates delivery of wild-type lambda and stf chimeras with different insertion sites on a variety of encapsulated strains (O and K capsules).
- Lambda packaged phagemids were diluted 1:5 in LB plus 5mM CaCh and 10 pL added in each well. 90 pL of cells grown to an ODeoo of around 0.5 were then added
- FIG. 5B Left panel, wild type lambda packaged phagemids; rest of panels, three different ADAKKS (SEQ ID NO:191)-stf variants.
- FIG. 5B Left panel, wild type lambda packaged phagemids; rest of panels, three different SASAAA (SEQ ID NO: 193)-stf variants.
- FIG. 5C Left panel, wild type lambda packaged phagemids; rest of panels, three different MDETNR (SEQ ID NO:192)-stf variants. For all panels, red circles show strains with improved delivery efficiency as compared to lambda wild-type.
- FIG. 6 depicts a phmmer search that was performed with a 50aa sliding window (step 10) on the representative proteome database (rp75). The number of significant hits
- FIG. 7A-B depicts branched stf architectures with 2 subunits.
- FIG. 7A is a schematic view of a delivery vehicle with a 2 subunits branched stf architecture. ID: “Interaction Domain”.
- FIG. 7B is a schematic view of the genetic architecture of an engineered lambda stf construct.
- FIG. 8 demonstrates delivery of branched lambda stf packaged phagemids.
- Lambda packaged lambda- stf- WW 11.1 stf, lambda-stf-KlF or the branched construct shown in FIG. 7 (WW11.1-K1F) were produced and titrated against 057 and K1 strains.
- FIG. 9A-B depicts branched stf architectures with 4 subunits.
- FIG. 9 A is a schematic view of a delivery vehicle with a 4 subunits branched stf architecture. Actual interactions among different ID may be different in the biological assembly from the graph depicted here.
- FIG. 9B depicts a genetic circuit encoding the 4 subunits branched stf under the control of an inducible promoter.
- FIG 10. depicts architecture of the engineered lambda stf-T4-like DTF chimera.
- the semicircles denote RBS sites; the T sign, a transcriptional terminator; the arrow, a promoter.
- FIG. 11 shows screening of phagemid particles with chimeric lambda stf-T4- like DTFs.
- Left panel wild- type lambda stf
- middle panel chimeric lambda-stf-WW13
- right panel chimeric lambda-stf-PP-1.
- FIG 12. demonstrates screening of phagemid particles with chimeric lambda stf- T4-like DTFs.
- Left panel wild-type lambda stf; middle panel, chimeric lambda- stf-WW55; right panel, chimeric lambda-stf-WW34.
- FIG. 13 depicts screening of phagemid particles with chimeric lambda stf-T4- like DTFs. All points shown refer to the universal insertion site of the DTF, located within amino acid range from position 1 to 90 with reference to WW13 amino acid sequence.
- FIG. 14. depicts dot scoring system to quantify delivery efficiency. Density 0, 5 or fewer colonies; density 1, more than 5 colonies but not enough to define a clear circular drop; density 2, several colonies, but the background is clearly visible and some colonies are still separated; density 3, many colonies, the background is still visible but the colonies are hardly discernible as separate; density 4, spot almost completely dense, the background can only be seen faintly in some parts of the drop; density 5, spot looks completely dense, background cannot be seen.
- FIG. 15 depicts raw dot titrations of delivery particles with chimeric stf in 40 human strains of the ECOR collection. Below each panel, the name of the chimeric stf. Above each dot, the 1-2 letter code used to identify strains.
- FIG. 16 represents bar- formatted delivery data of Figure 15. From 0 (no entry, grey background) to 5 (maximum delivery). The bar length is proportional to the entry score from 1 (smallest bars) to 5 (longest bars).
- the synthetic bacterial delivery vehicles are characterized by a chimeric receptor binding protein (RBP), wherein the chimeric RBP comprises a fusion between the N-terminal domain of a RBP from a lambda-like bacteriophage, or lambda bacteriophage, and the C-terminal domain of a different RBP.
- RBP chimeric receptor binding protein
- branched-RBP engineered branched receptor binding multi-subunit protein complex
- the engineered branched-RBP comprises two or more associated receptor binding proteins, derived from bacteriophages, which associate with one another based on the presence of interaction domains (IDs).
- IDs interaction domains
- Each of the polypeptide subunits are engineered to contain IDs that function as “anchors” for association of one subunit RBP with another.
- the association of one subunit with another can be non-covalent or covalent.
- the branched-RBP may comprise multiple RBP subunits, including, for example, two, three, four, etc. subunits.
- a receptor binding protein or RBP is a polypeptide that recognizes, and optionally binds and/or modifies or degrades a substrate located on the bacterial outer envelope, such as, without limitation, bacterial outer membrane, LPS, capsule, protein receptor, channel, structure such as the flagellum, pili, secretion system.
- the substrate can be, without limitation, any carbohydrate or modified carbohydrate, any lipid or modified lipid, any protein or modified protein, any amino acid sequence, and any combination thereof.
- a lambda-like bacteriophage refers to any bacteriophage encoding a RBP having amino acids sequence homology of around 35% identity for 45 amino acids or more, around 50% identify for 30 amino acids or more, or around 90% identity for 18 amino acids or more in one or more of three amino acids regions ranging from positions 1-150, 320-460, and 495-560 with reference to the lambda bacteriophage stf sequence of SEQ ID NO: 1, independently of other amino acids sequences encoded by said bacteriophage.
- the present disclosure provides a chimeric receptor binding protein (RBP), wherein the chimeric RBP comprises a fusion between an N-terminal domain of a RBP from a lambda-like bacteriophage, or lambda bacteriophage, and a C-terminal domain of a different bacteriophage RBP.
- RBP chimeric receptor binding protein
- Such bacteriophage RBPs include, for example,“L-shape fibers”,“side tail fibers (stfs)”,“long tail fibers” or“tailspikes.”
- a lambda- like bacteriophage receptor binding protein such as a stf protein
- RBP lambda- like bacteriophage receptor binding protein
- stfs bacteriophage receptor binding protein
- specific fusion positions in the RBPs have been identified which allow one to obtain a functional chimeric RBP.
- Such chimeric RBPs include those having an altered host range and/or biological activity such as, for example, depolymerase activity.
- the chimeric receptor binding protein is one wherein the chimeric RBP comprises a fusion between an N-terminal domain of a RBP derived from a lambda-like bacteriophage, or lambda bacteriophage, and a C-terminal domain of a different RBP wherein said N-terminal domain of the RBP is fused to said C-terminal domain of a different RBP within one of the amino acids regions selected from positions 1-150, 320- 460, or 495-560 of the N-terminal RBP with reference to the lambda stf sequence (SEQ ID NO: 1) or a similar region of a RBP having homology with one or more of three amino acids regions ranging from positions 1-150, 320-460, and 495-560 of the RBP with reference to the lambda stf sequence (SEQ ID NO:l).
- the different RBP of the chimeric receptor binding protein (RBP) is derived from any bacteri
- the RBP from the lambda-like bacteriophage, the lambda bacteriophage, or the different RBP contain homology with one or more of three amino acids regions ranging from positions 1-150, 320-460, and 495-560 of the RBP with reference to the lambda bacteriophage stf sequence (SEQ ID NO:l).
- the homology between the lambda-like bacteriophage, the lambda bacteriophage, or the different RBP and the one or more amino acids regions is around 35% identity for 45 amino acids or more, around 50% identify for 30 amino acids or more, and around 90% identity for 18 amino acids or more.
- the chimeric RBP comprises the N-terminal domain of the chimeric RBP fused to the C-terminal domain of the chimeric RBP within one of the amino acids regions selected from positions 80- 150, 320-460, or 495-560 with reference to the lambda bacteriophage stf sequence (SEQ ID NO: 1).
- the chimeric RBP comprises an N- terminal domain and a C-terminal domain fused within one of the three amino acids regions at an insertion site having at least 80%, preferably at least 85%, at least 90%, at least 95%, at least 98% or at least 99%, identity with an insertion site selected from the group consisting of amino acids SAGDAS (SEQ ID NO: 190), ADAKKS (SEQ ID NO: 191), MDETNR (SEQ ID NO: 192), S AS AAA (SEQ ID NO: 193), GAGENS (SEQ ID NO: 194), ATLKQI (SEQ ID NO: 195), IIQLED (SEQ ID NO: 196), GNIIDL (SEQ ID NO: 197), IATRV (SEQ ID NO: 198), TPGEL (SEQ ID NO: 199), GAIIN (SEQ ID NO:200), NQIID (SEQ ID NO:201), GQIVN (SEQ ID NO:202), and VDRAV (SEQ ID NO: 190),
- IDs may be inserted at such insertion sites thereby acting to fuse the N-terminal domain to the C-terminal domain.
- an ID domain may be fused to either an N-terminal domain, or C-terminal domain, of a bacteriophage RBP, to provide a non-chimeric protein subunit of an engineered branched RBP.
- the N-terminal domain, or C-terminal domain may be chosen depending on the desired function of the domain, e.g. host range or biological function. Where such non-chimeric protein subunits are utilized for production of an engineered branched-RBP, the ID domain may be fused at the preferred insertion sites disclosed herein, or alternatively, at insertion sites that permit maintainance of the function of the chosen domain.
- the disclosure provides chimeric RBPs.
- Such chimeric RBPs may function as protein subunits of an engineered branched-RBP protein complex.
- SEQ ID NOS 2-61, 135-165, 215-242, 271, 273, 282 and 283 disclose the amino acid sequences of such chimeric RBPs and in addition, in some instances, their corresponding natural chaperone proteins (designated“AP”).
- AP proteins assist in the folding of the chimeric RBPs.
- the RBP comprises the amino acid sequence of SEQ ID NO: 2, 4, 7, 9, 12, 15, 17, 20, 23, 24, 25, 27, 29, 31, 33, 35, 37, 39, 41, 42, 44, 46, 47, 48, 49, 50, 51, 52, 53, 56, 59,135 to 144, 147, 150, 151, 154, 157, 160, 163, 215, 216, 219, 221, 223, 225, 227, 229, 232, 325, 237, 239, 241, 282 or 283.
- the RBP comprises the amino acid sequence of SEQ ID NO: 2, 4, 7, 9, 12, 15, 17, 20, 23, 24, 25, 27, 29, 31, 33, 35, 37, 39, 41, 42, 44, 46, 47, 48, 49, 50, 51, 52, 53, 56 or 59.
- the present disclosure also provides nucleotide sequences encoding for the chimeric RBPs disclosed herein.
- nucleic acids encoding such chimeric RBPs, as well as corresponding AP proteins are depicted in SEQ ID NOS 62-120, 166-189, 206-212, 243-270, 272, 274 and 284.
- the nucleic acids encoding the chimeric RBP comprise the nucleotide sequence of SEQ ID NO: 62, 64, 67, 69, 72, 75, 77, 80, 83, 84, 85, 87, 89, 91, 93, 95, 97, 99, 101, 102, 104, 106, 107, 108, 109, 110, 111, 112, 113, 116, 119, 166, 167, 168, 171, 174, 175, 178, 181, 184, 187, 206, 207, 208, 209, 210, 211, 212, 243, 244, 247, 249, 251, 253, 255, 257, 260, 263, 265, 267, 269 or 284.
- the nucleic acids encoding such chimeric RBPs comprise the nucleotide sequence of SEQ ID NO: 62, 64, 67, 69, 72, 75, 77, 80, 83, 84, 85, 87, 89, 91, 93, 95, 97, 99, 101, 102, 104, 106, 107, 108, 109, 110, 111, 112, 113, 116, or 119.
- said chimeric RBPs may be further engineered to contain ID domains that act to mediate the association of the various engineered branched-RBP protein subunits with one another.
- the different RBP domain of the chimeric RBP comprises depolymerase activity against an encapsulated bacterial strain.
- the depolymerase is an endosialidase such as, for example, a K1F or K5 endosialidase
- any of the chimeric RBPs disclosed herein may be used as RBP subunits, wherein said RBPs may be further engineered to contain IDs.
- RBPs may be further engineered to contain IDs.
- engineering branched-RBPs can alter the host range of the resulting delivery particle.
- Nucleic acid molecules encoding the chimeric RBPs and branched-RBPs, disclosed herein are provided. Such nucleic acids may be included in vectors such as bacteriophages, plasmids, phagemids, viruses, and other vehicles which enable transfer and expression of the chimeric RBP encoding nucleic acids.
- Bacterial delivery vehicles are provided which enable transfer of a nucleic acid payload, encoding a protein or nucleic acid of interest, into a desired target bacterial host cell.
- Such bacterial delivery vehicles are characterized by having a chimeric RBP comprising a fusion between the N-terminal domain of a RBP from a lambda- like bacteriophage, or lambda bacteriophage, and the C-terminal domain of a different RBP.
- the bacterial delivery vehicles contain a chimeric RBP comprising a fusion between an N-terminal domain of a RBP derived from a lambda-like bacteriophage, or lambda bacteriophage, and a C-terminal domain of a different RBP wherein said N-terminal domain of the chimeric RBP is fused to said C- terminal domain of a different RBP within one of the amino acids regions selected from positions 1-150, 320-460, or 495-560 of the N-terminal domain RBP with reference to the lambda stf sequence (SEQ ID NO: 1).
- the RBP from the lambda-like bacteriophage, the lambda bacteriophage, and the different RBP contain homology in one or more of three amino acids regions ranging from positions 1-150, 320-460, and 495-560 of the N-terminal RBP with reference to the lambda bacteriophage stf sequence.
- the homology is around 35% identity for 45 amino acids or more, around 50% identify for 30 amino acids or more, or around 90% identity for 18 amino acids or more within the one or more of three amino acids regions ranging from positions 1-150, 320-460, and 495-560 of the N-terminal RBP with reference to the lambda bacteriophage stf sequence (SEQ ID NO: 1).
- the different RBP domain of the chimeric receptor binding protein is derived from a bacteriophage or a bacteriocin.
- the chimeric RBP comprises an N-terminal domain of a RBP fused to a C-terminal domain of a RBP within one of the amino acids regions selected from 80-150, 320-460, or 495- 560 of the RBPs with reference to the lambda stf sequence (SEQ ID NO: 1).
- the chimeric RBP comprises an N-terminal domain of a RBP and a C-terminal domain of a RBP fused within a site of the N-terminal RBPs having at least 80%, preferably at least 85%, at least 90%, at least 95%, at least 98% or at least 99%, identity with a site selected from the group consisting of amino acids SAGDAS (SEQ ID NO: 190), ADAKKS (SEQ ID NO: 191), MDETNR (SEQ ID NO: 192), S AS AAA (SEQ ID NO: 193), GAGENS (SEQ ID NO: 194), ATLKQI (SEQ ID NO: 195), IIQLED (SEQ ID NO: 196), GNIIDL (SEQ ID NO: 197), IATRV (SEQ ID NO: 198), TPGEL (SEQ ID NO: 199), GAIIN (SEQ ID NO:200), NQIID (SEQ ID NO:201), GQIVN (SEQ ID NO:
- the disclosure provides a bacterial delivery vehicle comprising a chimeric RBP.
- SEQ ID NOS 2-61, 135-165, 215-242, 271, 273, 282 and 283 disclose the amino acid sequences of such chimeric RBPs and in addition, in some instances, their corresponding natural chaperone proteins (designated“AP”). Such AP proteins assist in the folding of the chimeric RBPs.
- the RBP comprises the amino acid sequence of SEQ ID NO: 2, 4, 7, 9, 12, 15, 17, 20, 23, 24, 25, 27, 29, 31, 33, 35, 37, 39, 41, 42, 44, 46, 47, 48, 49, 50, 51, 52, 53, 56, 59, 135 to 144, 147, 150, 151, 154, 157, 160, 163, 215, 216, 219, 221, 223, 225, 227, 229, 232, 325, 237, 239, 241, 282 or 283.
- the RBP comprises the amino acid sequence of SEQ ID NO: 2, 4, 7, 9, 12, 15, 17, 20, 23, 24, 25, 27, 29, 31, 33, 35, 37, 39, 41, 42, 44, 46, 47, 48, 49, 50, 51, 52, 53, 56 or 59.
- the present disclosure also provides nucleotide sequences encoding for the chimeric RBPs disclosed herein.
- nucleic acids encoding such chimeric RBPs, as well as corresponding AP proteins are depicted in SEQ ID NOS 62-120, 166-189, 206-212, 243-270, 272, 274 and 284.
- the nucleic acids encoding the chimeric RBPs comprise the nucleotide sequence of SEQ ID NO: 62, 64, 67, 69, 72, 75, 77, 80, 83, 84, 85, 87, 89, 91, 93, 95, 97, 99, 101, 102, 104, 106, 107, 108, 109, 110, 111, 112, 113, 116, 119, 166, 167, 168, 171, 174, 175, 178, 181, 184, 187, 206, 207, 208, 209, 210, 211, 212, 243, 244, 247,
- nucleic acids encoding such chimeric RBPs comprise the nucleotide sequence of SEQ ID NO: 62, 64, 67, 69, 72, 75, 77, 80, 83, 84, 85, 87, 89, 91, 93, 95, 97, 99, 101, 102, 104, 106, 107, 108, 109, 110, 111, 112, 113, 116, or 119.
- the different RBP domain of the chimeric RBP comprises a domain having depolymerase activity against an encapsulated bacterial strain.
- the depolymerase is an endosialidase, such as for example, a K1F or K5 endosialidase.
- the present disclosure provides synthetic bacterial delivery vehicles that are characterized by the presence of an engineered branched receptor binding multi-subunit protein complex (“branched-RBP”).
- the engineered branched-RBP comprises two or more associated receptor binding proteins, derived from bacteriophages, which associate with one another based on the presence of interaction domains (IDs).
- IDs interaction domains
- the association of one subunit with another can be non-covalent or covalent.
- Each of the polypeptide subunits contain IDs that function as“anchors” for association of one subunit RBP with another.
- the branched-RBP may comprise multiple RBP subunits, including, for example, two, three, four, etc. subunits.
- the individual RBP subunit may bring different biological functions to the overall engineered branched-RBP. Such functions include but are not limited to host recognition and enzymatic activity. Such enzymatic activity includes depolymerase activity.
- ID polypeptides that are able to function as ID polypeptides.
- IDs for purposes of the present invention, are those amino acid sequences that provide for non-covalent or covalent association of one receptor binding protein to another.
- An interaction domain is a polypeptide whose function mediates the association of one biological molecule, e.g., a protein, to another biological molecule.
- the biological molecule can be a protein, a part of a protein, a carbohydrate, a lipid and a nucleic acid.
- the IDs may be naturally occurring bacteriophage IDs, IDs derived from non bacteriophage polypeptides that naturally associate with one another, or recombinantly derived IDs that function to mediate non-covalent or covalent association of two proteins or polypeptide domains.
- the two or more associated receptor binding proteins of the branched-RBP include, but are not limited to, chimeric receptor binding proteins (RBPs) described herein that comprise a fusion between the N-terminal domain of a RBP derived from a lambda-like, or lambda bacteriophage and the C-terminal domain of a different RBP wherein said chimeric RBP further comprises an ID domain.
- RBPs chimeric receptor binding proteins
- RBPs receptor binding proteins
- An RBP subunit of the branched-RBP may be a polypeptide that recognizes, and optionally binds and/or modifies or degrades a substrate located on the bacterial outer envelope, such as, without limitation, bacterial outer membrane, LPS, capsule, protein receptor, channel, structure such as the flagellum, pili, secretion system.
- the substrate can be, without limitation, any carbohydrate or modified carbohydrate, any lipid or modified lipid.
- the bacterial delivery vehicles provided herein enable transfer of a nucleic acid payload, encoding a protein or nucleic acid of interest, into a desired target bacterial host cell.
- delivery vehicle refers to any means that allows the transfer of a payload into a bacterium.
- delivery vehicles encompassed by the present invention including, without limitation, bacteriophage scaffold, virus scaffold, chemical based delivery vehicle (e.g., cyclodextrin, calcium phosphate, cationic polymers, cationic liposomes), protein-based or peptide-based delivery vehicle, lipid-based delivery vehicle, nanoparticle-based delivery vehicles, non- chemical-based delivery vehicles (e.g., transformation, electroporation, sonoporation, optical transfection), particle-based delivery vehicles (e.g., gene gun, magnetofection, impalefection, particle bombardment, cell-penetrating peptides) or donor bacteria (conjugation). Any combination of delivery vehicles is also encompassed by the present invention.
- chemical based delivery vehicle e.g., cyclodextrin, calcium phosphate, cationic polymers, cationic liposomes
- protein-based or peptide-based delivery vehicle e.g., lipid-based delivery vehicle, nanoparticle-based delivery vehicles,
- the delivery vehicle can refer to a bacteriophage derived scaffold and can be obtained from a natural, evolved or engineered capsid.
- the delivery vehicle is the payload as bacteria are naturally competent to take up a payload from the environment on their own.
- Delivery vehicles as disclosed herein include packaged phagemids, as well as bacteriophage, comprising the chimeric and/or branched-RBPs disclosed herein.
- the engineering of such delivery vehicles are well known to those skilled in the art. Such engineering techniques may employ production cell lines engineered to express the chimeric RBPs or branched-RBP disclosed herein.
- Generation of packaged phagemids and bacteriophage particles are routine techniques well-known to one skilled in the art.
- a satellite phage and/or helper phage may be used to promote the packaging of the payload in delivery vehicles of the present invention. Helper phages provide functions in trans and are well known to the man skilled in the art.
- the helper phage comprises all the genes coding for the structural and functional proteins that are indispensable for the payload to be packaged, according to the invention (i.e. the helper phage provides all the necessary gene products for the assembly of the delivery vehicle).
- the helper phage may contain a defective origin of replication or packaging signal, or completely lack the latter, and hence it is uncapable of self-packaging, thus only bacterial delivery particles carrying the payload or plasmid will be produced.
- Helper phages may be chosen so that they cannot induce lysis of the host used for the delivery particle production.
- One skilled in the art would understand that some bacteriophages are defective and need a helper phage for payload packaging.
- sequences coding for one or more proteins or regulatory processes necessary for the assembly or production of packaged payloads may be supplied in trans.
- the RBPs of the present dislcosure may be provided in a plasmid under the control of an inducible promoter or expressed constitutively.
- the phage wild-type sequence may or not contain a deletion of the gene or sequence supplied in trans.
- chimeric or modified phage sequences encoding a new function may be directly inserted into the desired position in the genome of the helper phage, hence bypassing the necessity of providing the modified sequence in trans.
- Methods for both supplying a sequence or protein in trans in the form of a plasmid, as well as methods to generate direct genomic insertions, modifications and mutations are well known to those skilled in the art.
- the term“payload” refers to any nucleic acid sequence or amino acid sequence, or a combination of both (such as, without limitation, peptide nucleic acid or peptide-oligonucleotide conjugate) transferred into a bacterium with a delivery vehicle.
- the term“payload” may also refer to a plasmid, a vector or a cargo.
- the payload can be a phagemid or phasmid obtained from natural, evolved or engineered bacteriophage genome.
- the payload can also be composed only in part of phagemid or phasmid obtained from natural, evolved or engineered bacteriophage genome.
- nucleic acid refers to a sequence of at least two nucleotides covalently linked together which can be single- stranded or double- stranded or contains portion of both single-stranded and double-stranded sequence.
- Nucleic acids of the present invention can be naturally occurring, recombinant or synthetic.
- the nucleic acid can be in the form of a circular sequence or a linear sequence or a combination of both forms.
- the nucleic acid can be DNA, both genomic or cDNA, or RNA or a combination of both.
- the nucleic acid may contain any combination of deoxyribonucleotides and ribonucleotides, and any combination of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xathanine, hypoxathanine, isocytosine, 5-hydroxymethylcytosine and isoguanine.
- bases including uracil, adenine, thymine, cytosine, guanine, inosine, xathanine, hypoxathanine, isocytosine, 5-hydroxymethylcytosine and isoguanine.
- modified bases that can be used in the present invention are detailed in Chemical Reviews 2016, 116 (20) 12655-12687.
- nucleic acid also encompasses any nucleic acid analogs which may contain other backbones comprising, without limitation, phosphoramide, phosphorothioate, phosphorodithioate, O-methylphophoroamidite linkage and/or deoxyribonucleotides and ribonucleotides nucleic acids. Any combination of the above features of a nucleic acid is also encompassed by the present invention.
- Origins of replication known in the art have been identified from species -specific plasmid DNAs (e.g. CoIEl, Rl, pT181, pSClOl, pMBl, R6K, RK2, pl5a and the like), from bacterial vims (e.g. cpX174, M13, FI and P4) and from bacterial chromosomal origins of replication (e.g. oriC).
- the phagemid according to the disclosure comprises a bacterial origin of replication that is functional in the targeted bacteria.
- the plasmid according to the disclosure does not comprise any functional bacterial origin of replication or contain an origin of replication that is inactive in the targeted bacteria. Thus, the plasmid of the disclosure cannot replicate by itself once it has been introduced into a bacterium by the bacterial virus particle.
- the origin of replication on the plasmid to be packaged is inactive in the targeted bacteria, meaning that this origin of replication is not functional in the bacteria targeted by the bacterial virus particles, thus preventing unwanted plasmid replication.
- the plasmid comprises a bacterial origin of replication that is functional in the bacteria used for the production of the bacterial virus particles.
- Plasmid replication depends on host enzymes and on plasmid-controlled cis and trans determinants. For example, some plasmids have determinants that are recognized in almost all gram-negative bacteria and act correctly in each host during replication initiation and regulation. Other plasmids possess this ability only in some bacteria (Kues, U and Stahl, U 1989 Microbiol Rev 53:491-516).
- Plasmids are replicated by three general mechanisms, namely theta type, strand displacement, and rolling circle (reviewed by Del Solar et al. 1998 Microhio and Molec
- Origins of replication used on the plasmid of the disclosure may be of moderate copy number, such as colEl ori from pBR322 (15-20 copies per cell) or the R6K plasmid (15-20 copies per cell) or may be high copy number, e.g. pUC oris (500-700 copies per cell), pGEM oris (300-400 copies per cell), pTZ oris (>1000 copies per cell) or pBluescript oris (300-500 copies per cell).
- moderate copy number such as colEl ori from pBR322 (15-20 copies per cell) or the R6K plasmid (15-20 copies per cell) or may be high copy number, e.g. pUC oris (500-700 copies per cell), pGEM oris (300-400 copies per cell), pTZ oris (>1000 copies per cell) or pBluescript oris (300-500 copies per cell).
- the bacterial origin of replication is selected in the group consisting of ColEl, pMBl and variants (pBR322, pET, pUC, etc), pl5a, ColA, ColE2, pOSAK, pSClOl, R6K, IncW (pSa etc), IncFII, pT181, PI, F IncP, IncC, IncJ, IncN, IncPl, IncP4, IncQ, IncHl l, RSF1010, CloDF13, NTP16, Rl, f5, pPSlO, pC194, pE194, BBR1, pBCl, pEP2, pWVOl, pLF1311, pAPl, pWKSl, pLSl, pLSl l, pUB6060, pJD4, pIJlOl, pSN22, pAMbetal, pIP501, pIP407, ZM6100(Sa), pCUl
- the bacterial origin of replication is a E.coli origin of replication selected in the group consisting of ColEl, pMBl and variants (pBR322, pET, pUC, etc), pl5a, ColA, ColE2, pOSAK, pSClOl, R6K, IncW (pSa etc), IncFII, pT181, PI, F IncP, IncC, IncJ, IncN, IncPl, IncP4, IncQ, IncHl l, RSF1010, CloDF13, NTP16, Rl, f5 and pPSlO.
- E.coli origin of replication selected in the group consisting of ColEl, pMBl and variants (pBR322, pET, pUC, etc), pl5a, ColA, ColE2, pOSAK, pSClOl, R6K, IncW (pSa etc), IncFII, pT181, PI, F IncP, IncC, IncJ, IncN, IncPl, IncP4,
- the bacterial origin of replication is selected in the group consisting of pC194, pE194, BBR1, pBCl, pEP2, pWVOl, pFF1311, pAPl, pWKSl, pFSl, pFSl l, pUB6060, pJD4, pIJlOl, pSN22, pAMbetal, pIP501, pIP407, ZM6100(Sa), pCUl, RA3, pMOF98, RK2/RP4/RP1/R68, pBlO, R300B, pR01614, pRO1600, pECB2, pCMl, pFA3, RepFIA, RepFIB, RepFIC, pYVE439-80, R387, phasyl, RA1, TF-FC2, pMV158 and pUB113.
- the bacterial origin of replication is ColEl .
- the delivered nucleic acid sequence according to the disclosure may comprise a phage replication origin which can initiate, with complementation of a complete phage genome, the replication of the delivered nucleic acid sequence for later encapsulation into the different capsids.
- a phage origin of replication comprised in the delivered nucleic acid sequence of the disclosure can be any origin of replication found in a phage.
- the phage origin of replication can be the wild-type or non-wildtype sequence of the M13, fl, cpX174, P4, lambda, P2, lambda-like, HK022, mEP237, HK97, HK629, HK630, mEP043, mEP213, mEP234, mEP390, mEP460, mEPxl, mEPx2, phi80, mEP234, T2, T4, T5, T7, RB49, phiX174, R17, PRD1 Pl-like, P2-like, P22, P22- like, N15 and N 15-like bacteriophages.
- the phage origin of replication is selected in the group consisting of phage origins of replication of M13, fl, cpX174, P4, and lambda.
- the phage origin of replication is the lambda or P4 origin of replication.
- the delivered nucleic acid of interest comprises a nucleic acid sequence under the control of a promoter.
- the nucleic acid of interest is selected from the group consisting of a Cas nuclease gene, a Cas9 nuclease gene, a guide RNA, a CRISPR locus, a toxin gene, a gene expressing an enzyme such as a nuclease or a kinase, a TALEN, a ZFN, a meganuclease, a recombinase, a bacterial receptor, a membrane protein, a structural protein, a secreted protein, a gene expressing resistance to an antibiotic or to a drug in general, a gene expressing a toxic protein or a toxic factor, and a gene expressing a virulence protein or a virulence factor, or any of their combination.
- the nucleic acid payload encodes a therapeutic protein.
- the sequence of interest is a programmable nuclease circuit to be delivered to the targeted bacteria.
- This programmable nuclease circuit is able to mediate in vivo sequence- specific elimination of bacteria that contain a target gene of interest (e.g. a gene that is harmful to humans).
- Some embodiments of the present disclosure relate to engineered variants of the Type II CRISPR-Cas (Clustered Regularly Interspaced Short Palindromic Repeats-CRIS PR-associated) system of Streptococcus pyogenes.
- programmable nucleases that can be used include other CRISPR-Cas systems, engineered TALEN (Transcription Activator-Like Effector Nuclease) variants, engineered zinc finger nuclease (ZFN) variants, natural, evolved or engineered meganuclease or recombinase variants, and any combination or hybrids of programmable nucleases.
- the engineered autonomously distributed nuclease circuits provided herein may be used to selectively cleave DNA encoding a gene of interest such as, for example, a toxin gene, a virulence factor gene, an antibiotic resistance gene, a remodeling gene or a modulatory gene (cf. WO2014124226).
- sequences of interest can be added to the delivered nucleic acid sequence so as to be delivered to targeted bacteria.
- sequence of interest added to the delivered nucleic acid sequence leads to cell death of the targeted bacteria.
- nucleic acid sequence of interest added to the plasmid may encode holins or toxins.
- sequence of interest circuit added to the delivered nucleic acid sequence does not lead to bacteria death.
- sequence of interest may encode reporter genes leading to a luminescence or fluorescence signal.
- sequence of interest may comprise proteins and enzymes achieving a useful function such as modifying the metabolism of the bacteria or the composition of its environment.
- the nucleic sequence of interest is selected in the group consisting of Cas9, a single guide RNA (sgRNA), a CRISPR locus, a gene expressing an enzyme such as a nuclease or a kinase, a TALEN, a ZFN, a meganuclease, a recombinase, a bacterial receptor, a membrane protein, a structural protein, a secreted protein, resistance to an antibiotic or to a drug in general, a gene expressing a toxic protein or a toxic factor and a gene expressing a virulence protein or a virulence factor.
- sgRNA single guide RNA
- CRISPR locus a gene expressing an enzyme such as a nuclease or a kinase, a TALEN, a ZFN, a meganuclease, a recombinase, a bacterial receptor, a membrane protein, a structural protein,
- the delivered nucleic acid sequence according to the disclosure comprises a nucleic acid sequence of interest that encodes a bacteriocin, which can be a proteinaceous toxin produced by bacteria to kill or inhibit growth of other bacteria.
- Bacteriocins are categorized in several ways, including producing strain, common resistance mechanisms, and mechanism of killing. Such bacteriocin had been described from gram negative bacteria (e.g. microcins, colicin-like bacteriocins and tailocins) and from gram positive bacteria (e.g. Class I, Class II, Class III or Class IV bacteriocins).
- the delivered nucleic acid sequence according to the disclosure further comprises a sequence of interest encoding a toxin selected in the group consisting of microcins, colicin-like bacteriocins, tailocins, Class I, Class II, Class III and Class IV bacteriocins.
- the corresponding immunity polypeptide i.e. anti toxin
- the corresponding immunity polypeptide may be used to protect bacterial cells (Cotter et ah, Nature Reviews Microbiology 11: 95, 2013) for delivered nucleic acid sequence production and encapsidation purpose but is absent in the pharmaceutical composition and in the targeted bacteria in which the delivered nucleic acid sequence of the disclosure is delivered.
- the CRISPR system is included in the delivered nucleic acid sequence.
- the CRISPR system contains two distinct elements, i.e. i) an endonuclease, in this case the CRISPR associated nuclease (Cas or "CRISPR associated protein") and ii) a guide RNA.
- the guide RNA is in the form of a chimeric RNA which consists of the combination of a CRISPR (RNAcr) bacterial RNA and a RNAtracr (trans-activating RNA CRISPR) (Jinek et al., 2012, Science 337: 816-821).
- the guide RNA combines the targeting specificity of the RNAcr corresponding to the "spacing sequences" that serve as guides to the Cas proteins, and the conformational properties of the RNAtracr in a single transcript.
- the target genomic sequence can be permanently modified or interrupted. The modification is advantageously guided by a repair matrix.
- the CRISPR system includes two main classes depending on the nuclease mechanism of action. Class 1 is made of multi-subunit effector complexes and includes type I, III and IV.
- Class 2 is made of single-unit effector modules, like Cas9 nuclease, and includes type II (II-A,II-B,II-C,II-C variant), V (V-A,V-B,V-C,V-D,V-E,V-U1,V- U2,V-U3,V-U4,V-U5) and VI (VI-A,VI-B1,VI-B2,VI-C,VI-D)
- the sequence of interest comprises a nucleic acid sequence encoding Cas protein.
- CRISPR enzymes are available for use as a sequence of interest on the plasmid.
- the CRISPR enzyme is a Type II CRISPR enzyme.
- the CRISPR enzyme catalyzes DNA cleavage.
- the CRISPR enzyme catalyzes RNA cleavage.
- the CRISPR enzymes may be coupled to a sgRNA.
- the sgRNA targets a gene selected in the group consisting of an antibiotic resistance gene, virulence protein or factor gene, toxin protein or factor gene, a bacterial receptor gene, a membrane protein gene, a structural protein gene, a secreted protein gene and a gene expressing resistance to a drug in general.
- Non-limiting examples of Cas proteins as part of a multi- subunit effector or as a single-unit effector include Casl, CaslB, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl and Csxl2), CaslO, Casl l (SS), Casl2a (Cpfl), Casl2b (C2cl), Casl2c (C2c3), Casl2d (CasY), Casl2e (CasX), C2c4, C2c8, C2c5, C2cl0, C2c9, Casl3a (C2c2), Casl3b (C2c6), Casl3c (C2c7), Casl3d, Csa5, Cscl, Csc2, Csel, Cse2, Csyl, Csy2, Csy3, Csfl, Csf2, Csl
- the CRISPR enzyme is any Cas9 protein, for instance any naturally-occurring bacterial Cas9 as well as any variants, homologs or orthologs thereof.
- Cas9 is meant a protein Cas9 (also called Csnl or Csxl2) or a functional protein, peptide or polypeptide fragment thereof, i.e. capable of interacting with the guide RNA(s) and of exerting the enzymatic activity (nuclease) which allows it to perform the double-strand cleavage of the DNA of the target genome.
- Cas9 can thus denote a modified protein, for example truncated to remove domains of the protein that are not essential for the predefined functions of the protein, in particular the domains that are not necessary for interaction with the gRNA(s).
- Cas9 the entire protein or a fragment thereof
- the sequence encoding Cas9 can be obtained from any known Cas9 protein (Fonfara et al., Nucleic Acids Res 42 (4), 2014; Koonin et al., Nat Rev Microbiol 15(3), 2017).
- Cas9 proteins useful in the present disclosure include, but are not limited to, Cas9 proteins of Streptococcus pyogenes (SpCas9), Streptococcus thermophilus (StlCas9, St3Cas9), Streptococcus mutans, Staphylococcus aureus (SaCas9), Campylobacter jejuni (CjCas9), Francisella novicida (FnCas9) and Neisseria meningitides (NmCas9).
- Cpfl (Casl2a) (the entire protein or a fragment thereof) as used in the context of the disclosure can be obtained from any known Cpfl (Casl2a) protein (Koonin et al., Nat Rev Microbiol 15(3), 2017).
- Cpfl(Casl2a) proteins useful in the present disclosure include, but are not limited to, Cpfl(Casl2a) proteins of Acidaminococcus sp, Lachnospiraceae bacteriu and Francisella novicida.
- Casl3a (the entire protein or a fragment thereof) can be obtained from any known Casl3a (C2c2) protein (Abudayyeh et ah, 2017, Nature 550: 280-284) .
- Casl3a (C2c2) proteins useful in the present disclosure include, but are not limited to, Casl3a (C2c2) proteins of Leptotrichia wadei (LwaCasl3a).
- Casl3d (the entire protein or a fragment thereof) can be obtained from any known Casl3d protein (Yan et ah, 2018, Mol Cell 70: 327-339).
- Casl3d proteins useful in the present disclosure include, but are not limited to, Casl3d proteins of Eubacterium siraeum and Ruminococcus sp.
- the nucleic sequence of interest is a CRISPR/Cas9 system for the reduction of gene expression or inactivation of a gene selected in the group consisting of an antibiotic resistance gene, virulence factor or protein gene, toxin factor or protein gene, a gene expressing a bacterial receptor, a membrane protein, a structural protein, a secreted protein, and a gene expressing resistance to a drug in general.
- the CRISPR system is used to target and inactivate a virulence factor.
- a virulence factor can be any substance produced by a pathogen that alter host-pathogen interaction by increasing the degree of damage done to the host.
- Virulence factors are used by pathogens in many ways, including, for example, in cell adhesion or colonization of a niche in the host, to evade the host's immune response, to facilitate entry to and egress from host cells, to obtain nutrition from the host, or to inhibit other physiological processes in the host.
- Virulence factors can include enzymes, endotoxins, adhesion factors, motility factors, factors involved in complement evasion, and factors that promote biofilm formation.
- such targeted virulence factor gene can be E.
- coli virulence factor gene such as, without limitation, EHEC-HlyA, Stxl (VT1), Stx2 (VT2), Stx2a (VT2a), Stx2b (VT2b), Stx2c (VT2c), Stx2d (VT2d), Stx2e (VT2e) and Stx2f (VT2f), Stx2h (VT2h), fimA, fimF, fimH, neuC, kpsE, sfa, foe, iroN, aer, iha, papC, papGI, papGII, papGIII, hlyC, cnfl, hra, sat, ire A, usp ompT, ibeA, malX, fyuA, irp2, traT, afaD, ipaH, eltB, estA, bfpA, eaeA, espA, aa
- such targeted virulence factor gene can be Shigella dysenteriae virulence factor gene such as, without limitation, stxl and stx2.
- such targeted virulence factor gene can be Yersinia pestis virulence factor gene such as, without limitation, yscF (plasmid-borne (pCDl) T3SS external needle subunit).
- yscF plasmid-borne (pCDl) T3SS external needle subunit
- such targeted virulence factor gene can be Francisella tularensis virulence factor gene such as, without limitation, fslA.
- such targeted virulence factor gene can be Bacillus anthracis virulence factor gene such as, without limitation, pag (Anthrax toxin, cell-binding protective antigen).
- such targeted virulence factor gene can be Vibrio cholera virulence factor gene such as, without limitation, ctxA and ctxB (cholera toxin), tcpA (toxin co-regulated pilus), and toxT (master virulence regulator).
- Vibrio cholera virulence factor gene such as, without limitation, ctxA and ctxB (cholera toxin), tcpA (toxin co-regulated pilus), and toxT (master virulence regulator).
- such targeted virulence factor gene can be Pseudomonas aeruginosa virulence factor genes such as, without limitation, pyoverdine (e.g., sigma factor pvdS, biosynthetic genes pvdF, pvdl, pvdJ, pvdH, pvdA, pvdF, pvdQ, pvdN, pvdM, pvdO, pvdP, transporter genes pvdE, pvdR, pvdT, opmQ), siderophore pyochelin (e.g., pchD, pchC, pchB, pchA, pchE, pchF and pchG, and toxins (e.g., exoU, exoS and exoT).
- pyoverdine e.g., sigma factor pvdS, bio
- such targeted virulence factor gene can be Klebsiella pneumoniae virulence factor genes such as, without limitation, fimA (adherence, type I fimbriae major subunit), and cps (capsular polysaccharide).
- Klebsiella pneumoniae virulence factor genes such as, without limitation, fimA (adherence, type I fimbriae major subunit), and cps (capsular polysaccharide).
- such targeted virulence factor gene can be Acinetobacter baumannii virulence factor genes such as, without limitation, ptk (capsule polymerization) and epsA (assembly).
- such targeted virulence factor gene can be Salmonella enterica Typhi virulence factor genes such as, without limitation, MIA (invasion, SPI-1 regulator), ssrB (SPI-2 regulator), and those associated with bile tolerance, including efflux pump genes acrA, acrB and tolC.
- such targeted virulence factor gene can be Fusobacterium nucleatum virulence factor genes such as, without limitation, FadA and TIGIT.
- such targeted virulence factor gene can be Bacteroides fragilis virulence factor genes such as, without limitation, bft.
- the CRISPR/Cas9 system is used to target and inactivate an antibiotic resistance gene such as, without limitation, GyrB, ParE, ParY, AAC(l), AAC(2'), AAC(3), AAC(6'), ANT(2"), ANT(3"), ANT(4'), ANT(6), ANT(9), APH(2"), APH(3"), APH(3'), APH(4), APH(6), APH(7"), APH(9), ArmA, RmtA, RmtB, RmtC, Sgm, AER, BLA1, CTX-M, KPC, SHV, TEM, BlaB, CcrA, IMP, NDM, VIM, ACT, AmpC, CMY, LAT, PDC, OXA b-lactamase, mecA, Omp36, OmpF, PIB, bla (blal, blaRl) and mec (mecl, mecR
- an antibiotic resistance gene
- the CRISPR/Cas9 system is used to target and inactivate a bacterial toxin gene.
- Bacterial toxin can be classified as either exotoxins or endotoxins. Exotoxins are generated and actively secreted; endotoxins remain part of the bacteria. The response to a bacterial toxin can involve severe inflammation and can lead to sepsis.
- Such toxin can be for example Botulinum neurotoxin, Tetanus toxin, Staphylococus toxins, Diphteria toxin, Anthrax toxin, Alpha toxin, Pertussis toxin, Shiga toxin, Heat- stable enterotoxin (E.
- the bacteria targeted by bacterial delivery vehicles disclosed herein can be any bacteria present in a mammal organism.
- the bacteria are targeted through interaction of the chimeric RBPs and/or the branched-RBPs expressed by the delivery vehicles with the bacterial cell. It can be any commensal, symbiotic or pathogenic bacteria of the microbiota or microbiome.
- a microbiome may comprise of a variety of endogenous bacterial species, any of which may be targeted in accordance with the present disclosure.
- the genus and/or species of targeted endogenous bacterial cells may depend on the type of bacteriophages being used for preparing the bacterial delivery vehicles. For example, some bacteriophages exhibit tropism for, or preferentially target, specific host species of bacteria. Other bacteriophages do not exhibit such tropism and may be used to target a number of different genus and/or species of endogenous bacterial cells.
- Examples of bacterial cells include, without limitation, cells from bacteria of the genus Yersinia spp., Escherichia spp., Klebsiella spp., Acinetobacter spp., Bordetella spp., Neisseria spp., Aeromonas spp., Franciesella spp., Corynebacterium spp., Citrobacter spp., Chlamydia spp., Hemophilus spp., Brucella spp., Mycobacterium spp., Legionella spp., Rhodococcus spp., Pseudomonas spp., Helicobacter spp., Vibrio spp., Bacillus spp., Erysipelothrix spp., Salmonella spp., Streptomyces spp., Streptococcus spp., Staphylococcus
- bacterial delivery vehicles may target (e.g., specifically target) a bacterial cell from any one or more of the foregoing genus of bacteria to specifically deliver the payload of interest according to the disclosure.
- the targeted bacteria can be selected from the group consisting of Yersinia spp., Escherichia spp., Klebsiella spp., Acinetobacter spp., Pseudomonas spp., Helicobacter spp., Vibrio spp, Salmonella spp., Streptococcus spp., Staphylococcus spp., Bacteroides spp., Clostridium spp., Shigella spp., Enterococcus spp., Enterobacter spp., and Listeria spp.
- bacterial cells of the present disclosure are anaerobic bacterial cells (e.g., cells that do not require oxygen for growth).
- Anaerobic bacterial cells include facultative anaerobic cells such as but not limited to Escherichia coli, Shewanella oneidensis and Listeria.
- Anaerobic bacterial cells also include obligate anaerobic cells such as, for example, Bacteroides and Clostridium species.
- anaerobic bacteria are most commonly found in the gastrointestinal tract.
- the targeted bacteria are thus bacteria most commonly found in the gastrointestinal tract.
- Bacteriophages used for preparing the bacterial virus particles, and then the bacterial virus particles may target (e.g., to specifically target) anaerobic bacterial cells according to their specific spectra known by the person skilled in the art to specifically deliver the plasmid.
- the targeted bacterial cells are, without limitation, Bacteroides thetaiotaomicron, Bacteroides fragilis, Bacteroides distasonis, Bacteroides vulgatus, Clostridium leptum, Clostridium coccoides, Staphylococcus aureus, Bacillus subtilis, Clostridium butyricum, Brevibacterium lactofermentum, Streptococcus agalactiae, Lactococcus lactis, Leuconostoc lactis, Actinobacillus actinobycetemcomitans, cyanobacteria, Escherichia coli, Helicobacter pylori, Selnomonas ruminatium, Shigella sonnei, Zymomonas mobilis, Mycoplasma mycoides, Treponema denticola, Bacillus thuringiensis, Staphilococcus lugdunensis, Le
- the targeted bacteria are Escherichia coli.
- bacteriophages used for preparing the bacterial delivery vehicles, and then the bacterial delivery vehicles may target (e.g., specifically target) a bacterial cell from any one or more of the foregoing genus and/or species of bacteria to specifically deliver the payload of interest.
- the targeted bacteria are pathogenic bacteria.
- the targeted bacteria can be virulent bacteria.
- the targeted bacteria can be antibacterial resistance bacteria, preferably selected from the group consisting of extended- spectrum beta-lactamase-producing (ESBL) Escherichia coli, ESBL Klebsiella pneumoniae , vancomycin-resistant Enterococcus (VRE), methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant (MDR) Acinetobacter baumannii, MDR Enterobacter spp., and a combination thereof.
- the targeted bacteria can be selected from the group consisting of extended- spectrum beta-lactamase-producing (ESBL) Escherichia coli strains.
- the targeted bacterium can be a bacterium of the microbiome of a given species, preferably a bacterium of the human microbiota.
- the present disclosure is directed to bacterial delivery vehicle containing the payload as described herein.
- the bacterial delivery vehicles are prepared from bacterial virus.
- the bacterial delivery vehicles are chosen in order to be able to introduce the payload into the targeted bacteria.
- Bacterial viruses from which the bacterial delivery vehicles having chimeric receptor binding proteins and/or branched-RBPs may be derived, are preferably bacteriophages.
- the bacteriophage is selected from the Order Caudovirales consisting of, based on the taxonomy of Krupovic et al, 2015, Arch Virol, 161(1): 233- 247:
- Bacteriophages may be selected from the family Myoviridae (such as, without limitation, genus Cp220virus, Cp8virus, Ea214virus, Felixolvirus, Mooglevirus, Suspvirus, Hplvirus, P2virus, Kayvirus, PlOOvirus, Silviavirus, Spolvirus, Tsarbombavirus, Twortvirus, Cc31virus, Jdl8virus, Js98virus, Kpl5virus, Moonvirus, Rb49virus, Rb69virus, S16virus, Schizot4virus, Spl8virus, T4virus, Cr3virus, Selvirus, V5virus, Abouovirus, Agatevirus, Agrican357virus, Ap22virus, Arvlvirus, B4virus, Bastillevirus, Bc431virus, Bcep78virus, Bcepmuvirus, Biquartavirus, Bxzlvirus, Cdl l9virus, Cp51virus, CvmlOvirus, Eah2virus, Elvirus, Hapun
- Bacteriophages may be selected from the family Podoviridae (such as, without limitation, genus Frilvirus, Kp32virus, Kp34virus, Phikmvvims, Pradovirus, Sp6virus, T7virus, Cplvirus, P68virus, Phi29vims, Nona33vims, Pocjvirus, T12011virus, Bcep22virus, Bpplvirus, Cba41virus, Dfll2virus, Ea92virus, Epsilon 15vims, F116vims, G7cvims, Jwalphavims, Kflvims, Kpp25vims, Litlvims, Luz24virus, Luz7virus, N4vims, Nonanavims, P22virus, Pagevirus, Phieco32virus, Prtbvims, Sp58vims, Una961vims and Vp5vims)
- Podoviridae such as, without limitation, genus Fril
- - Bacteriophages may be selected from the family Siphoviridae (such as, without limitation, genus Camvirus, Likavims, R4vims, Acadianvims, Coopervirus, Pglvims, Pipefishvims, Rosebushvirus, Bmjitavirus, Che9cvims, Hawkeyevims, Plotvirus, Jerseyvirus, Klgvims, Sp31vims, Lmdlvims, Una4vims, Bongovirus, Reyvirus, Buttersvirus, Charlievirus, Redivims, Baxtervims, Nymphadoravirus, Bignuzvirus, Fishburnevirus, Phayoncevirus, Kp36virus, Roguelvirus, Rtpvims, Tlvirus, Tlsvirus, Abl8vims, Amigovirus, Anatolevims, Andromedavirus, Attisvirus, Bamyardvirus, Bemall3vims, Biseptimavims, Bron
- Bacteriophages may be selected from the family Ackermannviridae (such as, without limitation, genus Ag3virus, Limestonevirus, Cbal20virus and Vilvirus)
- the bacteriophage is not part of the order Caudovirales but from families with unassigned order such as, without limitation, family Tectiviridae (such as genus Alphatectivirus, Betatectivirus), family Corticoviridae (such as genus Corticovirus), family Inoviridae (such as genus Fibrovirus, Habenivirus, Inovirus, Lineavirus, Plectrovirus, Saetivirus, Vespertilio virus), family Cystoviridae(such as genus Cystovirus), family Leviviridae(such as genus Allolevivirus, Levivirus), family Microviridae (such as genus Alpha3 micro virus, G4microvirus, Phixl74microvirus, Bdellomicrovirus, Chlamydiamicrovirus, Spiromicrovirus) and family Plasmaviridae (such as genus Plasmavirus).
- family Tectiviridae such as genus Alphatectivirus, Betatecti
- the bacteriophage is targeting Archea not part of the Order Caudovirales but from families with Unassigned order such as, without limitation, Ampullaviridae, FuselloViridae, Globuloviridae, Guttaviridae, Lipothrixviridae, Pleolipoviridae, Rudiviridae, Salterprovirus and Bicaudaviridae.
- chimeric RBPs and/or the branched RBPs and the bacterial delivery vehicles disclosed herein may be engineered, as non-limiting examples, from the following phages.
- Synonyms and spelling variants are indicated in parentheses. Homonyms are repeated as often as they occur (e.g., D, D, d). Unnamed phages are indicated by "NN" beside their genus and their numbers are given in parentheses.
- Bacteria of the genus Actinomyces can be infected by the following phages: Av-I, Av-2, Av-3, BF307, CT1, CT2, CT3, CT4, CT6, CT7, CT8 and 1281.
- Bacteria of the genus Bacillus can be infected by the following phages: A, aizl, Al-K-I, B, BCJA1, BC1, BC2, BLL1, BL1, BP142, BSL1, BSL2, BS1, BS3, BS8, BS15, BS18, BS22, BS26, BS28, BS31, BS104, BS105, BS106, BTB, B1715V1, C, CK-I, Coll, Corl, CP-53, CS-I, CSi, D, D, D, D5, entl, FP8, FP9, FSi, FS2, FS3, FS5, FS8, FS9, G, GH8, GT8, GV-I, GV-2, GT-4, g3, gl2, gl3, gl4, gl6, gl7, g21, g23, g24, g29, H2, kenl, KK-88, Ku
- the following Bacillus- specific phages are defective: DLP10716, DLP-11946, DPB5, DPB12, DPB21, DPB22, DPB23, GA-2, M, No. IM, PBLB, PBSH, PBSV, PBSW, PBSX, PBSY, PBSZ, phi, SPa, type 1 and m.
- Bacteria of the genus Bacteriodes can be infected by the following phages: ad 12, Baf-44, Baf-48B, Baf-64, Bf-I, Bf-52, B40-8, FI, b ⁇ , fAI, fBGqI, fBG02, 11, 67.1, 67.3,
- Bacteria of the genus Bordetella can be infected by the following phages: 134 and NN-Bordetella (3).
- Bacteria of the genus Borrellia can be infected by the following phages: NN- Borrelia (1) and NN-Borrelia (2).
- Bacteria of the genus Burkholderia can be infected by the following phages: CP75, NN-Burkholderia (1) and 42.
- Bacteria of the genus Enterococcus can be infected by the following phages: DF78, FI, F2, 1, 2, 4, 14, 41, 867, Dl, SB24, 2BV, 182, 225, C2, C2F, E3, E62, DS96,
- Bacteria of the genus Erysipelothrix can be infected by the following phage: NN- Eiysipelothrix (1).
- Bacteria of the genus Fusobacterium can be infected by the following phages: NN-Fusobacterium (2), fv83-554/3, fv88-531/2, 227, fv2377, fv2527 and fv8501.
- Bacteria of the genus Haemophilus can be infected by the following phages: HP1, S2 and N3.
- Bacteria of the genus Helicobacter can be infected by the following phages: HP1 and AA -Helicobacter (1).
- Bacteria of the genus Lepitospira can be infected by the following phages: LEI, LE3, LE4 and ⁇ NN-Leptospira (1).
- Bacteria of the genus Morganella can be infected by the following phage: 47.
- Bacteria of the genus Neisseria can be infected by the following phages: Group I, group II and NP1.
- Bacteria of the genus Nocardia can be infected by the following phages: MNP8, NJ-L, NS-8, N5 and TtiN-Nocardia.
- Bacteria of the genus Proteus can be infected by the following phages: Pm5, 13vir, 2/44, 4/545, 6/1004, 13/807, 20/826, 57, 67b, 78, 107/69, 121, 9/0, 22/608, 30/680, Pml, Pm3, Pm4, Pm6, Pm7, Pm9, PmlO, Pml 1, Pv2, p ⁇ , (pm, 7/549, 9B/2, 10A/31, 12/55, 14, 15, 16/789, 17/971, 19A/653, 23/532, 25/909, 26/219, 27/953, 32 A/909, 33/971, 34/13, 65, 5006M, 7480b, VI, 13/3a, Clichy 12, p2600, fc7, 1/1004, 5/742, 9, 12, 14, 22, 24/860, 2600/D52, Pm8 and 24/2514.
- Bacteria of the genus Providencia can be infected by the following phages: PL25, PL26, PL37, 9211/9295, 9213/921 lb, 9248, 7/R49, 7476/322, 7478/325, 7479,
- Bacteria of the genus Rickettsia can be infected by the following phage: NN- Rickettsia.
- Bacteria of the genus Serratia can be infected by the following phages: A2P, PS20, SMB3, SMP, SMP5, SM2, V40, V56, ic, ⁇ DCP-3, ⁇ DCP-6, 3M, 10/la, 20A, 34CC, 34H, 38T, 345G, 345P, 501B, SMB2, SMP2, BC, BT, CW2, CW3, CW4, CW5, Lt232, L2232, L34, L.228, SLP, SMP A, V.43, s, cpCWl, ⁇ DCP6-1, FOR6-2, ⁇ DCP6-5, 3T, 5, 8, 9F, 10/1, 20E, 32/6, 34B, 34CT, 34P, 37, 41, 56, 56D, 56P, 60P, 61/6, 74/6, 76/4, 101/8900, 226, 227, 228, 229F, 286, 289, 290F, 512, 764
- Bacteria of the genus Treponema can be infected by the following phage: NN- Treponema (1).
- Bacteria of the genus Yersinia can be infected by the following phages: H, H-I, H-2, H-3, H-4, Lucas 110, Lucas 303, Lucas 404, YerA3, YerA7, YerA20, YerA41, 3/M 64-76, 5/G394-76, 6/C753-76, 8/C239-76, 9/F18167, 1701, 1710, PST, 1/F2852-76, D'Herelle, EV, H, Kotljarova, PTB, R, Y, YerA41, fUeG03-12, 3, 4/C1324-76, 7/F783- 76, 903, 1/M6176 and Yer2AT.
- the bacteriophage is selected in the group consisting of Salmonella virus SKML39, Shigella virus AG3, Dickeya virus Limestone, Dickeya virus RC2014, Escherichia virus CBA120, Escherichia virus Phaxl, Salmonella virus 38, Salmonella virus Det7, Salmonella virus GG32, Salmonella virus PM 10, Salmonella virus SFP10, Salmonella virus SH19, Salmonella virus SJ3, Escherichia virus ECML4, Salmonella virus Marshall, Salmonella virus Maynard, Salmonella virus SJ2, Salmonella virus STML131, Salmonella virus Vil, Erwinia virus Ea2809, Klebsiella virus 0507KN21, Serratia virus IME250, Serratia virus MAM1, Campylobacter virus CP21, Campylobacter virus CP220, Campylobacter virus CPtlO, Campylobacter virus IBB35, Campylobacter virus CP81, Campylobacter virus CP
- Mycobacterium vims Manad Mycobacterium vims Oline, Mycobacterium virus Osmaximus, Mycobacterium virus Pgl, Mycobacterium vims Soto, Mycobacterium virus Suffolk, Mycobacterium virus Athena, Mycobacterium vims Bernardo, Mycobacterium vims Gadjet, Mycobacterium virus Pipefish, Mycobacterium vims Godines, Mycobacterium virus Rosebush, Mycobacterium virus Babsiella,
- Mycobacterium virus Brujita, Mycobacterium virus Che9c, Mycobacterium vims Sbash, Mycobacterium virus Hawkeye, Mycobacterium virus Plot, Salmonella virus AG11, Salmonella vims Entl, Salmonella virus H8SE, Salmonella vims Jersey, Salmonella virus L13, Salmonella vims LSPA1, Salmonella vims SE2, Salmonella vims SETP3, Salmonella vims SETP7, Salmonella virus SETP13, Salmonella virus SP101, Salmonella virus SS3e, Salmonella virus wksl3, Escherichia vims K1G, Escherichia virus K1H, Escherichia vims Klindl, Escherichia virus Klind2, Salmonella vims SP31, Leuconostoc vims Lmdl, Leuconostoc vims LN03, Leuconostoc vims LN04, Leuconostoc vims LN12, Leuconostoc vim
- Mycobacterium virus Fruitloop, Mycobacterium virus Gumbie, Mycobacterium virus Ibhubesi, Mycobacterium virus Llij, Mycobacterium virus Mozy, Mycobacterium virus Mutaformal3, Mycobacterium virus Pacc40, Mycobacterium virus PMC, Mycobacterium virus Ramsey, Mycobacterium virus Rockyhorror, Mycobacterium virus SG4, Mycobacterium virus Shaunal, Mycobacterium virus Shilan, Mycobacterium virus Spartacus, Mycobacterium virus Taj, Mycobacterium virus Tweety, Mycobacterium virus Wee, Mycobacterium virus Yoshi, Salmonella virus Chi, Salmonella virus FSLSP030, Salmonella virus FSLSP088, Salmonella virus iEPS5, Salmonella virus SPN19, Mycobacterium virus 244, Mycobacterium virus Bask21, Mycobacterium virus CJW1, Mycobacterium virus Eureka, Mycobacterium virus Kostya, Mycobacterium virus Porky, Mycobacterium virus
- PHL082M03 Propionibacterium virus PHL092M00, Propionibacterium virus PHL095N00, Propionibacterium virus PHL111M01, Propionibacterium vims PHL112N00, Propionibacterium vims PHL113M01, Propionibacterium vims
- Propionibacterium vims PHL308M00 Propionibacterium vims Pirate, Propionibacterium vims Procrassl, Propionibacterium vims SKKY, Propionibacterium vims Solid, Propionibacterium vims Stormbom, Propionibacterium vims Wizzo, Pseudomonas vims PaMx28, Pseudomonas vims PaMx74, Mycobacterium vims Patience, Mycobacterium vims PBI1, Rhodococcus vims Pepy6, Rhodococcus vims Poco6, Propionibacterium vims PFR1, Streptomyces vims phiBTl, Streptomyces vims phiC31, Streptomyces vims TGI, Caulobacter vims Karma, Caulobacter vims Magneto, Caulobacter vims phiCbK, Caulobacter vims
- the bacterial vims particles target E. coli and includes the capsid of a bacteriophage selected in the group consisting of BW73, B278, D6, D108, E, El, E24, E41, FI-2, FI-4, FI-5, HI8A, Ffl8B, i, MM, Mu, 025, Phi-5, Pk, PSP3, PI, P1D, P2, P4, SI, Wcp, cpK13, ⁇ pl, q>2, q>7, cp92, 7 A, 8 ⁇ p, 9f, 18, 28-1, 186, 299, HH-Escherichia (2), AB48, CM, C4, C16, DD-VI, E4, E7, E28, FI1, FI3, H, HI, H3, H8, K3, M, N, NO- 2, ND-3, ND4, ND-5, ND6, ND-7, Ox-I, Ox-2, Ox-3, Ox
- a "prebiotic” refers to an ingredient that allows specific changes, both in the composition and/or activity in the gastrointestinal microbiota that may confer benefits upon the host.
- a prebiotic can be a comestible food or beverage or ingredient thereof.
- a prebiotic may be a selectively fermented ingredient.
- Prebiotics may include complex carbohydrates, amino acids, peptides, minerals, or other essential nutritional components for the survival of the bacterial composition.
- Prebiotics include, but are not limited to, amino acids, biotin, fructo-oligosaccharide, galacto-oligosaccharides, hemicelluloses (e.g., arabinoxylan, xylan, xyloglucan, and glucomannan), inulin, chitin, lactulose, mannan oligosaccharides, oligofructose-enriched inulin, gums (e.g., guar gum, gum arabic and carregenaan), oligofructose, oligodextrose, tagatose, resistant maltodextrins (e.g., resistant starch), trans- galactooligosaccharide, pectins (e.g., xylogalactouronan, citrus pectin, apple pectin, and rhamnogalacturonan-I), dietary fibers (e.g., soy fiber, sugarbeet fiber,
- a“probiotic” refers to a dietary supplement based on living microbes which, when taken in adequate quantities, has a beneficial effect on the host organism by strengthening the intestinal ecosystem.
- Probiotic can comprise a non- pathogenic bacterial or fungal population, e.g., an immunomodulatory bacterial population, such as an anti-inflammatory bacterial population, with or without one or more prebiotics. They contain a sufficiently high number of living and active probiotic microorganisms that can exert a balancing action on gut flora by direct colonisation.
- probiotic is taken to mean any biologically active form of probiotic, preferably but not limited to lactobacilli, bifidobacteria, streptococci, enterococci, propionibacteria or saccharomycetes but even other microorganisms making up the normal gut flora, or also fragments of the bacterial wall or of the DNA of these microorganisms.
- lactobacilli preferably but not limited to lactobacilli, bifidobacteria, streptococci, enterococci, propionibacteria or saccharomycetes but even other microorganisms making up the normal gut flora, or also fragments of the bacterial wall or of the DNA of these microorganisms.
- Probiotics include, but are not limited to lactobacilli, bifidobacteria, streptococci, enterococci, propionibacteria, saccharomycetes, lactobacilli, bifidobacteria, or proteobacteria.
- the antibiotic can be selected from the group consisting in penicillins such as penicillin G, penicillin K, penicillin N, penicillin O, penicillin V, methicillin, benzylpenicillin, nafcillin, oxacillin, cloxacillin, dicloxacillin, ampicillin, amoxicillin, pivampicillin, hetacillin, bacampicillin, metampicillin, talampicillin, epicillin, carbenicillin, ticarcillin, temocillin, mezlocillin, and piperacillin; cephalosporins such as cefacetrile, cefadroxil, cephalexin, cefaloglycin, cefalonium, cefaloridine, cefalotin, cefapirin, cefatrizine, cefazaflur, cefazedone, cefazolin, cefradine, cefroxadine, ceftezole, cefaclor, cef
- the present invention provides pharmaceutical or veterinary compositions comprising one or more of the bacterial delivery vehicles disclosed herein and a pharmaceutically-acceptable carrier.
- the bacterial delivery vehicles may be formulated as a pharmaceutical preparation or compositions comprising at least one bacterial delivery vehicles and at least one pharmaceutically acceptable carrier, diluent or excipient, and optionally one or more further pharmaceutically active compounds.
- Such a formulation may be in a form suitable for oral administration, for parenteral administration (such as by intravenous, intramuscular or subcutaneous injection or intravenous infusion), for topical administration, for administration by inhalation, by a skin patch, by an implant, by a suppository, etc.
- Such administration forms may be solid, semi-solid or liquid, depending on the manner and route of administration.
- formulations for oral administration may be provided with an enteric coating that will allow the synthetic bacterial delivery vehicles in the formulation to resist the gastric environment and pass into the intestines.
- synthetic bacterial delivery vehicle formulations for oral administration may be suitably formulated for delivery into any desired part of the gastrointestinal tract.
- suitable suppositories may be used for delivery into the gastrointestinal tract.
- Various pharmaceutically acceptable carriers, diluents and excipients useful in bacterial delivery vehicle compositions are known to the skilled person.
- kits for treating a bacterial infection using the synthetic bacterial delivery vehicles disclosed herein include administering the synthetic bacterial delivery vehicles or compositions disclosed herein to a subject having a bacterial infection in need of treatment.
- the subject is a mammal. In some embodiments, the subject is a human.
- the pharmaceutical or veterinary composition according to the disclosure may further comprise a pharmaceutically acceptable vehicle.
- a solid pharmaceutically acceptable vehicle may include one or more substances which may also act as flavouring agents, lubricants, solubilisers, suspending agents, dyes, fillers, glidants, compression aids, inert binders, sweeteners, preservatives, dyes, coatings, or tablet- disintegrating agents.
- Suitable solid vehicles include, for example calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
- the pharmaceutical or veterinary composition may be prepared as a sterile solid composition that may be suspended at the time of administration using sterile water, saline, or other appropriate sterile injectable medium.
- the pharmaceutical or veterinary compositions of the disclosure may be administered orally in the form of a sterile solution or suspension containing other solutes or suspending agents (for example, enough saline or glucose to make the solution isotonic), bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 8o (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like.
- the particles according to the disclosure can also be administered orally either in liquid or solid composition form.
- compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixirs, and suspensions.
- forms useful for enteral administration include sterile solutions, emulsions, and suspensions.
- the bacterial delivery vehicles according to the disclosure may be dissolved or suspended in a pharmaceutically acceptable liquid vehicle such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats.
- a pharmaceutically acceptable liquid vehicle such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats.
- the liquid vehicle can contain other suitable pharmaceutical additives such as solubilisers, emulsifiers, buffers, preservatives, sweeteners, flavouring agents, suspending agents, thickening agents, colours, viscosity regulators, stabilizers or osmo-regulators.
- suitable examples of liquid vehicles for oral and enteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g.
- the vehicle can also be an oily ester such as ethyl oleate and isopropyl myristate.
- Sterile liquid vehicles are useful in sterile liquid form compositions for enteral administration.
- the liquid vehicle for pressurized compositions can be a halogenated hydrocarbon or other pharmaceutically acceptable propellant.
- the pharmaceutical or veterinary composition can be formulated into ointment, cream or gel form and appropriate penetrants or detergents could be used to facilitate permeation, such as dimethyl sulfoxide, dimethyl acetamide and dimethylformamide.
- nasal sprays for transmucosal administration, nasal sprays, rectal or vaginal suppositories can be used.
- the active compounds can be incorporated into any of the known suppository bases by methods known in the art. Examples of such bases include cocoa butter, polyethylene glycols (carbowaxes), polyethylene sorbitan monostearate, and mixtures of these with other compatible materials to modify the melting point or dissolution rate.
- the present invention relates to a method for treating a disease or disorder caused by bacteria comprising administering a therapeutically amount of the pharmaceutical or veterinary composition as disclosed herein to a subject having such disease or disorder and in need of treatment. It also relates to the pharmaceutical or veterinary composition as disclosed herein for use in the treatment of a disease or disorder caused by bacteria. It further relates to the use of a pharmaceutical or veterinary composition as disclosed herein for the manufacture of a medicament for treating a disease or disorder caused by bacteria.
- the diseases or disorders caused by bacteria may be selected from the group consisting of abdominal cramps, acne vulgaris, acute epiglottitis, arthritis, bacteraemia, bloody diarrhea, botulism, Brucellosis, brain abscess, chancroid venereal disease, Chlamydia, Crohn’s disease, conjunctivitis, cholecystitis, colorectal cancer, polyposis, dysbiosis, Lyme disease, diarrhea, diphtheria, duodenal ulcers, endocarditis, erysipelothricosis, enteric fever, fever, glomerulonephritis, gastroenteritis, gastric ulcers, Guillain-Barre syndrome tetanus, gonorrhoea, gingivitis, inflammatory bowel diseases, irritable bowel syndrome, leptospirosis, leprosy, listeriosis, tuberculosis, Lady Widermere syndrome, Legionaire’s disease, meningitis
- the disease or disorder caused by bacteria may be a bacterial infection selected from the group consisting of skin infections such as acne, intestinal infections such as esophagitis, gastritis, enteritis, colitis, sigmoiditis, rectitis, and peritonitis, urinary tract infections, vaginal infections, female upper genital tract infections such as salpingitis, endometritis, oophoritis, myometritis, parametritis and infection in the pelvic peritoneum, respiratory tract infections such as pneumonia, intra-amniotic infections, odontogenic infections, endodontic infections, fibrosis, meningitis, bloodstream infections, nosocomial infection such as catheter-related infections, hospital acquired pneumonia, post-partum infection, hospital acquired gastroenteritis, hospital acquired urinary tract infections, and a combination thereof.
- the infection according to the disclosure is caused by a bacterium presenting an antibiotic resistance.
- the infection is caused by a bacterium as listed
- the disease or disorder caused by bacteria may also be a metabolic disorder, for example, obesity and diabetes.
- the disclosure thus also concerns a pharmaceutical or veterinary composition as disclosed herein for use in the treatment of metabolic disorder including, for example, obesity and diabetes. It further concerns a method for treating a metabolic disorder comprising administering a therapeutically amount of the pharmaceutical or veterinary composition as disclosed herein, and the use of a pharmaceutical or veterinary composition as disclosed herein for the manufacture of a medicament for treating a metabolic disorder.
- the disease or disorder caused by bacteria may also be a pathology involving bacteria of the human microbiome.
- the disclosure concerns a pharmaceutical or veterinary composition as disclosed herein for use in the treatment of pathologies involving bacteria of the human microbiome, such as inflammatory and auto-immune diseases, cancers, infections or brain disorders. It further concerns a method for treating a pathology involving bacteria of the human microbiome comprising administering a therapeutically amount of the pharmaceutical or veterinary composition as disclosed herein, and the use of a pharmaceutical or veterinary composition as disclosed herein for the manufacture of a medicament for treating a pathology involving bacteria of the human microbiome.
- the present disclosure relates also to modulating microbiome composition to improve the efficacy of immunotherapies based, for example, on CAR-T (Chimeric Antigen Receptor T) cells, TIL (Tumor Infiltrating Lymphocytes) and Tregs (Regulatory T cells) also known as suppressor T cells.
- CAR-T Chimeric Antigen Receptor T
- TIL Tumor Infiltrating Lymphocytes
- Tregs Regulatory T cells
- Modulation of the microbiome composition to improve the efficacy of immunotherapies may also include the use of immune checkpoint inhibitors well known in the art such as, without limitation, PD-1 (programmed cell death protein 1) inhibitor, PD-L1 (programmed death ligand 1) inhibitor and CTLA-4 (cytotoxic T lymphocyte associated protein 4).
- immune checkpoint inhibitors well known in the art such as, without limitation, PD-1 (programmed cell death protein 1) inhibitor, PD-L1 (programmed death ligand 1) inhibitor and CTLA-4 (cytotoxic T lymphocyte associated protein 4).
- Some bacteria of the microbiome can also secrete molecules that will affect the brain.
- a further object of the disclosure is a method for controlling the microbiome of a subject, comprising administering an effective amount of the pharmaceutical composition as disclosed herein in said subject.
- the disclosure also relates to a method for personalized treatment for an individual in need of treatment for a bacterial infection comprising: i) obtaining a biological sample from the individual and determining a group of bacterial DNA sequences from the sample; ii) based on the determining of the sequences, identifying one or more pathogenic bacterial strains or species that were in the sample; and iii) administering to the individual a pharmaceutical composition according to the disclosure capable of recognizing each pathogenic bacterial strain or species identified in the sample and to deliver the packaged plasmid.
- the biological sample comprises pathological and non-pathological bacterial species, and subsequent to administering the pharmaceutical or veterinary composition according to the disclosure to the individual, the amount of pathogenic bacteria on or in the individual are reduced, but the amount of non-pathogenic bacteria is not reduced.
- the disclosure concerns a pharmaceutical or veterinary composition according to the disclosure for use in order to improve the effectiveness of drugs.
- some bacteria of the microbiome without being pathogenic by themselves, are known to be able to metabolize drugs and to modify them in ineffective or harmful molecules.
- composition according to the invention may further comprise at least one additional active ingredient, for instance a prebiotic and/or a probiotic and/or an antibiotic, and/or another antibacterial or antibiofilm agent, and/or any agent enhancing the targeting of the bacterial delivery vehicle to a bacteria and/or the delivery of the payload into a bacteria.
- additional active ingredient for instance a prebiotic and/or a probiotic and/or an antibiotic, and/or another antibacterial or antibiofilm agent, and/or any agent enhancing the targeting of the bacterial delivery vehicle to a bacteria and/or the delivery of the payload into a bacteria.
- the disclosure concerns the in-situ bacterial production of any compound of interest, including therapeutic compound such as prophylactic and therapeutic vaccine for mammals.
- the compound of interest can be produced inside the targeted bacteria, secreted from the targeted bacteria or expressed on the surface of the targeted bacteria.
- an antigen is expressed on the surface of the targeted bacteria for prophylactic and/or therapeutic vaccination.
- the present disclosure also relates to a non-therapeutic use of the bacterial delivery particles.
- the non-therapeutic use can be a cosmetic use or a use for improving the well-being of a subject, in particular a subject who does not suffer from a disease, and in particular from a disease or disorder caused by bacteria.
- the present disclosure also relates to a cosmetic composition or a non- therapeutic composition comprising the bacterial delivery particles of the disclosure.
- a significative portion of a lambda receptor binding protein e.g. the stf protein
- RBP lambda receptor binding protein
- specific fusion positions in the lambda RBP have been identified which allow one to obtain a functional chimeric RBP.
- the data demonstrate in a non-limiting embodiment that in the case of packaged phagemids derived from bacteriophage lambda, modifying the side tail fiber protein results in an expanded host range.
- K1+ strains are immune to T7 infection because the capsule forms a physical barrier that prevents attachment of the phage, but if purified K1F enzyme is added to the cells before infection, T7 is able to lyse them [21], confirming that the presence of bacterial capsules is a powerful mechanism to avoid recognition by bacteriophages.
- K1+ strains are immune to T7 infection because the capsule forms a physical barrier that prevents attachment of the phage, but if purified K1F enzyme is added to the cells before infection, T7 is able to lyse them [21], confirming that the presence of bacterial capsules is a powerful mechanism to avoid recognition by bacteriophages.
- sequence of K1F tail fiber (SEQ ID NO: 121) is:
- the stf gene was modified to include the K1F endosialidase at its C-terminus using a Cas9-mediated gene exchange protocol [22] and resulted in a lambda-KlF chimeric stf of nucleotide sequence SEQ ID NO: 106 and aminoacid sequence SEQ ID NO: 46.
- Lambda-KIF packaged phagemids were produced as in [23] and titrated against some K1+ strains, specifically E. coli UTI89 and S88.
- a delta-stf lambda production strain was produced with the lambda-K5 stf fusion gene expressed in trans under the control of an inducible promoter.
- FIG. 3 there was some residual delivery using the wild- type lambda-stf, probably due to the presence of some cells with a thinner K5 capsule.
- the addition of lambda-stf-K5 chimeras allows for an improvement in delivery of more than 10 6 fold.
- side tail fibers can be found that have some degree of homology to lambda stf, although no crystal structure is available.
- the insertion site was designed as the last stretch of amino acids with identity to lambda stf.
- the predicted side tail fiber proteins are as follows:
- the addition of a chimeric stf allows the lambda-based packaged phagemid to show increased delivery efficiency in 25 out of 96 strains tested (more than 25% of the collection). In some cases, the increase is modest; in others, it allows for very good delivery efficiency in strains that had no or very low entry with wild- type lambda packaged phagemids. It is also worth noting that AG22 belongs to the Siphovirus_ family, like lambda, but SIEA11 is a P2-like phage. This highlights the significant observation that stf modules can be exchanged across bacteriophage genera.
- the lambda stf protein consists of 774 aminoacids.
- the insertion sites can be found closer to the N-terminus (amino acid 131 , insertion point ADAKKS (SEQ ID NO: 191)) or closer to the C-terminus (amino acid 529, insertion point GAGENS (SEQ ID NO: 194)).
- Stf chimeras with aminoacid sequences of SEQ ID NO: 2-45 and 48-61 and corresponding nucleotide sequences of SEQ ID NO: 62- 105 and 108- 120 were engineered using these insertion sites.
- stf chimeras for the insertion sites ADAKKS (SEQ ID NO: 191), SASAAA (SEQ ID NO: 193) and MDETNR (SEQ ID NO: 192).
- SEQ ID NO: 191 SEQ ID NO: 191
- SASAAA SEQ ID NO: 193
- MDETNR SEQ ID NO: 192
- the results described herein show that it is possible to build chimeric tail fibers that combine the part of one tail fiber that attaches to the capsid of one phage (usually the N-terminus of the protein) with the part of another fiber that interacts with the bacterium (usually the C-terminus of the protein). Stretches of homology between the sequences of different tail fibers can be considered as preferable recombination sites.
- phages contain a single stf protein, which is a very important factor determining their host specificity. However, there are also several examples of phages encoding more than one stf gene, which is a beneficial trait since, presumably, each of them recognizes a different host.
- phages have found different solutions to achieve this feature: some of them, like phi92, encode up to 6 stfs that bind to different parts of the baseplate/viral particle, and probably to other stfs [29]; others, like CBA120 [30], encode 4 stfs that form a tetrameric structure in which one of the stfs attaches to the phage particle while the other three attach to the first one through interaction; and others, like DT57C, contain an stf that binds the particle and a second one that attaches to the first through an interaction domain (branched stfs) [32] (FIG. 7A).
- branched stfs branched stfs
- an engineered lambda stf was constructed based on a branched architecture.
- a phage referred to as WW11, contains two stfs of SEQ ID NO: 124 and 125 that follow the same order and contain homology to phage DT57C, which has been suggested to have branched stfs.
- the interaction domains of stf- 1 and stf-2 in phage WW11 have been identified and used as modules to attach to the lambda stf.
- the final construct contains the N-terminal part of the lambda stf of SEQ ID NO: 1 up to the GAGENS insertion site SEQ ID NO: 194 fused to WW11 stf- 1 interaction domain ID1 of SEQ ID NO: 280 and WW11 stf- 1 proper; after this, a synthetic RBS was inserted and immediately after, the stf-2 interaction domain ID2 of SEQ ID NO: 281 was fused to the C-terminal part of the K1F tail fiber of SEQ ID NO: 121 (see bold sequence of section [198] (FIG. 7B).
- the GAGENS insertion site of SEQ ID NO: 194 was chosen as the insertion site.
- Both chimeric proteins were transcribed from a polycistronic mRNA. This construction resulted in a final branched stf WW11-K1F of aminoacid sequence SEQ ID NO: 282 and 283 and of nucleotide sequence of SEQ ID NO: 284.
- the K1F stf in the branched architecture seems to be less efficient than in the particle containing only one stf, further engineering such as, for example, (i) choosing a more efficient RBS between both stfs,(ii) increasing the length or (iii) introducing flexible linkers between the interaction domains and the fusion stfs and/or (iv) increasing the translation rate of the first stf in the polycistron (since this is known to affect the translation rate of the second CDS in a polycistronic message).
- An advantage of this approach is also that the stfs are present in the phagemid particle in a 1:1 ratio, assuming proper expression of both components, which may be important for regulatory purposes.
- CBA120 is a phage with 4 fibers (called stf; See, FIG. 9). Their sequences are below:
- Stf4 also called TSP4 of FIG. 9 (orf213, protein ID YP_004957867.1) (SEQ ID NO: 127), stf3 (also called TSP3) of FIG. 9 (orf212, protein ID YP_004957866.1) (SEQ ID NO: 128), stf2 (also called TSP2) of FIG. 9 (orf211, protein ID YP_004957865.1) (SEQ ID NO: 129), and stfl(also called TSP1) of FIG. 9 (orf210, protein ID YP_004957864.1) (SEQ ID NO: 130).
- the N-termini have homology to phages G7C/WW11/DT57C, which is a strong indication that these stfs associate to form a tetrameric complex.
- the first stf to be translated, according to the TSP operon in the CBA120 genome, is TSP4, then TSP3, then TSP2, then TSP1. From this information, it was assumed that the main stf is TSP4, since it’s the one to be expressed first. It may encode an ID domain to which more than one TSP attaches.
- the N-terminal domains also share homology to one another, which helps in the identification of the presumable ID domains.
- TSP4 ID4 Of FIG. 9 SEQ ID NO: 131
- ID4 seems to have an extra domain at the N-terminus that may be involved in capsid binding, so it will be left out of the final construct
- TSP3 ID3 of FIG. 9 SEQ ID NO: 132
- TSP2 ID2 of FIG. 9 SEQ ID NO: 133
- TSP1 ID1 of FIG. 9 SEQ ID NO: 134.
- Recoding is a very common process, and the objective is two-fold.
- First recoding is done to avoid codon bias based on the fact that the codons used for a given amino acid vary depending on the organism. Accordingly, to avoid expression problems, which can lead to truncated, mutated or misfolded proteins, sequences were recoded with the codon usage of the host organism (in this case E. coli).
- Second, removal of unknown layers of regulation may be advantageous.
- operons phages and in general any other sequences with high "density information", like a phage genome; they have a limited amount of DNA that can be packaged, so several signals and functions may be encoded within a region, and this may impact the ability to use a genetic part in the desired way.
- Plasmid pPhlF-Tetra STF Bsal cloning (pSClOl 37C, KanR) has been cloned, containing a fusion to Lambda stf GAGENS of SEQ ID NO: 194 with TSP4 interaction domain SEQ ID NO: 131 to 134.
- the other TSP interaction domains are preceded by a synthetic RBS to avoid including unknown layers of regulation from the phage.
- This plasmid allows the TypellS cloning (BSal) of 4 stfs fused to each of the TSP interaction domains.
- the final architecture for expression of the tetrameric is depicted in FIG. 9B, although such an expression scheme may be modified, since the plasmid will be large (>16 kb) and the length of the transcribed mRNA is >9kb.
- T4-like phages are a very diverse family of bacteriophages that share a common long tail fiber architecture: a proximal tail fiber that attaches to the phage particle and a distal tail fiber (DTF) that encodes host specificity linked by proteins acting as“hinge connectors” (Desplats and Krisch, 2003, Res. Microbiol. 154:259-267; Bartual et al. 2010, Proc. Natl. Acad. Sci. 107: 20287-20292). It is thought that the main host range determinants of the tail fiber reside in the distal part.
- DTF distal tail fiber
- T4-like phage which are known to be very broad, to any other phage or packaged phagemid of interest.
- the distal tail fiber (C-terminal domain of the T4-like long tail fiber) of several T4-like phages were screened for possible functional insertion sites, several fusions with the Lambda stf gene were generated and their host range screened.
- a synthetic linker encoding a RBS was designed to replace the natural DNA linker between the DTF gene and the adhesin; immediately downstream, another synthetic RBS preceding the chaperone gp57A was added, hence creating a polycistronic mRNA encoding for all the functions needed for the proper folding of the DTF (FIG. 10).
- This construct was built in a plasmid under the control of an inducible promoter and complemented in trans in a strain producing lambda-based phagemids.
- FIG 10. depicts the architecture of an engineered lambda stf-T4-like DTF chimera.
- the semicircles denote RBS sites; the T sign, a transcriptional terminator; the arrow, a promoter.
- Several parts of the C-terminus of the DTF were screened and fused to the lambda stf gene at the GAGENS (SEQ ID NO: 194) insertion site.
- Several variants of the chimera lambda stf-WW13 were functional, as assessed by production of phagemid particles and transduction of a chloramphenicol marker in a collection of E. coli strains. The functional chimeras shown in FIG.
- T4-like phages like PP-1, sharing sequence homology with WW13 were also tested and verified to produce functional chimeras (FIG. 11). These functional chimeras show a IATRV (SEQ ID NO: 198) insertion site at the beginning of PP-1 DTF part.
- FIG. 11 depicts screening of phagemid particles with chimeric lambda stf-T4- like DTFs and in particular chimeric lambda stf-WW13 and chimeric lambda stf-PPl of aminoacids sequences SEQ ID NO: 142 to 149 and nucleotide sequences of SEQ ID NO: 166 to 173 including their respective chaperones proteins.
- Left panel represents wild-type lambda stf; the middle panel represents chimeric lambda-stf- WW13; and the right panel, represents chimeric lambda- stf-PP-1.
- the insertion sites found for WW13 do not always exist in a given T4-like DTF, thereby complicating the analysis.
- Another functional insertion site without homology to WW13 was discovered for a second phage (WW55, FIG. 12).
- the same TPGEL (SEQ ID NO: 199) insertion site could be found in a subset of T4-like phages and proven to yield functional chimeras with at least one of them, WW34 (FIG. 12), and at MDETNR (SEQ ID NO: 192) insertion site in lambda stf.
- FIG. 12. shows screening of phagemid particles with chimeric lambda stf-T4-like DTFs and in particular chimeric lambda stf-WW55 and chimeric lambda stf-WW34 of aminoacids sequences SEQ ID NO: 150 to 156 and nucleotide sequences of SEQ ID NO: 174 to 180 including their respective chaperones proteins.
- the left panel represents wild-type lambda stf; the middle panel represents chimeric lambda-stf-WW55; and the right panel represents chimeric lambda-stf-WW34.
- T4-like DTF proteins may or may not share common sites for insertion, attempts were made to identify a universal insertion site that exists in all T4-like DTFs. When several T4-like DTFs are aligned, no homology along the whole DTF gene present in all the sequences exists, except for the N-terminus which is well conserved. The N-terminus of the DTF is thought to interact with the hinge connectors for attachment to the main phage particle.
- chimeric lambda stf-WW14 chimeric lambda stf- WW170 and chimeric lambda stf-202 of aminoacids sequences SEQ ID NO: 157 to 165 and nucleotide sequences of SEQ ID NO: 181 to 189 including their respective chaperones proteins.
- the present disclosure is useful for the generation of phage and phagemid particles with altered host ranges, since it provides a practical framework for the construction of chimeras using the DTFs from any T4-like phage, highlighting its modularity and translatability.
- the human microbiome comprises different zones of the body, including gut, skin, vagina and mouth [29].
- the microbiota in these areas is composed of differentcommunities of microorganisms, such as bacteria, archaea and fungi [29]-[31]. While numerous studies have been made that try to elucidate the specific composition of these communities, it is becoming clear that while there may exist a "core microbiome", there are many variations in the relative content of each microorganism depending on several factors, such as geographical location, diet or age [32]-[35].
- packaged phagemids are of great interest, since they do not kill the host (unless their payload carries genes aimed at killing the host), payload does not replicate and expand and does not contain any endogenous phage genes.
- a diagnostic study would be needed to identify the specific serotypes/variants of bacteria that exist in the patient before the treatment in order to find or design a packaged phagemid that allows for delivery of a payload adding a function to the target bacteria without killing them.
- engineered delivery vehicles that are able to recognize a large number of strains belonging to different serotypes and phylogenetic groups (i.e., engineered particles having a "broad host range"), with a focus on Escherichia coli.
- a therapeutic delivery approach does not need a priori to reach a large percentage of bacteria; the delivery needs to be high enough for the therapeutic payload to be expressed at the correct levels, which may be highly variable depending on the application.
- the payload can be expressed by different serotypes or phylogenetic groups. This approach increases the chance that the particle will deliver a payload expressed in vivo in the majority of patients.
- the ECOR collection is a set of strains isolated from different sources that is thought to represent the variability of this bacterium in Nature [42]. Some phage have been shown to have a broad host range against this collection (for instance, about 53% of the ECOR strains can be lysed with phage AR1 [43] and about 60% with phage SU16 [44]). As opposed to this, a single phage is able to infect 95% of Staphylococcus aureus strains [40].
- the density of the dots was scored from 0 to 5, with 0 being no transductants and 5 being a spot with very high density [FIG. 14].
- the density of the spots is directly related to the delivery efficiency of the packaged phagemids, since it corresponds to the number of bacteria that have received a payload containing a chloramphenicol acetyltransferase gene.
- stf s can be considered as broad host range because the delivery efficiency in the selected ECOR strains is significantly higher than when using the wild type stf. For example, for stf EB6 or stf 68B, about 50% of the strains show medium to high delivery efficiencies, as compared to 17.5% of the strains with the wild type stf. These stf are good candidates for in vivo delivery, since they are able to deliver in different phylogenetic groups as well as serotypes. At the bottom of the Table in FIG.
- a bar- formatted representation for density scores higher than 3 is shown, where the threshold for a broad host range stf is set at an increase of at least 2X compared to the basal line of the wild type stf; this is, stf that are able to deliver with scores of 3 and higher in at least 35% of the strains.
- Other stf also show an increased delivery as compared to the wild type stf, so a less stringent threshold was set for stf able to deliver with scores 3 or higher with at least a 50% increase compared to the number of strains delivered with the wild- type stf (this is, delivery with scores of 3 and higher in at least 26.25% of the strains).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862783258P | 2018-12-21 | 2018-12-21 | |
US201962802777P | 2019-02-08 | 2019-02-08 | |
PCT/EP2019/082640 WO2020109339A1 (en) | 2018-11-27 | 2019-11-26 | Chimeric receptor binding proteins for use in bacterial delivery vehicles |
US16/696,769 US11661443B2 (en) | 2018-11-27 | 2019-11-26 | Chimeric receptor binding proteins for use in bacterial delivery vehicles |
PCT/EP2019/086990 WO2020128108A1 (en) | 2018-12-21 | 2019-12-23 | Branched receptor binding multi-subunit protein complexes for use in bacterial delivery vehicles |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3898953A1 true EP3898953A1 (en) | 2021-10-27 |
Family
ID=71101098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19829637.8A Withdrawn EP3898953A1 (en) | 2018-12-21 | 2019-12-23 | Branched receptor binding multi-subunit protein complexes for use in bacterial delivery vehicles |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP3898953A1 (ko) |
JP (1) | JP2022514700A (ko) |
KR (1) | KR20210107053A (ko) |
CN (1) | CN113498435A (ko) |
CA (1) | CA3120160A1 (ko) |
IL (1) | IL283796A (ko) |
WO (1) | WO2020128108A1 (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11584781B2 (en) | 2019-12-30 | 2023-02-21 | Eligo Bioscience | Chimeric receptor binding proteins resistant to proteolytic degradation |
TR202014396A2 (tr) * | 2020-09-10 | 2022-03-21 | Univ Yildiz Teknik | Mikroorganizma hedefli, antimikrobiyal bileşen/bileşenler içeren nanoformülasyonlar. |
WO2022144382A1 (en) * | 2020-12-30 | 2022-07-07 | Eligo Bioscience | Chimeric receptor binding proteins resistant to proteolytic degradation |
EP4342538A1 (en) * | 2022-09-20 | 2024-03-27 | Technische Universität München | Simultaneous production of structural proteins from heterologous bacteriophage in cell-free expression system |
WO2024102973A1 (en) * | 2022-11-10 | 2024-05-16 | Laboratory Corporation Of America Holdings | Synthetic phage with recombinant tail-spike proteins and related methods |
CN116003531B (zh) * | 2022-12-28 | 2023-09-05 | 山东省农业科学院畜牧兽医研究所 | 噬菌体受体结合蛋白po86在大肠杆菌o抗原血清型分型鉴定中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014124226A1 (en) | 2013-02-07 | 2014-08-14 | The Rockefeller University | Sequence specific antimicrobials |
CA2971205A1 (en) * | 2014-12-16 | 2016-06-23 | Synthetic Genomics, Inc. | Compositions of and methods for in vitro viral genome engineering |
-
2019
- 2019-12-23 KR KR1020217022651A patent/KR20210107053A/ko unknown
- 2019-12-23 JP JP2021536201A patent/JP2022514700A/ja active Pending
- 2019-12-23 CN CN201980085305.8A patent/CN113498435A/zh active Pending
- 2019-12-23 WO PCT/EP2019/086990 patent/WO2020128108A1/en unknown
- 2019-12-23 EP EP19829637.8A patent/EP3898953A1/en not_active Withdrawn
- 2019-12-23 CA CA3120160A patent/CA3120160A1/en active Pending
-
2021
- 2021-06-07 IL IL283796A patent/IL283796A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN113498435A (zh) | 2021-10-12 |
WO2020128108A1 (en) | 2020-06-25 |
JP2022514700A (ja) | 2022-02-14 |
IL283796A (en) | 2021-07-29 |
CA3120160A1 (en) | 2020-06-25 |
KR20210107053A (ko) | 2021-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11512116B2 (en) | Chimeric receptor binding proteins for use in bacterial delivery vehicles | |
US11208437B2 (en) | Branched receptor binding multi-subunit protein complexes for use in bacterial delivery vehicles | |
EP3898953A1 (en) | Branched receptor binding multi-subunit protein complexes for use in bacterial delivery vehicles | |
US11952594B2 (en) | Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof | |
US11970716B2 (en) | Transcriptional control in prokaryotic cells using DNA-binding repressors | |
US20210196828A1 (en) | Bacterial delivery vehicles for in vivo delivery of a dna payload | |
CA3164131A1 (en) | Bacterial delivery vehicles for in vivo delivery of a dna payload | |
US11584781B2 (en) | Chimeric receptor binding proteins resistant to proteolytic degradation | |
US20220064223A1 (en) | Branched receptor binding multi-subunit protein complexes for use in bacterial delivery vehicles | |
US20230134572A1 (en) | Chimeric receptor binding proteins resistant to proteolytic degradation | |
JP2024501871A (ja) | タンパク質分解に耐性のキメラ受容体結合タンパク質 | |
WO2022144382A1 (en) | Chimeric receptor binding proteins resistant to proteolytic degradation | |
CN116940676A (zh) | 抵抗蛋白水解降解的嵌合受体结合蛋白 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210617 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40062949 Country of ref document: HK |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ELIGO BIOSCIENCE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220901 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230513 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20240103 |